

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
3 July 2003 (03.07.2003)

PCT

(10) International Publication Number  
**WO 03/053974 A1**

- (51) International Patent Classification<sup>7</sup>: C07D 487/04, 473/00, A61K 31/395, A61P 3/06, 3/10, 9/10, 19/10, 29/02, 35/00
- (21) International Application Number: PCT/IB02/05442
- (22) International Filing Date: 17 December 2002 (17.12.2002)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:  
1029/MAS/2001 21 December 2001 (21.12.2001) IN
- (71) Applicant (for all designated States except US): DR. REDDY'S LABORATORIES LTD. [IN/IN]; Ameerpet, 7-1-27, 500016 Hyderabad, Andhra Pradesh (IN).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DAS, Saibal, Kumar [IN/IN]; Discovery Research, Dr. Reddy's Laboratories Ltd., 7-1-27, Ameerpet, 500016 Hyderabad, Andhra Pradesh (IN). BHUNIYA, Debnath [IN/IN]; Discovery Research, Dr. Reddy's Laboratories Ltd., 7-1-27, Ameerpet, 500016 Hyderabad, Andhra Pradesh (IN). MADHAVAN, Gurram, Ranga [IN/IN]; Discovery Research, Dr. Reddy's Laboratories Ltd., 7-1-27, Ameerpet, 500016 Hyderabad, Andhra Pradesh (IN). IQBAL, Javed [IN/IN]; Discovery Research, Dr. Reddy's Laboratories Ltd., 7-1-27, Ameerpet, 500016 Hyderabad, Andhra Pradesh (IN). CHAKRABARTI, Ranjan [IN/IN]; Discovery Research, Dr. Reddy's Laboratories Ltd., 7-1-27, Ameerpet, 500016 Hyderabad, Andhra Pradesh (IN).
- (74) Common Representative: DR. REDDY'S LABORATORIES LTD.; Ameerpet, 7-1-27, 500016 Hyderabad, Andhra Pradesh (IN).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).



Declaration under Rule 4.17:

- of inventorship (Rule 4.17(iv)) for US only


Published:

- with international search report  
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

**WO 03/053974 A1**

(54) Title: NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM




compositions containing them. More particularly, the present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

(57) Abstract: The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

NOVEL COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR  
PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Field of the Invention

5       The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and  
hypcholesterolemic compounds, their derivatives, their analogs, their tautomeric forms,  
their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their  
pharmaceutically acceptable solvates and pharmaceutically acceptable compositions  
containing them. More particularly, the present invention relates to novel alkyl carboxylic  
10      acids of the general formula (I), their derivatives, their analogs, their tautomeric forms,  
their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their  
pharmaceutically acceptable solvates and pharmaceutically acceptable compositions  
containing them.



15     The present invention also relates to a process for the preparation of the above said  
compounds, their analogs, their derivatives, their tautomeric forms, their stereoisomers,  
their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically  
acceptable solvates and pharmaceutical compositions containing them.

20     The present invention also relates to novel intermediates, processes for their  
preparation, their use in the preparation of compounds of formula (I) and their use as  
antidiabetic, hypolipidemic, antiobesity and hypcholesterolemic compounds.

The present invention also relates to novel intermediates, processes for their  
preparation and their use in the preparation of compounds of formula (I).

25     The compounds of the present invention lower plasma glucose, triglycerides, lower  
total cholesterol (TC) and increase high density lipoprotein (HDL) and decrease low  
density lipoprotein (LDL), which have a beneficial effect on coronary heart disease and  
atherosclerosis.

30     The compounds of general formula (I) are useful in reducing body weight and for  
the treatment and/or prophylaxis of diseases such as atherosclerosis, stroke, peripheral  
vascular diseases and related disorders. These compounds are useful for the treatment of  
hyperlipidemia, hyperglycemia, hypercholesterolemia, lowering of atherogenic  
lipoproteins, VLDL (very low density lipoprotein) and LDL. The compounds of the

present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis and nephropathy. The compounds of general formula (I) are also useful for the treatment and/or prophylaxis of leptin resistance, impaired glucose tolerance, disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease and other cardiovascular disorders. These compounds may also be useful as aldose reductase inhibitors, for improving cognitive functions in dementia, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, arteriosclerosis, retinopathy, xanthoma, eating disorders, inflammation and for the treatment of cancer. The compounds of the present invention are also useful in the treatment and/or prophylaxis of the above said diseases in combination/concomittant with one or more HMG CoA reductase inhibitor; cholesterol absorption inhibitor; antiobesity drug; lipoprotein disorder treatment drug; hypoglycemic agent; insulin; biguanide; sulfonylurea; thiazolidinedione; dual PPAR $\alpha$  and  $\gamma$  agonists or a mixture thereof.

#### Background of the Invention

Atherosclerosis and other peripheral vascular diseases effect the quality of life of millions of people. Therefore, considerable attention has been directed towards understanding the etiology of hypercholesterolemia and hyperlipidemia and development of effective therapeutic strategies.

Hypercholesterolemia has been defined as plasma cholesterol level that exceeds arbitrarily defined value called "normal" level. Recently, it has been accepted that "ideal" plasma levels of cholesterol are much below the "normal" level of cholesterol in the general population and the risk of coronary artery disease (CAD) increases as cholesterol level rises above the "optimum" (or "ideal") value. There is clearly a definite cause and effect-relationship between hypercholesterolemia and CAD, particularly for individuals with multiple risk factors. Most of the cholesterol is present in the esterified forms with various lipoproteins such as Low density lipoprotein (LDL), Intermediate density lipoprotein (IDL), High density lipoprotein (HDL) and partially as Very low density lipoprotein (VLDL). Studies clearly indicate that there is an inverse relationship between CAD and atherosclerosis with serum HDL-cholesterol concentrations, (Stampfer *et al.*, *N. Engl. J. Med.*, 325 (1991), 373-381) and the risk of CAD increases with increasing levels of LDL and VLDL.

In CAD, generally "fatty streaks" in carotid, coronary and cerebral arteries, are

found which are primarily free and esterified cholesterol. Miller *et al.*, (*Br. Med. J.*, 282 (1981), 1741 - 1744) have shown that increase in HDL-particles may decrease the number of sites of stenosis in coronary arteries of human, and high level of HDL-cholesterol may protect against the progression of atherosclerosis. Picardo *et al.*, *Arteriosclerosis* 6 (1986) 5 434 - 441 have shown by *in vitro* experiment that HDL is capable of removing cholesterol from cells. They suggest that HDL may deplete tissues of excess free cholesterol and transfer it to liver, which is known as reverse cholesterol transport, (Macikinnon *et al.*, *J. Biol. chem.* 261 (1986), 2548 - 2552). Therefore, agents that increase HDL cholesterol would have therapeutic significance for the treatment of hypercholesterolemia and 10 coronary heart diseases (CHD).

Obesity is a disease highly prevalent in affluent societies and in the developing world and is a major cause of morbidity and mortality. It is a state of excess body fat accumulation. The causes of obesity are unclear. It is believed to be of genetic origin or promoted by an interaction between the genotype and environment. Irrespective of the 15 cause, the result is fat deposition due to imbalance between the energy intake versus energy expenditure. Dieting, exercise and appetite suppression have been a part of obesity treatment. There is a need for efficient therapy to fight this disease since it may lead to coronary heart disease, diabetes, stroke, hyperlipidemia; gout, osteoarthritis, reduced fertility and many other psychological and social problems.

20 Diabetes and insulin resistance is yet another disease which severely effects the quality of large population in the world. Insulin resistance is the diminished ability of insulin to exert its biological action across a broad range of concentrations. In insulin resistance, the body secretes abnormally high amounts of insulin to compensate for this defect; failing which, the plasma glucose concentration inevitably raises and develops into 25 diabetes. Among the developed countries, diabetes mellitus is a common problem and is associated with a variety of abnormalities including obesity, hypertension, hyperlipidemia (*J. Clin. Invest.*, 75 (1985) 809 - 817; *N. Engl. J. Med.* 317 (1987) 350-357; *J. Clin. Endocrinol. Metab.*, 66 (1988) 580 - 583; *J. Clin. Invest.*, 68 (1975) 957 - 969) and other renal complications (patent publication No. WO 95/21608). It is now increasingly being 30 recognized that insulin resistance and relative hyperinsulinemia have a contributory role in obesity, hypertension, atherosclerosis and type 2 diabetes mellitus. The association of insulin resistance with obesity, hypertension and angina has been described as a syndrome having insulin resistance as the central pathogenic link-Syndrome-X.

Hyperlipidemia is the primary cause for cardiovascular (CVD) and other peripheral

vascular diseases. High risk of CVD is related to the higher LDL (Low Density Lipoprotein) and VLDL (Very Low Density Lipoprotein) seen in hyperlipidemia. Patients having glucose intolerance/insulin resistance in addition to hyperlipidemia have higher risk of CVD. Numerous studies in the past have shown that lowering of plasma triglycerides and total cholesterol, in particular LDL and VLDL and increasing HDL cholesterol help in preventing cardiovascular diseases.

Peroxisome proliferator activated receptors (PPAR) are members of the nuclear receptor super family. The gamma ( $\gamma$ ) isoform of PPAR (PPAR $\gamma$ ) has been implicated in regulating differentiation of adipocytes (*Endocrinology*, 135 (1994) 798-800) and energy homeostasis (*Cell*, 83 (1995) 803-812), whereas the alpha ( $\alpha$ ) isoform of PPAR (PPAR $\alpha$ ) mediates fatty acid oxidation (*Trend. Endocrin. Metab.*, 4 (1993) 291-296) thereby resulting in reduction of circulating free fatty acid in plasma (*Current Biol.* 5 (1995) 618 - 621). PPAR $\alpha$  agonists have been found useful for the treatment of obesity (WO 97/36579). It has been recently disclosed that compounds which are agonists for both PPAR $\alpha$  and PPAR $\gamma$  are suggested to be useful for the treatment of syndrome X (WO 97/25042). Similar effect between the insulin sensitizer (PPAR $\gamma$  agonist) and HMG CoA reductase inhibitor has been observed which may be useful for the treatment of atherosclerosis and xanthoma (EP 0 753 298).


It is known that PPAR $\gamma$  plays an important role in adipocyte differentiation (*Cell*, 87 (1996) 377-389). Ligand activation of PPAR is sufficient to cause complete terminal differentiation (*Cell*, 79 (1994) 1147-1156) including cell cycle withdrawal. PPAR $\gamma$  is consistently expressed in certain cells and activation of this nuclear receptor with PPAR $\gamma$  agonists would stimulate the terminal differentiation of adipocyte precursors and cause morphological and molecular changes characteristics of a more differentiated, less malignant state (*Molecular Cell*, (1998), 465-470; *Carcinogenesis*, (1998), 1949-53; *Proc. Natl. Acad. Sci.*, 94 (1997) 237-241) and inhibition of expression of prostate cancer tissue (*Cancer Research* 58 (1998) 3344-3352). This would be useful in the treatment of certain types of cancer, which express PPAR $\gamma$  and could lead to a quite nontoxic chemotherapy.

Leptin resistance is a condition wherein the target cells are unable to respond to leptin signal. This may give rise to obesity due to excess food intake and reduced energy expenditure and cause impaired glucose tolerance, type 2 diabetes, cardiovascular diseases and such other interrelated complications. Kallen *et al* (*Proc. Natl. Acad. Sci.* (1996) 93, 5793-5796) have reported that insulin sensitizers which perhaps due to the PPAR agonist expression lower plasma leptin concentrations. However, it has been recently disclosed

that compounds having insulin sensitizing property also possess leptin sensitization activity. They lower the circulating plasma leptin concentrations by improving the target cell response to leptin (WO 98/02159).

A few alkyl carboxylic acids, their derivatives and their analogs have been reported 5 to be useful in the treatment of hyperglycemia and hypercholesterolemia. Some of such compounds described in the prior art are outlined below:


i). In our international publication No. WO 99/08501 we have disclosed the compounds of general formula (IIa)



10 where X represents O or S ; the groups R<sup>1</sup>, R<sup>2</sup> and group R<sup>3</sup> when attached to the carbon atom, may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, acyl, acyloxy, hydroxyalkyl, amino, acylamino, 15 alkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>1</sup>, R<sup>2</sup> along with the adjacent atoms to which they are attached may also form a 5-6 membered substituted or unsubstituted cyclic 20 structure containing carbon atoms with one or more double bonds, which may optionally contain one or more heteroatoms selected from oxygen, nitrogen and sulfur; R<sup>3</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or optionally substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, heterocyclyl, heteroaryl, heteroaralkyl, acyl, acyloxy, hydroxyalkyl, amino, acylamino, alkylamino, 25 arylamino, aralkylamino, aminoalkyl, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid derivatives, or sulfonic acid derivatives; the linking group represented by -(CH<sub>2</sub>)<sub>n</sub>-O- may be attached either through 30 nitrogen atom or through carbon atom where n is an integer ranging from 1 – 4; Ar represents an optionally substituted divalent single or fused aromatic or heterocyclic group; R<sup>4</sup> represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, optionally


substituted aralkyl group or forms a bond together with the adjacent group R<sup>5</sup>; R<sup>5</sup> represents hydrogen, hydroxy, alkoxy, halogen, lower alkyl group, acyl, optionally substituted aralkyl or R<sup>5</sup> forms a bond together with R<sup>4</sup>; R<sup>6</sup> may be hydrogen, optionally substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, alkoxyalkyl,  
5 alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl, acyl, heterocycl, heteroaryl, heteroaralkyl groups, with a provision that R<sup>6</sup> does not represent hydrogen when R<sup>7</sup> represents hydrogen or lower alkyl group; R<sup>7</sup> may be hydrogen or optionally substituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl, heteroaralkyl groups; Y represents oxygen or NR<sup>8</sup>, where R<sup>8</sup> represents  
10 hydrogen, alkyl, aryl, hydroxyalkyl, aralkyl, heterocycl, heteroaryl, heteroaralkyl groups; R<sup>7</sup> and R<sup>8</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, which may optionally contain one or more heteroatoms selected from oxygen, sulfur or nitrogen.

An example of these compounds is shown in formula (IIj)



15


ii) International publication No. WO 00/64888 disclose the compounds of general formula (IIc)




wherein Ar<sup>1</sup> and Ar<sup>2</sup> are independently aryl, fused arylcycloalkenyl, fused arylcycloalkyl,  
20 fused arylheterocyclenyl, fused arylheterocycl, heteroaryl, fused heteroarylalkenyl, fused heteroarylcycloalkyl, fused heteroarylcyclenyl or fused heteroarylheterecycl; A is O, S, SO<sub>2</sub>, NR<sup>13</sup>, C(O), NR<sup>14</sup>C(O), C(O)NR<sup>14</sup>, NR<sup>14</sup>C(O)N(R<sup>15</sup>), C(R<sup>14</sup>)=N; chemical bond and the like; B is O, S, NR<sup>19</sup>, a chemical bond, C(O), N(R<sup>20</sup>)C(O) or C(O)N(R<sup>20</sup>); E is a chemical bond or an ethylene group; a is 0-6; b is 0-4; c is 0-4; d is 0-6; g is 1-5; h is 1-4; R<sup>1</sup>, R<sup>3</sup>, R<sup>5</sup> and R<sup>7</sup> are independently hydrogen, halogen, alkyl, carbonyl, alkoxycarbonyl, or aralkyl; R<sup>2</sup>, R<sup>4</sup>, R<sup>6</sup> and R<sup>8</sup> are independently -(CH<sub>2</sub>)<sub>q</sub>-X; q is 0-3; X is  
25

hydrogen, halogen, alkyl, alkenyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, aralkyl, heteroaralkyl, hydroxy, alkoxy, aralkoxy, heteroaralkoxy, carbonyl, alkoxy carbonyl, tetrazolyl, acyl, acyl HNSO<sub>2</sub>, and the like; Z is R<sup>21</sup>O<sub>2</sub>C, R<sup>21</sup>OC, cyclo-imide; CN, R<sup>21</sup>O<sub>2</sub>SHNCO, R<sup>21</sup>O<sub>2</sub>SNH, R<sup>21</sup>NCO, R<sup>21</sup>O-2,4-thiazolidinonyl or tetrazolyl.


- 5 An example of these compounds is shown in formula (II d)




iii) International publication Nos. WO 95/03038 and WO 96/04260 disclose compounds of formula (II e)



- 10 wherein R<sup>a</sup> represents 2-benzoxazolyl or 2-pyridyl and R<sup>b</sup> represent CF<sub>3</sub>, CH<sub>2</sub>OCH<sub>3</sub> or CH<sub>3</sub>. A typical example is (S)-3-[4-[2-[N-(2-benzoxazolyl)N-methylamino]ethoxy]phenyl]-2-(2,2,2-trifluoroethoxy)propanoic acid (II f).




- 15 iv) International publication Nos. WO 94/13650, WO 94/01420 and WO 95/17394 disclose the compounds of general formula (II g)




- wherein A<sup>1</sup> represent aromatic heterocycle, A<sup>2</sup> represents substituted benzene ring and A<sup>3</sup> represents moiety of formula (CH<sub>2</sub>)<sub>m</sub>-CH-(OR<sup>1</sup>), wherein R<sup>1</sup> represents alkyl groups, m is an integer of 1-5; X represents substituted or unsubstituted N; Y represents C=O or C=S, 20 R<sup>2</sup> represents OR<sup>3</sup> where R<sup>3</sup> may be hydrogen, alkyl, aralkyl, or aryl group and n is an integer of 2-6.

An example of these compounds is shown in formula (II h)




- v) International publication No. WO 00/49005 disclose the compounds of general 25 formula (II i)




wherein Het is an optionally substituted, saturated partially saturated or fully unsaturated 8 to 10 membered bicyclic ring,  $\text{R}^1$  is optionally substituted aryl or optionally substituted heteroaryl,  $\text{R}^2$  is hydrogen halogen, lower alkyl or lower alkoxy,  $\text{L}^1$  is an  $-\text{R}^3\text{-R}^4$  linkage where  $\text{R}^3$  is alkylene, alkenylene or alkynylene and  $\text{R}^4$  is a direct bond, cycloalkylene, heterocycloalkylene, arylene, heteroarylidinyl,  $-\text{C}(=\text{Z}^2)\text{-NR}^5$ ,  $\text{NR}^5\text{-C}(=\text{Z}^2)$ ,  $-\text{Z}^2-$ ,  $-\text{C}(=\text{O})$ ,  $-\text{C}(=\text{NOR}^5)-$ ,  $-\text{NR}^5-$ ,  $\text{NR}^5\text{-C}(=\text{Z}^2)\text{-NR}^5$ ,  $\text{SO}_2\text{-NR}^5$ ,  $\text{NR}^5\text{-SO}_2$ ,  $-\text{O-C}(=\text{O})-$ ,  $-\text{C}(=\text{O})\text{-O}$ ,  $-\text{O-C}(=\text{O})\text{-NR}^5$ ,  $-\text{NR}^5\text{-C}(=\text{O})\text{-O}$ ;  $\text{L}^2$  is optionally substituted alkylene or alkenylene, Y is carboxy or an acid bioisostere and  $\text{Z}^1$  is  $\text{NR}^5$  and the corresponding N-oxides and their prodrugs and pharmaceutically acceptable salts and solvates.

An example of these compounds is shown in formula (II j)




vi) International publication No. WO 94/12181 disclose the compounds of general formula (II k)



$\text{X}$  is a 6 membered aromatic ring containing 0, 1, 2 or 3 nitrogen atoms and either unsubstituted or substituted with  $\text{R}^8$  and  $\text{R}^9$ ;  $\text{X}$  represents  $\text{NH}_2$ ,  $\text{NH-C}(=\text{NH})-$ , and the like or 4 to 10 membered mono or polycyclic aromatic or nonaromatic ring system and containing 0, 1, 2, 3 or 4 heteroatoms selected from N, O or S either unsubstituted or substituted;  $\text{Y}$  is selected from  $\text{C}_{0-8}$  alkyl,  $\text{C}_{4-10}$  cycloalkyl,  $\text{C}_{0-8}$  alkyl- $\text{NR}^3\text{-CO-C}_{0-8}$  alkyl,  $\text{C}_{0-8}$  alkyl- $\text{CONR}^3\text{-C}_{0-8}$  alkyl,  $\text{C}_{0-8}$  alkyl- $\text{O-C}_{0-8}$  alkyl,  $\text{C}_{0-8}$  alkyl- $\text{S(O)}_n\text{-C}_{0-8}$  alkyl,  $(\text{CH}_2)_{0-8}$  aryl- $(\text{CH}_2)_{0-8}$ ,  $(\text{CH}_2)_{0-6}$  aryl- $\text{SO}_n-$ ,  $(\text{CH}_2)_{0-8}$  aryl- $\text{CO-(CH}_2)_{0-8}$ ,  $(\text{CH}_2)_{0-6}$  aryl- $\text{SO}_2\text{-}(\text{CH}_2)_{0-6}-$ ,  $(\text{CH}_2)_{0-6}$   $\text{NR}^3\text{-}(\text{CH}_2)_{0-6}-$ ,  $(\text{CH}_2)_{0-6}$  aryl- $\text{CH(OH)}\text{-}(\text{CH}_2)_{0-6}-$ ,  $(\text{CH}_2)_{0-8}\text{-CONH-}(\text{CH}_2)_{0-8}-$ ,  $\text{C}_{0-8}$  alkyl- $\text{SO}_2\text{-NR}^3\text{-C}_{0-8}$  alkyl,  $\text{C}_{0-8}$  alkyl- $\text{CO-C}_{0-8}$  alkyl,  $\text{C}_{0-8}$  alkyl- $\text{CH(OH)}\text{-C}_{0-8}$  alkyl, where n is an integer from 0-2;  $\text{Z}$  and  $\text{A}$  are independently chosen from  $(\text{CH}_2)_m$ ,  $(\text{CH}_2)_m\text{O}(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{NR}^3(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{NR}^3(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{CONR}^{11}(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{CO}(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{CS}(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{SO}_2(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{S}(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{SO}_2(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{SO}(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{SO}_2\text{NR}^3(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{NR}^3\text{SO}_2(\text{CH}_2)_n$ ,  $(\text{CH}_2)_m\text{CR}^3=\text{CR}^4(\text{CH}_2)_n$ ,


$(CH_2)_mC\equiv C(CH_2)_n$ ,  $(CH_2)_mCH(OH)(CH_2)_n$ ; where m and n are each independently an integer from 0 to 6; Aryl is a 6 membered aromatic ring system containing 0, 1, 2, 3 or 4 N atoms and either unsubstituted or substituted with  $R^5$ , provided that when A is  $(CH_2)_m$ , the Aryl ring, bonded by Z and A must contain at least one heteroatom;

5 B is




$R^6$ ,  $R^7$ ,  $R^8$ ,  $R^9$ ,  $R^{10}$  and  $R^{11}$ , are independently selected from hydrogen, fluorine, ( $C_{1-8}$ ) alkyl, hydroxy, hydroxy( $C_{1-6}$ ) alkyl, carboxy( $C_{0-6}$ )alkyl, ( $C_{1-6}$ )alkyloxy, aryl( $C_{0-6}$ )alkyloxy, ( $C_{3-8}$ )cycloalkyl, aryl( $C_{0-6}$ )alkyl, ( $C_{1-6}$ )alkylcarbonyloxy, ( $C_{0-6}$ )alkylamino( $C_{0-6}$ )alkyl and the like;  $R^{12}$  is selected from hydroxy, ( $C_{1-8}$ ) alkyloxy, aryl ( $C_{0-6}$ ) alkyl and the like;

10 An example of these compounds is shown in formula (II I)



vii) International publication No. WO 93/16697 and US patent No. 5,227,490 disclose the compounds of general formula (II m)




15  $R^1$  is chosen from hydrogen,  $C_{1-6}$  alkyl, aryl  $C_{4-10}$  alkyl, aryl, carboxy,  $C_{1-6}$  alkyloxy, carboxy  $C_{0-6}$  alkyl, carboxy  $C_{1-6}$  alkyloxy, hydroxy  $C_{0-6}$  alkyl,  $C_{1-4}$  alkylsulfonyl  $C_{0-6}$  alkyl,  $C_{0-4}$  alkylamino  $C_{0-6}$  alkyl, aryl  $C_{0-10}$  alkylamino  $C_{0-6}$  alkyl,  $C_{2-10}$  acylamino  $C_{0-6}$  alkyl,  $C_{1-4}$  carboalkoxy  $C_{0-6}$  alkyl halogen,  $R^2$  is independently chosen from hydrogen, halogen, hydroxy,  $C_{1-6}$  alkyl, wherein the alkyl group is substituted or unsubstituted,  $C_{1-6}$  alkyloxy, aryl  $C_{0-4}$  alkyl, aryl  $C_{0-6}$  alkyloxy and the like;  $R^3$  hydrogen,  $C_{1-6}$  alkyl, aryl  $C_{1-10}$  alkyl; Z is  $NR_4R^5$  or a 4 - 9 membered mono or bicyclic ring system containing 1, 2 or 3 heteroatoms selected from N, O or S and either unsubstituted or substituted; Y is  $C_{1-6}$  alkyl either unsubstituted or substituted,  $C_{4-8}$  cycloalkyl, aryl,  $-C(=O)NH-$ ,  $-NH(C=O)-$  and the like; X is O, SO,  $SO_2$ , S, CO,  $-NR^4CO-$ ,  $CONR^4-$ ,  $CH_2$  and the like;

20

25

An example of these compounds is shown in formula (II n)



Summary of the Invention

- 5 With an objective to develop novel compounds for reducing blood glucose, lipid levels, lowering cholesterol and reducing body weight with beneficial effects in the treatment and/or prophylaxis of diseases related to increased levels of lipids, atherosclerosis, coronary artery diseases, Syndrome-X, impaired glucose tolerance, insulin resistance, insulin resistance leading to type 2 diabetes and diabetic complications thereof,
- 10 for the treatment of diseases wherein insulin resistance is the pathophysiological mechanism and for the treatment of hypertension, with better efficacy, potency and lower toxicity, we focused our research to develop new compounds effective in the treatment of the above mentioned diseases. Effort in this direction has led to compounds having general formula (I). *C1 F ① and description in brief.*
- 15 The main objective of the present invention is therefore, to provide novel alkyl carboxylic acids, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them, or their mixtures.
- 20 Another objective of the present invention is to provide novel alkyl carboxylic acids, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures which may have agonist activity against PPAR $\alpha$  and/or PPAR $\gamma$ , and optionally inhibit HMG CoA reductase, in addition to having agonist activity against PPAR $\alpha$  and/or PPAR $\gamma$ .

Another objective of the present invention is to provide novel alkyl carboxylic acids, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutical compositions containing them or their mixtures having enhanced activities, without toxic effect or with reduced toxic effect.

Yet another objective of the present invention is to provide a process for the preparation of alkyl carboxylic acids of formula (I), their derivatives, their analogs, their

tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts and their pharmaceutically acceptable solvates.


Still another objective of the present invention is to provide pharmaceutical compositions containing compounds of the general formula (I), their analogs, their derivatives, their tautomers, their stereoisomers, their polymorphs, their salts, solvates or their mixtures in combination with suitable carriers, solvents, diluents and other media normally employed in preparing such compositions.

Another objective of the present invention is to provide novel intermediates, a process for their preparation and use of the intermediates in processes for preparation of alkyl carboxylic acids of formula (I), their derivatives, their analogs, their tautomers, their stereoisomers, their polymorphs, their salts and their pharmaceutically acceptable solvates and their use as antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds.

15


## Detailed Description of the Invention

## Novel alkyl carboxylic acids of compound of the general formula (I)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, alkanoyl, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, 20 alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen or NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, 25 heterocyclyl, heteroaryl or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms 30

selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, 5 aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, alkanoyloxy, aroyl, aralkanoyl, heterocycl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid or its derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents 10 hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



15 where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, 20 arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, 25 cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl,

aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives.

Suitable groups represented by R<sup>1</sup> may be selected from hydrogen, hydroxy, (C<sub>1</sub>-C<sub>6</sub>) alkyl groups such as methyl, ethyl, propyl and the like; (C<sub>1</sub>-C<sub>6</sub>) alkoxy such as methoxy, ethoxy, propoxy and the like; halogen atom such as fluorine, chlorine, bromine or iodine; (C<sub>2</sub>-C<sub>10</sub>) alkanoyl group such as acetyl, propanoyl, butanoyl, pentanoyl, benzoyl and the like; aralkyl such as benzyl, phenethyl and the like, which may be unsubstituted or substituted or R<sup>1</sup> together with R<sup>7</sup> forms a bond. The substituents are selected from halogen, hydroxy or alkyl groups.

Suitable groups represented by R<sup>2</sup> may be selected from hydrogen, hydroxy, halogen atom such as chlorine, bromine, iodine or fluorine; linear or branched (C<sub>1</sub>-C<sub>16</sub>) alkyl, preferably (C<sub>1</sub>-C<sub>12</sub>) alkyl group such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, pentyl, hexyl, heptyl, octyl and the like, the alkyl group may be substituted; (C<sub>1</sub>-C<sub>10</sub>) alkoxy such as methoxy, ethoxy, propyloxy, butyloxy, iso-propyloxy, hexyloxy, octyloxy and the like, which may be substituted; (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; (C<sub>3</sub>-C<sub>7</sub>) cycloalkyl (C<sub>1</sub>-C<sub>10</sub>) alkyl group such as cyclohexylmethyl, cyclohexylethyl, cyclohexylpropyl, cyclohexylbutyl and the like, which may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; aralkyl group such as benzyl, phenethyl and the like, the aralkyl group may be substituted; aryloxy group such as phenoxy, naphthoxy and the like, the aryloxy group may be substituted; aralkoxy group such as benzyloxy, phenethoxy, naphthylmethoxy, phenylpropyloxy and the like, the aralkoxy group may be substituted; heteroaryl group such as pyridyl, thienyl, pyrrolyl, furyl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl, pyridinemethyl, oxazolemethyl, oxazoleethyl and the like, the heteroaralkyl group may be substituted; heteroaryloxy and heteroaralkoxy, wherein heteroaryl and heteroaralkyl moieties are as defined earlier and may be substituted; heterocyclyl group such as aziridinyl, pyrrolidinyl, piperidinyl and the like, the heterocyclyl group may be substituted; linear or branched (C<sub>2</sub>-C<sub>16</sub>) alkanoyl group such as acetyl, propanoyl, butanoyl, benzoyl, octanoyl, decanoyl and the like, which may be substituted; alkanoyloxy group such as OOCMe, OOCEt, OOCPh and the like which may be substituted; alkoxyalkyl group such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like, the alkoxyalkyl group may be substituted; (C<sub>1</sub>-

$C_6$ )alkoxycarbonyl group such as methoxycarbonyl, ethoxycarbonyl and the like, the alkoxycarbonyl group may be substituted; aryloxycarbonyl such as phenoxy carbonyl, naphthoxy carbonyl and the like, the aryl group may be substituted; ( $C_1-C_6$ )alkylaminocarbonyl such as methylaminocarbonyl, ethylaminocarbonyl, 5 propylaminocarbonyl and the like, which may be substituted; arylaminocarbonyl such as PhNHCO, naphthylaminocarbonyl and the like, the aryl moiety may be substituted. The substituents may be selected from halogen, hydroxy, nitro or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, alkanoyl, alkanoyloxy, hydroxyalkyl, amino, 10 alkanoylamino, arylamino, aminoalkyl, aryloxy, aralkoxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, aryloxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives or sulfonic acid or its derivatives.

Suitable groups represented by  $R^3$  may be selected from hydrogen, linear or branched ( $C_1-C_{16}$ )alkyl, preferably ( $C_1-C_{12}$ )alkyl group such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, pentyl, hexyl, heptyl, octyl and the like, the alkyl group may be substituted; ( $C_3-C_7$ )cycloalkyl such as cyclopropyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; heteroaryl group such as pyridyl, thiophenyl, pyrrolyl, furyl and the like, the heteroaryl group may be substituted; heteroaralkyl group such as furanmethyl, pyridinemethyl, oxazolemethyl, oxazoleethyl and the like, the heteroaralkyl group may be substituted; aralkyl group such as benzyl, phenethyl and the like, the aralkyl group may be substituted; heterocyclyl group such as aziridinyl, pyrrolidinyl, piperidinyl and the like, the heterocyclyl group may be substituted. The substituents on  $R^3$  may be selected from halogen, hydroxy, nitro or unsubstituted or substituted groups selected from 15 alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, alkanoyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, arylamino, aminoalkyl, aryloxy, aralkoxy, alkoxycarbonyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives such as amides, like CONH<sub>2</sub>, CONHMe, CONMe<sub>2</sub>, CONHET<sub>2</sub>, CONHPh and the like, or esters such as 20 COOCH<sub>3</sub>, COOC<sub>2</sub>H<sub>5</sub>, COOC<sub>3</sub>H<sub>7</sub> and the like, the carboxylic acid derivatives may be substituted; sulfonic acid or its derivatives such as SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHMe, SO<sub>2</sub>NMe<sub>2</sub>, SO<sub>2</sub>NHCF<sub>3</sub> and the like, or sulfonates such as mesylate, tosylate, triflate, OSO<sub>2</sub>C<sub>2</sub>H<sub>5</sub> and the like, the sulfonic acid derivatives may be substituted.

Suitable groups represented by  $R^4$ ,  $R^5$  and  $R^6$  may be selected from hydrogen,

substituted or unsubstituted linear or branched (C<sub>1</sub>-C<sub>16</sub>) alkyl, preferably (C<sub>1</sub>-C<sub>12</sub>) alkyl group such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, pentyl, hexyl, heptyl, octyl and the like; hydroxy(C<sub>1</sub>-C<sub>6</sub>) alkyl such as hydroxymethyl, hydroxyethyl, hydroxybutyl and the like; aryl group such as phenyl, naphthyl and the like, the aryl group 5 may be substituted; aralkyl group such as benzyl, phenethyl, phenyl propyl, phenyl butyl, phenyl pentyl, phenyl hexyl, phenyl heptyl and the like, the aralkyl group may be substituted; carboxyalkyl group such as carboxymethyl, carboxyethyl, carboxypropyl and the like, which may be substituted; (C<sub>2</sub>-C<sub>6</sub>) alkanoyl group such as acetyl, propanoyl, butanoyl, pentanoyl, benzoyl and the like, which may be substituted; aralkanoyl group 10 such as phenyl acetyl, naphthyl acetyl and the like, which may be substituted; aroyl such as benzoyl, substituted benzoyl and the like; alkanoyloxy group such as OOCMe, OOCEt, OOCPh and the like which may be substituted; heterocyclyl group such as aziridinyl, pyrrolidinyl, piperidinyl and the like; heteroaryl group such as pyridyl, thienyl, pyrrolyl, furyl and the like; heteroaralkyl group such as furanmethyl, pyridinemethyl, 15 oxazolemethyl, oxazoleethyl and the like; (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid such as methyl carboxylic acid, ethyl carboxylic acid, propyl carboxylic acid, butyl carboxylic acid, hexy carboxylic acid, heptyl carboxylic acid and the like and their derivatives such as esters or amides. The substituents may be selected from halogen, hydroxy, nitro or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, 20 aryloxy, aralkoxy, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, hydroxyalkyl, amino, arylamino, aminoalkyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives such as amides, like CONH<sub>2</sub>, CONHMe, CONMe<sub>2</sub>, CONHEt, CONEt<sub>2</sub>, CONHPh and the like, or esters such as COOCH<sub>3</sub>, COOC<sub>2</sub>H<sub>5</sub>, COOC<sub>3</sub>H<sub>7</sub> and the like, the carboxylic acid derivatives may be substituted; sulfonic acid or 25 its derivatives such as SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHMe, SO<sub>2</sub>NMe<sub>2</sub>, SO<sub>2</sub>NHCF<sub>3</sub> and the like, or sulfonates such as mesylate, tosylate, triflate, OSO<sub>2</sub>C<sub>2</sub>H<sub>5</sub> and the like. The sulfonic acid derivatives may be substituted.

Suitable ring structures formed by R<sup>3</sup> and R<sup>4</sup> together may be selected from pyrrolidinyl, piperidinyl, morpholinyl, piperazinyl and the like.

30 Suitable groups represented by R<sup>7</sup> may be selected from hydrogen, hydroxy, halogen atom such as fluorine, chlorine, bromine or iodine; lower alkyl groups such as methyl, ethyl, propyl and the like; (C<sub>1</sub>-C<sub>3</sub>)alkoxy such as methoxy, ethoxy, propoxy and the like; substituted or unsubstituted aralkyl such as benzyl, phenethyl and the like or R<sup>7</sup> together with R<sup>1</sup> represents a bond. When the aralkyl group is substituted, the substituents

may be selected from hydroxy, halogen atom, nitro or amino groups.

Suitable groups represented by R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> may be selected from hydrogen, halogen atom such as fluorine, chlorine, bromine, or iodine; hydroxy, cyano, nitro, formyl; substituted or unsubstituted (C<sub>1</sub>-C<sub>12</sub>)alkyl group, especially, linear or branched (C<sub>1</sub>-C<sub>10</sub>)alkyl group, such as methyl, ethyl, *n*-propyl, *i*-propyl, *n*-butyl, *i*-butyl, *t*-butyl, *n*-pentyl, *i*-pentyl, hexyl, heptyl, octyl and the like; cyclo (C<sub>3</sub>-C<sub>6</sub>)alkyl group such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like, the cycloalkyl group may be substituted; (C<sub>1</sub>-C<sub>6</sub>)alkoxy such as methoxy, ethoxy, propyloxy, butyloxy, iso-propyloxy and the like, the alkoxy group may be substituted; cyclo(C<sub>3</sub>-C<sub>6</sub>)alkoxy group such as 5 cyclopropyloxy, cyclobutyloxy, cyclopentyloxy, cyclohexyloxy and the like, the cycloalkoxy group may be substituted; aryl group such as phenyl, naphthyl and the like, the aryl group may be substituted; aryloxy group such as phenoxy, naphthoxy and the like, the aryloxy group may be substituted; aralkyl such as benzyl, phenethyl, C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>, naphthylmethyl and the like, the aralkyl group may be substituted; 10 15 20 25 30 35 40 45 50 55 60 65 70 75 80 85 90 95 100 105 110 115 120 125 130 135 140 145 150 155 160 165 170 175 180 185 190 195 200 205 210 215 220 225 230 235 240 245 250 255 260 265 270 275 280 285 290 295 300 305 310 315 320 325 330 335 340 345 350 355 360 365 370 375 380 385 390 395 400 405 410 415 420 425 430 435 440 445 450 455 460 465 470 475 480 485 490 495 500 505 510 515 520 525 530 535 540 545 550 555 560 565 570 575 580 585 590 595 600 605 610 615 620 625 630 635 640 645 650 655 660 665 670 675 680 685 690 695 700 705 710 715 720 725 730 735 740 745 750 755 760 765 770 775 780 785 790 795 800 805 810 815 820 825 830 835 840 845 850 855 860 865 870 875 880 885 890 895 900 905 910 915 920 925 930 935 940 945 950 955 960 965 970 975 980 985 990 995 1000 1005 1010 1015 1020 1025 1030 1035 1040 1045 1050 1055 1060 1065 1070 1075 1080 1085 1090 1095 1100 1105 1110 1115 1120 1125 1130 1135 1140 1145 1150 1155 1160 1165 1170 1175 1180 1185 1190 1195 1200 1205 1210 1215 1220 1225 1230 1235 1240 1245 1250 1255 1260 1265 1270 1275 1280 1285 1290 1295 1300 1305 1310 1315 1320 1325 1330 1335 1340 1345 1350 1355 1360 1365 1370 1375 1380 1385 1390 1395 1400 1405 1410 1415 1420 1425 1430 1435 1440 1445 1450 1455 1460 1465 1470 1475 1480 1485 1490 1495 1500 1505 1510 1515 1520 1525 1530 1535 1540 1545 1550 1555 1560 1565 1570 1575 1580 1585 1590 1595 1600 1605 1610 1615 1620 1625 1630 1635 1640 1645 1650 1655 1660 1665 1670 1675 1680 1685 1690 1695 1700 1705 1710 1715 1720 1725 1730 1735 1740 1745 1750 1755 1760 1765 1770 1775 1780 1785 1790 1795 1800 1805 1810 1815 1820 1825 1830 1835 1840 1845 1850 1855 1860 1865 1870 1875 1880 1885 1890 1895 1900 1905 1910 1915 1920 1925 1930 1935 1940 1945 1950 1955 1960 1965 1970 1975 1980 1985 1990 1995 2000 2005 2010 2015 2020 2025 2030 2035 2040 2045 2050 2055 2060 2065 2070 2075 2080 2085 2090 2095 2100 2105 2110 2115 2120 2125 2130 2135 2140 2145 2150 2155 2160 2165 2170 2175 2180 2185 2190 2195 2200 2205 2210 2215 2220 2225 2230 2235 2240 2245 2250 2255 2260 2265 2270 2275 2280 2285 2290 2295 2300 2305 2310 2315 2320 2325 2330 2335 2340 2345 2350 2355 2360 2365 2370 2375 2380 2385 2390 2395 2400 2405 2410 2415 2420 2425 2430 2435 2440 2445 2450 2455 2460 2465 2470 2475 2480 2485 2490 2495 2500 2505 2510 2515 2520 2525 2530 2535 2540 2545 2550 2555 2560 2565 2570 2575 2580 2585 2590 2595 2600 2605 2610 2615 2620 2625 2630 2635 2640 2645 2650 2655 2660 2665 2670 2675 2680 2685 2690 2695 2700 2705 2710 2715 2720 2725 2730 2735 2740 2745 2750 2755 2760 2765 2770 2775 2780 2785 2790 2795 2800 2805 2810 2815 2820 2825 2830 2835 2840 2845 2850 2855 2860 2865 2870 2875 2880 2885 2890 2895 2900 2905 2910 2915 2920 2925 2930 2935 2940 2945 2950 2955 2960 2965 2970 2975 2980 2985 2990 2995 3000 3005 3010 3015 3020 3025 3030 3035 3040 3045 3050 3055 3060 3065 3070 3075 3080 3085 3090 3095 3100 3105 3110 3115 3120 3125 3130 3135 3140 3145 3150 3155 3160 3165 3170 3175 3180 3185 3190 3195 3200 3205 3210 3215 3220 3225 3230 3235 3240 3245 3250 3255 3260 3265 3270 3275 3280 3285 3290 3295 3300 3305 3310 3315 3320 3325 3330 3335 3340 3345 3350 3355 3360 3365 3370 3375 3380 3385 3390 3395 3400 3405 3410 3415 3420 3425 3430 3435 3440 3445 3450 3455 3460 3465 3470 3475 3480 3485 3490 3495 3500 3505 3510 3515 3520 3525 3530 3535 3540 3545 3550 3555 3560 3565 3570 3575 3580 3585 3590 3595 3600 3605 3610 3615 3620 3625 3630 3635 3640 3645 3650 3655 3660 3665 3670 3675 3680 3685 3690 3695 3700 3705 3710 3715 3720 3725 3730 3735 3740 3745 3750 3755 3760 3765 3770 3775 3780 3785 3790 3795 3800 3805 3810 3815 3820 3825 3830 3835 3840 3845 3850 3855 3860 3865 3870 3875 3880 3885 3890 3895 3900 3905 3910 3915 3920 3925 3930 3935 3940 3945 3950 3955 3960 3965 3970 3975 3980 3985 3990 3995 4000 4005 4010 4015 4020 4025 4030 4035 4040 4045 4050 4055 4060 4065 4070 4075 4080 4085 4090 4095 4100 4105 4110 4115 4120 4125 4130 4135 4140 4145 4150 4155 4160 4165 4170 4175 4180 4185 4190 4195 4200 4205 4210 4215 4220 4225 4230 4235 4240 4245 4250 4255 4260 4265 4270 4275 4280 4285 4290 4295 4300 4305 4310 4315 4320 4325 4330 4335 4340 4345 4350 4355 4360 4365 4370 4375 4380 4385 4390 4395 4400 4405 4410 4415 4420 4425 4430 4435 4440 4445 4450 4455 4460 4465 4470 4475 4480 4485 4490 4495 4500 4505 4510 4515 4520 4525 4530 4535 4540 4545 4550 4555 4560 4565 4570 4575 4580 4585 4590 4595 4600 4605 4610 4615 4620 4625 4630 4635 4640 4645 4650 4655 4660 4665 4670 4675 4680 4685 4690 4695 4700 4705 4710 4715 4720 4725 4730 4735 4740 4745 4750 4755 4760 4765 4770 4775 4780 4785 4790 4795 4800 4805 4810 4815 4820 4825 4830 4835 4840 4845 4850 4855 4860 4865 4870 4875 4880 4885 4890 4895 4900 4905 4910 4915 4920 4925 4930 4935 4940 4945 4950 4955 4960 4965 4970 4975 4980 4985 4990 4995 5000 5005 5010 5015 5020 5025 5030 5035 5040 5045 5050 5055 5060 5065 5070 5075 5080 5085 5090 5095 5100 5105 5110 5115 5120 5125 5130 5135 5140 5145 5150 5155 5160 5165 5170 5175 5180 5185 5190 5195 5200 5205 5210 5215 5220 5225 5230 5235 5240 5245 5250 5255 5260 5265 5270 5275 5280 5285 5290 5295 5300 5305 5310 5315 5320 5325 5330 5335 5340 5345 5350 5355 5360 5365 5370 5375 5380 5385 5390 5395 5400 5405 5410 5415 5420 5425 5430 5435 5440 5445 5450 5455 5460 5465 5470 5475 5480 5485 5490 5495 5500 5505 5510 5515 5520 5525 5530 5535 5540 5545 5550 5555 5560 5565 5570 5575 5580 5585 5590 5595 5600 5605 5610 5615 5620 5625 5630 5635 5640 5645 5650 5655 5660 5665 5670 5675 5680 5685 5690 5695 5700 5705 5710 5715 5720 5725 5730 5735 5740 5745 5750 5755 5760 5765 5770 5775 5780 5785 5790 5795 5800 5805 5810 5815 5820 5825 5830 5835 5840 5845 5850 5855 5860 5865 5870 5875 5880 5885 5890 5895 5900 5905 5910 5915 5920 5925 5930 5935 5940 5945 5950 5955 5960 5965 5970 5975 5980 5985 5990 5995 6000 6005 6010 6015 6020 6025 6030 6035 6040 6045 6050 6055 6060 6065 6070 6075 6080 6085 6090 6095 6100 6105 6110 6115 6120 6125 6130 6135 6140 6145 6150 6155 6160 6165 6170 6175 6180 6185 6190 6195 6200 6205 6210 6215 6220 6225 6230 6235 6240 6245 6250 6255 6260 6265 6270 6275 6280 6285 6290 6295 6300 6305 6310 6315 6320 6325 6330 6335 6340 6345 6350 6355 6360 6365 6370 6375 6380 6385 6390 6395 6400 6405 6410 6415 6420 6425 6430 6435 6440 6445 6450 6455 6460 6465 6470 6475 6480 6485 6490 6495 6500 6505 6510 6515 6520 6525 6530 6535 6540 6545 6550 6555 6560 6565 6570 6575 6580 6585 6590 6595 6600 6605 6610 6615 6620 6625 6630 6635 6640 6645 6650 6655 6660 6665 6670 6675 6680 6685 6690 6695 6700 6705 6710 6715 6720 6725 6730 6735 6740 6745 6750 6755 6760 6765 6770 6775 6780 6785 6790 6795 6800 6805 6810 6815 6820 6825 6830 6835 6840 6845 6850 6855 6860 6865 6870 6875 6880 6885 6890 6895 6900 6905 6910 6915 6920 6925 6930 6935 6940 6945 6950 6955 6960 6965 6970 6975 6980 6985 6990 6995 7000 7005 7010 7015 7020 7025 7030 7035 7040 7045 7050 7055 7060 7065 7070 7075 7080 7085 7090 7095 7100 7105 7110 7115 7120 7125 7130 7135 7140 7145 7150 7155 7160 7165 7170 7175 7180 7185 7190 7195 7200 7205 7210 7215 7220 7225 7230 7235 7240 7245 7250 7255 7260 7265 7270 7275 7280 7285 7290 7295 7300 7305 7310 7315 7320 7325 7330 7335 7340 7345 7350 7355 7360 7365 7370 7375 7380 7385 7390 7395 7400 7405 7410 7415 7420 7425 7430 7435 7440 7445 7450 7455 7460 7465 7470 7475 7480 7485 7490 7495 7500 7505 7510 7515 7520 7525 7530 7535 7540 7545 7550 7555 7560 7565 7570 7575 7580 7585 7590 7595 7600 7605 7610 7615 7620 7625 7630 7635 7640 7645 7650 7655 7660 7665 7670 7675 7680 7685 7690 7695 7700 7705 7710 7715 7720 7725 7730 7735 7740 7745 7750 7755 7760 7765 7770 7775 7780 7785 7790 7795 7800 7805 7810 7815 7820 7825 7830 7835 7840 7845 7850 7855 7860 7865 7870 7875 7880 7885 7890 7895 7900 7905 7910 7915 7920 7925 7930 7935 7940 7945 7950 7955 7960 7965 7970 7975 7980 7985 7990 7995 8000 8005 8010 8015 8020 8025 8030 8035 8040 8045 8050 8055 8060 8065 8070 8075 8080 8085 8090 8095 8100 8105 8110 8115 8120 8125 8130 8135 8140 8145 8150 8155 8160 8165 8170 8175 8180 8185 8190 8195 8200 8205 8210 8215 8220 8225 8230 8235 8240 8245 8250 8255 8260 8265 8270 8275 8280 8285 8290 8295 8300 8305 8310 8315 8320 8325 8330 8335 8340 8345 8350 8355 8360 8365 8370 8375 8380 8385 8390 8395 8400 8405 8410 8415 8420 8425 8430 8435 8440 8445 8450 8455 8460 8465 8470 8475 8480 8485 8490 8495 8500 8505 8510 8515 8520 8525 8530 8535 8540 8545 8550 8555 8560 8565 8570 8575 8580 8585 8590 8595 8600 8605 8610 8615 8620 8625 8630 8635 8640 8645 8650 8655 8660 8665 8670 8675 8680 8685 8690 8695 8700 8705 8710 8715 8720 8725 8730 8735 8740 8745 8750 8755 8760 8765 8770 8775 8780 8785 8790 8795 8800 8805 8810 8815 8820 8825 8830 8835 8840 8845 8850 8855 8860 8865 8870 8875 8880 8885 8890 8895 8900 8905 8910 8915 8920 8925 8930 8935 8940 8945 8950 8955 8960 8965 8970 8975 8980 8985 8990 8995 9000 9005 9010 9015 9020 9025 9030 9035 9040 9045 9050 9055 9060 9065 9070 9075 9080 9085 9090 9095 9100 9105 9110 9115 9120 9125 9130 9135 9140 9145 9150 9155 9160 9165 9170 9175 9180 9185 9190 9195 9200 9205 9210 9215 9220 9225 9230 9235 9240 9245 9250 9255 9260 9265 9270 9275 9280 9285 9290 9295 9300 9305 9310 9315 9320 9325 9330 9335 9340 9345 9350 9355 9360 9365 9370 9375 9380 9385 9390 9395 9400 9405 9410 9415 9420 9425 9430 9435 9440 9445 9450 9455 9460 9465 9470 9475 9480 9485 9490 9495 9500 9505 9510 9515 9520 9525 9530 9535 9540 9545 9550 9555 9560 9565 9570 9575 9580 9585 9590 9595 9600 9605 9610 9615 9620 9625 9630 9635 9640 9645 9650 9655 9660 9665 9670 9675 9680 9685 9690 9695 9700 9705 9710 9715 9720 9725 9730 9735 9740 9745 9750 9755 9760 9765 9770 9775 9780 9785 9790 9795 9800 9805 9810 9815 9820 9825 9830 9835 9840 9845 9850 9855 9860 9865 9870 9875 9880 9885 9890 9895 9900 9905 9910 9915 9920 9925 9930 9935 9940 9945 9950 9955 9960 9965 9970 9975 9980 9985 9990 9995 9999

substituted; aryloxycarbonyl group such as phenoxy carbonyl, naphthyl oxycarbonyl and the like, which may be substituted; aralkoxycarbonyl group such as benzyl oxycarbonyl, phenethyl oxycarbonyl, naphthyl methoxy carbonyl and the like, which may be substituted; alkoxy alkyl group such as methoxymethyl, ethoxymethyl, methoxyethyl, ethoxyethyl and the like, the alkoxy alkyl groups may be substituted; aryloxy alkyl group such as C<sub>6</sub>H<sub>5</sub>OCH<sub>2</sub>, C<sub>6</sub>H<sub>5</sub>OCH<sub>2</sub>CH<sub>2</sub>, naphthyl oxymethyl and the like, which may be substituted; aralkoxy alkyl group such as C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>OCH<sub>2</sub>, C<sub>6</sub>H<sub>5</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>2</sub> and the like, which may be substituted; thio(C<sub>1</sub>-C<sub>6</sub>)alkyl such as thiomethyl, thioethyl and the like, which may be substituted; (C<sub>1</sub>-C<sub>6</sub>)alkylthio such as methylthio, ethylthio and the like, which may be substituted; alkoxy carbonylamino group such as NHCOOC<sub>2</sub>H<sub>5</sub>, NHCOOCH<sub>3</sub> and the like, which may be substituted; aryloxycarbonylamino group such as NHCOOC<sub>6</sub>H<sub>5</sub>, N(CH<sub>3</sub>)COOC<sub>6</sub>H<sub>5</sub>, N(C<sub>2</sub>H<sub>5</sub>)COOC<sub>6</sub>H<sub>5</sub>, NHCOOC<sub>6</sub>H<sub>4</sub>CH<sub>3</sub>, NHCOOC<sub>6</sub>H<sub>4</sub>OCH<sub>3</sub> and the like, which may be substituted; aralkoxycarbonylamino group such as NHCOOCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, NHCOOCH<sub>2</sub>CH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, N(CH<sub>3</sub>)COOCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, N(C<sub>2</sub>H<sub>5</sub>)COOCH<sub>2</sub>C<sub>6</sub>H<sub>5</sub>, 15 NHCOOCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>CH<sub>3</sub>, NHCOOCH<sub>2</sub>C<sub>6</sub>H<sub>4</sub>OCH<sub>3</sub> and the like, which may be substituted; carboxylic acid or its derivatives such as amides, like CONH<sub>2</sub>, CONHMe, CONMe<sub>2</sub>, CONHEt, CONEt<sub>2</sub>, CONHPh and the like, or esters such as COOCH<sub>3</sub>, COOC<sub>2</sub>H<sub>5</sub>, COOC<sub>3</sub>H<sub>7</sub> and the like, the carboxylic acid derivatives may be substituted; sulfonic acid or its derivatives such as SO<sub>2</sub>NH<sub>2</sub>, SO<sub>2</sub>NHMe, SO<sub>2</sub>NMe<sub>2</sub>, SO<sub>2</sub>NHCF<sub>3</sub>, or sulfonates such as 20 mesylate, tosylate, triflate, OSO<sub>2</sub>C<sub>2</sub>H<sub>5</sub> and the like.

When the groups represented by R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are substituted, the substituent may be selected from halogen, hydroxy, nitro or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, hydroxyalkyl, amino, arylamino, 25 aminoalkyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or sulfonic acid.

Suitable groups represented by Ar may be selected from substituted or unsubstituted groups selected from divalent phenylene, naphthylene, pyrrolyl, pyridyl, quinolinyl, benzofuryl, dihydrobenzofuryl, benzopyranyl, dihydrobenzopyranyl, indolyl, 30 indolinyl, azaindolyl, azaindolinyl, pyrazolyl, benzothiazolyl, benzoxazolyl and the like. The substituents on the group represented by Ar may be selected from linear or branched optionally halogenated (C<sub>1</sub>-C<sub>6</sub>)alkyl, optionally halogenated (C<sub>1</sub>-C<sub>3</sub>)alkoxy, halogen, acyl, amino, acylamino, thio or carboxylic or sulfonic acids and their derivatives. The substituents are defined as they are for R<sup>8</sup>-R<sup>10</sup>.

It is more preferred that Ar represent substituted or unsubstituted divalent, phenylene, naphthylene, benzofuryl, pyrrolyl, indolyl, indolinyl, quinolinyl, azaindolyl, azaindolinyl, benzothiazolyl or benzoxazolyl groups.

Suitable n is an integer ranging from 1-4.

5 Suitable m and p are integers ranging from 0-4.

Pharmaceutically acceptable salts forming part of this invention include salts derived from inorganic bases such as Li, Na, K, Ca, Mg, Fe, Cu, Zn, Al, Mn; salts of organic bases such as N,N'-diacetylethylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, hydrabamine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, theobromine, glycinol, diethylamine, triethylamine, trimethylamine, tripropylamine, tromethamine, adamentyl amine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide, dicyclohexylamine, metformin, benzylamine, phenylethylamine, thiamine, aminopyrimidine, aminopyridine, purine, spermidine, and the like; chiral bases like alkylphenylamine, phenyl glycinol and the like, salts of natural amino acids such as glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, 20 methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine, phenylalanine; unnatural amino acids such as D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or substituted ammonium salts. Salts may include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates, ketoglutarates and the like. Pharmaceutically acceptable solvates may be hydrates or comprising other solvents of crystallization such as alcohols.

30 Particularly useful compounds according to the present invention include :


Ethyl 2-[4-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)methyl(heptyl)carboxamido]phenylsulfanyl]pentanoate or its salts in its single enantiomeric form or as a racemate;

2-[4-(5-Ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)methyl-

- (heptyl)carboxamido]phenylsulfanyl]pentanoic acid or its salts in its single enantiomeric form or as a racemate;
- Ethyl 2-ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate or its salts in its single enantiomeric form or as a  
5 racemate;
- Methyl 2-ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate or its salts in its single enantiomeric form or as a  
racemate;
- 2-Ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-  
10 yloxy)ethoxy}phenyl]propanoic acid or its salts in its single enantiomeric form or as a  
racemate;
- Ethyl 3-[4-{2-(1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-  
yloxy)ethoxy}phenyl]-2-ethoxypropanoate or its salts in its single enantiomeric form or as  
a racemate;
- 15 3-[4-{2-(1,5-Dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)-ethoxy}phenyl]-2-  
ethoxypropanoic acid or its salts in its single enantiomeric form or as a racemate;
- Ethyl 2-ethoxy-3-[4-{2-(1-methyl-5-phenyl-3-propyl-1*H*-pyrazolo-[4,3-d]pyrimidin-7-  
yloxy)ethoxy}phenyl]propanoate or its salts in its single enantiomeric form or as a  
racemate;
- 20 3-[4-{2-(1-Methyl-5-phenyl-3-propyl-1*H*-pyrazolo-[4,3-d]pyrimidin-7-  
yloxy)ethoxy}phenyl]-2-ethoxypropanoic acid or its salts in its single enantiomeric form  
or as a racemate;
- Ethyl 3-[4-{2-(5-cyclopropyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-  
yloxy)ethoxy}phenyl]-2-ethoxypropanoate or its salts in its single enantiomeric form or as  
25 a racemate;
- 3-[4-{2-(5-Cyclopropyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-  
yloxy)ethoxy}phenyl]-2-ethoxypropanoic acid or its salts in its single enantiomeric form  
or as a racemate;
- Ethyl 6-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl{4-(1-  
30 ethyloxycarbonylbutoxyl)phenyl}carboxamido]hexanoate or its salts in its single  
enantiomeric form or as a racemate;
- 6-[4-(1-Carboxybutoxy)phenyl(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-  
7-yloxymethyl)carboxamido]hexanoic acid or its salts in its single enantiomeric form or as  
a racemate;

- Ethyl 3-[4-{1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl(4-fluorobenzyl)carboxamido}phenyl]-2-ethoxypropanoate or its salts in its single enantiomeric form or as a racemate;
- 3-[4-{1,5-Dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl(4-fluorobenzyl)carboxamido}phenyl]-2-ethoxypropanoic acid or its salts in its single enantiomeric form or as a racemate;
- Ethyl 2-(4-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl{4-(4-ethyloxycarbonylphenyl)butyl}carboxamido]phenoxy)pentanoate or its salts in its single enantiomeric form or as a racemate;
- 10 2-[4-{4-(4-Carboxyphenyl)butyl}(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl)carboxamido]phenoxy]pentanoic acid or its salts in its single enantiomeric form or as a racemate;

According to a feature of the present invention, the compounds of general formula  
 15 (I) where Y represents  $\text{CHR}^7$  group,  $\text{R}^7$  and  $\text{R}^1$  together represent a bond, G is O or S; Z represents oxygen atom; and all other symbols are as defined earlier, can be prepared by any of the following routes shown in Scheme-I below.




## Scheme - I

Route 1: The reaction of a compound of the general formula (IIIa) where all symbols are as defined earlier with a compound of formula (IIIb) where R<sup>11</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl, R represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and all other symbols are as defined earlier to yield compound of general formula (I) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined above may be carried out in the presence of a base such as alkali metal hydrides like NaH or KH; organolithiums such as LDA, TMEDA and the like; alkoxides such as NaOMe, NaOEt, t-BuOK<sup>+</sup> and the like or mixtures thereof. The reaction may be carried out in the presence of solvents such as THF, dioxane, DMF, DMSO, DME and the like or mixtures thereof. HMPA may be used as cosolvent. The reaction temperature may range from -78 °C to 50 °C, preferably at a temperature in the range of -10 °C to 30 °C. The reaction is more effective under anhydrous conditions. The compound of general formula (IIIb) may be prepared by Arbuzov reaction.

Alternatively, the compound of formula (I) may be prepared by reacting the compound of formula (IIIa) where all symbols are as defined earlier with Wittig reagents such as HalPh<sub>3</sub>P<sup>+</sup>CH<sub>2</sub>-(OR)CO<sub>2</sub>R<sup>3</sup> under similar reaction conditions as described above.

20

Route 2: The compound of general formula (IIIc) where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below : ??  
Is it  
well



wherein Q represents O or S and all other symbols are as defined earlier, because of the keto-enol tautomerism, enol form reacts with compound of general formula (IIId) where L<sup>1</sup> is a leaving group such as halogen atom, p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like; R<sup>1</sup> and R<sup>7</sup> together represent a bond and all other

symbols are as defined earlier to produce compound of formula (I) where all symbols are as defined above. The reaction may be carried out in the presence of solvents such as DMSO, DMF, DME, THF, dioxane, ether and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, argon, He and the like. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates such as sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride or potassium hydride; organometallic bases like n-butyl lithium; alkali metal amides like sodamide, organic base like triethyl amine or mixtures thereof. The amount of base may range from 1 to 5 equivalents, based on the amount of the compound of formula (IIIc), preferably the amount of base ranges from 1 to 3 equivalents. Phase transfer catalysts such as tetraalkylammonium halide or hydroxide may be added. Additives such as alkali metal halides such as LiBr may be added. The reaction may be carried out at a temperature in the range of 0 °C – 150 °C, preferably at a temperature in the range of 15 °C – 100 °C. The duration of the reaction may range from 0.25 to 72 hours, preferably from 0.25 to 24 hours.

Route 3: The reaction of a compound of the general formula (IIIa) where all symbols are as defined earlier, with a compound of formula (IIIe) where R<sup>1</sup> represents hydrogen atom and all other symbols are as defined earlier may be carried out in the presence of a base. The nature of the base is not critical. Any base normally employed for aldol condensation reaction may be employed; bases like metal hydride such as NaH, KH, metal alkoxides such as NaOMe, t-BuOK<sup>+</sup>, NaOEt, metal amides such as LiNH<sub>2</sub>, LiN(ipr)<sub>2</sub> may be used. Aprotic solvents such as THF, ether, dioxane may be used. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, Ar, or He and the reaction is more effective under anhydrous conditions. Temperature in the range of -80 °C to 35 °C may be used. The β-hydroxy product initially produced may be dehydrated under conventional dehydration conditions such as treating with p-TSA in solvents such as benzene or toluene. The nature of solvent and dehydrating agent is not critical. Temperature in the range of 20 °C to reflux temperature of the solvent used may be employed, preferably at reflux temperature of the solvent by continuous removal of water using a Dean-Stark water separator.

Route 4: The reaction of compound of formula (IIIf) where L<sup>1</sup> represents a leaving group

such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like; and all other symbols are as defined earlier with compound of formula (III $f$ ) where R<sup>1</sup> and R<sup>7</sup> together represent a bond and all other symbols are as defined earlier to produce a compound of the formula (I) defined above may be carried out in the presence 5 of aprotic solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of a base such as K<sub>2</sub>CO<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub> or NaH or mixtures thereof. Acetone may be used as solvent when Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub> is used as a base. The reaction temperature may range from 0 °C 10 – 120 °C, preferably at a temperature in the range of 30 °C – 100 °C. The duration of the reaction may range from 1 to 48 hours, preferably from 2 to 12 hours. The compound of formula (III $f$ ) can be prepared according to a known procedure by Wittig Horner reaction between the hydroxy protected aryl aldehyde such as benzyloxyaryl aldehyde and compound of formula (III $b$ ), followed by deprotection.

15


Route 5: The reaction of compound of general formula (III $h$ ) where A is as defined earlier and Hal represents halogen atom such as chlorine, bromine, fluorine or iodine, with compound of formula (III $i$ ) where R<sup>1</sup> and R<sup>7</sup> together represent a bond and all other symbols are as defined earlier to yield the compound of general formula (I) where all 20 symbols are as defined above may be carried out in the presence of a base such as alkali metal hydrides like NaH or KH; organolithiums such as TMEDA, LDA and the like; alkoxides such as NaOMe, NaOEt, *t*-BuOK<sup>+</sup> and the like or mixtures thereof. The reaction may be carried out in the presence of solvents such as THF, dioxane, DMF, DMSO, DME and the like or mixtures thereof. The reaction temperature may range from -78 °C to 120 °C, 25 preferably at a temperature in the range of -10 °C to 80 °C. The reaction is more effective under anhydrous conditions.

Route 6: The reaction of compound of general formula (III $j$ ) where all symbols are as defined earlier with a compound of general formula (III $f$ ) where R<sup>1</sup> and R<sup>7</sup> together 30 represent a bond and all other symbols are as defined earlier may be carried out using suitable coupling agents such as EDCI, dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh<sub>3</sub> / DEAD or DIAD and the like. The reaction may be carried out in the presence of solvents such as THF, DME, CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, toluene, acetonitrile, carbon tetrachloride and the like. The inert atmosphere may be maintained by

using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of DMAP, HOBr and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1 equivalents. The reaction temperature may be in the range of -20 °C to 100 °C, preferably at a temperature in the range of 0 °C to 80 °C. The duration of the 5 reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours. The above condensation may also be made using mixed anhydride methodology.

Route 7: The reaction of a compound of formula (IIIk) where all symbols are as defined earlier with a compound of formula (IIIl) where R represents substituted or unsubstituted 10 groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and where R<sup>3</sup> is as defined earlier excluding hydrogen to yield compound of general formula (I) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined above may be carried out neat in the presence of a base such as alkali metal hydrides like NaH, KH or 15 organolithiums like CH<sub>3</sub>Li, BuLi, TMEDA, LDA and the like or alkoxides such as NaOMe, NaOEt, t-BuOK<sup>+</sup> and the like or mixtures thereof. The reaction may be carried out in the presence of aprotic solvents such as THF, dioxane, DMF, DMSO, DME and the like or mixtures thereof. HMPA may be used as cosolvent. The reaction temperature may range from -78 °C to 100 °C, preferably at a temperature in the range of -10 °C to 50 °C.  
20 The reaction is more effective under anhydrous condition.


Route 8: The compound of general formula (IIIc) where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



25 wherein Q represents O or S and all other symbols are as defined earlier, because of the

keto-enol tautomerism, enol form reacts with compound of general formula (III $m$ ) which represents compound of formula (III $i$ ) when G represents oxygen, R<sup>1</sup> and R<sup>7</sup> together represent a bond and all other symbols are as defined earlier to produce compound of formula (I) where all symbols are as defined above. The reaction may be carried out using 5 suitable coupling agents such as EDCI, dicyclohexyl urea, triarylphosphine/dialkylazadicarboxylate such as PPh<sub>3</sub> / DEAD or DIAD and the like. The reaction may be carried out in the presence of solvents such as THF, DME, CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, toluene, acetonitrile, carbon tetrachloride and the like. The inert atmosphere may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the 10 presence of DMAP, HOEt and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1 equivalents. The reaction temperature may be in the range of -20 °C to 100 °C, preferably at a temperature in the range of 0 °C to 80 °C. The duration of the reaction may range from 0.5 to 120 hours, preferably from 6 to 24 hours.

15 In yet another embodiment of the present invention, the compounds of general formula (I) where Y represent CHR<sup>7</sup> group, wherein R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group; R<sup>1</sup> represents hydrogen atom, hydroxy, alkoxy, halogen, lower alkyl, substituted or unsubstituted aralkyl group; X, R<sup>2</sup>, R<sup>3</sup>, n, Ar and A are as defined earlier, G is O or S and Z represents oxygen 20 atom can be prepared by one or more of the processes shown in Scheme-II below :



**Scheme – II**

Route 9: The reduction of compound of the formula (IVa) which represents a compound of formula (I) where R<sup>1</sup> and R<sup>7</sup> together represent a bond and Z represents oxygen atom and all other symbols are as defined earlier, obtained as described earlier (Scheme-I), to 5 yield a compound of the general formula (I) where R<sup>1</sup> and R<sup>5</sup> each represent hydrogen atom and all symbols are as defined earlier, may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd(OH)<sub>2</sub>/C, Pd/C, Rh/C, Pt/C, Ra-Ni, and the like. Mixtures of catalysts may be used. The reaction may be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate, alcohol such as methanol, ethanol and 10 the like. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be preferably 5 - 10 % Pd/C and the amount of catalyst used may range from 5 - 100 % w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium in alcohol or sodium amalgam in alcohol, preferably methanol. The reaction temperature may range from 20 °C - 120 °C, preferably at a temperature in the 15 range of 25 °C – 100 °C. The duration of the reaction may range from 1 to 48 hours, preferably from 2 to 6 hours. The hydrogenation may be carried out in the presence of metal catalysts containing chiral ligands to obtain a compound of formula (I) in optically active form. The metal catalyst may contain Rhodium, Ruthenium, Indium and the like. The chiral ligands may preferably be chiral phosphines such as optically pure enantiomers 20 of 2,3-bis(diphenylphosphino)butane, 1,2-bis(diphenylphosphino) ethane, 1,2-bis(2-methoxyphenyl phenylphosphino)ethane, 2,3-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane and the like. Any suitable chiral catalyst may be employed which would give required optical purity of the product (I) (Ref: Principles of Asymmetric Synthesis, Tetrahedron Series Vol 14, pp311-316, Ed. Baldwin J. E.).

25

Route 10: The reaction of compound of formula (IVb) where L<sup>1</sup> is a leaving group such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like, R<sup>3</sup> is as defined earlier excluding hydrogen and all other symbols are as defined earlier with an alcohol of general formula (IVc), where R represents substituted or 30 unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and all other symbols are as defined earlier to yield compound of general formula (I) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all symbols earlier may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The

reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of a base such as KOH, NaOH, NaOMe, NaOEt, t-BuOK<sup>+</sup> or NaH or mixtures thereof. Phase transfer catalysts such as tetraalkyl ammonium halides or bisulphates or hydroxides may 5 be employed. The reaction temperature may range from 20 °C - 120 °C, preferably at a temperature in the range of 30 °C – 100 °C. The duration of the reaction may range from 1 to 24 hours, preferably from 2 to 6 hours.

10 Route 11: The reaction of compound of formula (IIIg) defined earlier with compound of formula (IIIf) where all symbols are as defined earlier to produce a compound of the formula (I) defined above, may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that is maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of a base such as Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, NaH and 15 the like or mixtures thereof. Acetone may be used as a solvent when Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub> is used as a base. The reaction temperature may range from 20 °C - 120 °C, preferably at a temperature in the range of 30 °C - 80 °C. The duration of the reaction may range from 1 to 48 hours, preferably from 2 to 12 hours. The compound of formula (IIIf) may be prepared by using Wittig Horner reaction between the protected hydroxyaryl aldehyde and 20 compound of formula (IIIb) followed by reduction of the double bond and deprotection.


25 Route 12: The reaction of compound of general formula (IIIj) defined earlier with a compound of general formula (IIIf) where all symbols are as defined above may be carried out using suitable coupling agents such as EDCI, dicyclohexyl urea, triarylphosphine/ dialkylazadicarboxylate such as PPh<sub>3</sub> / DEAD or DIAD and the like. The reaction may be carried out in the presence of solvents such as THF, DME, CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, toluene, acetonitrile, carbon tetrachloride and the like. The inert atmosphere may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of DMAP, HOBt and they may be used in the range of 0.05 to 2 equivalents, 30 preferably 0.25 to 1 equivalents. The reaction temperature may be in the range of -20 °C to 100 °C, preferably at a temperature in the range of 0 °C to 80 °C. The duration of the reaction may range from 0.5 to 24 hours, preferably from 6 to 12 hours. The above condensation may also be made using mixed anhydride methodology.


Route 13: The reaction of compound of formula (IVd), which represents a compound of formula (I), when R<sup>2</sup> represents hydroxy group and all other symbols are as defined above with a compound of formula (IVe) where R represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and L<sup>2</sup> is a halogen atom to yield compound of general formula (I) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all symbols are as defined earlier may be carried out in the presence of solvents such as THF, DMF, DMSO, DME and the like. The inert atmosphere may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of a base such as KOH, NaOH, NaOMe, t-BuO<sup>-</sup>K<sup>+</sup>, NaH, KH and the like. Phase transfer catalyst such as tetraalkyl ammonium halides or bisulphates or hydroxides may be employed. The reaction temperature may range from 20 °C to 150 °C, preferably at a temperature in the range of 25 °C to 100 °C. The duration of the reaction may range from 1 to 24 hours, preferably from 2 to 6 hours.

15

Route 14: The reaction of compound of general formula (IIIh) where Hal represents halogen atom and A is as defined earlier with the compound of formula (IIIi) where all other symbols are as defined earlier to yield the compound of general formula (I) where all symbols are as defined above may be carried out in the presence of a base such as alkali metal hydrides like NaH or KH; organolithiums such as TMEDA, LDA and the like; alkoxides such as NaOMe, NaOEt, t-BuO<sup>-</sup>K<sup>+</sup> and the like or mixtures thereof. The reaction may be carried out in the presence of solvents such as THF, dioxane, DMF, DMSO, DME and the like or mixtures thereof. The reaction temperature may range from -78 °C to 120 °C, preferably at a temperature in the range of -10 °C to 80 °C. The reaction is more effective under anhydrous conditions.

Route 15: The compound of general formula (IIIC) where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :






wherein Q represents O or S and all other symbols are as defined earlier, because of the keto-enol tautomerism, enol form reacts with reacts with compound of general formula (III<sup>m</sup>) which represents compound of formula (III<sup>i</sup>) when G is oxygen and all other 5 symbols are as defined earlier to produce compound of formula (I) where all symbols are as defined above. The reaction may be carried out using suitable coupling agents such as EDCI, dicyclohexyl urea, triarylphosphine/ dialkylazadicarboxylate such as PPh<sub>3</sub> / DEAD or DIAD and the like. The reaction may be carried out in the presence of solvents such as THF, DME, CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, toluene, acetonitrile, carbon tetrachloride and the like. The 10 inert atmosphere may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of DMAP, HOBt and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1 equivalents. The reaction temperature may be in the range of 0 °C to 100 °C, preferably at a temperature in the range of 20 °C to 80 °C. The duration of the reaction may range from 0.5 to 120 hours, 15 preferably from 6 to 24 hours.

Route 16: The reaction of a compound of the general formula (III<sup>a</sup>) as defined above with a compound of formula (III<sup>e</sup>) where R<sup>1</sup> represents hydrogen atom and all other symbols are as defined earlier may be carried out in the presence of base. The base is not critical. 20 Any base normally employed for aldol condensation reaction may be employed, metal hydride such as NaH or KH; metal alkoxides such as NaOMe, t-BuOK<sup>t</sup> or NaOEt; metal amides such as LiNH<sub>2</sub>, LiN(iPr)<sub>2</sub>. Aprotic solvent such as THF may be used. Inert atmosphere may be employed such as N<sub>2</sub> or argon or He and the reaction is more effective under anhydrous conditions. Temperature in the range of -80 °C to 25 °C may be used. 25 The β-hydroxy aldol product may be dehydroxylated using conventional methods, conveniently by ionic hydrogenation technique such as by treating with a trialkyl silane in the presence of an acid such as trifluoroacetic acid. Solvent such as CH<sub>2</sub>Cl<sub>2</sub> may be used. Favorably, reaction proceeds at 25 °C. Higher temperature may be employed if the reaction is slow.

Route 17: The compound of general formula (IIIc) where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




wherein Q represents O or S and all other symbols are as defined earlier, because of the keto-enol tautomerism, enol form reacts with reacts with compound of general formula (IIId) where L<sup>1</sup> is a leaving group such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like; all other symbols are as defined earlier to produce compound of formula (I) where all symbols are as defined above. The reaction may be carried out in the presence of solvents such as DMSO, DMF, DME, THF, dioxane, ether and the like or a combination thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide, potassium hydroxide; alkali metal carbonates like sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride or potassium hydride; organometallic bases like LDA, TMEDA; alkali metal amides like sodamide or mixtures thereof. The amount of base may range from 1 to 5 equivalents, based on the amount of the compound of formula (IIIc), preferably the amount of base ranges from 1 to 3 equivalents. Additives such as alkali metal halides such as LiBr may be added. The reaction may be carried out at a temperature in the range of 0 °C to 150 °C, preferably at a temperature in the range of 15 °C to 100 °C. The duration of the reaction may range from 0.25 to 48 hours, preferably from 0.25 to 24 hours.

Route 18: The conversion of compound of formula (IVf) where all symbols are as defined earlier to a compound of formula (I) may be carried out either in the presence of base or acid and the selection of base or acid is not critical. Any base normally used for hydrolysis of nitrile to acid may be employed, metal hydroxides such as NaOH or KOH in an

aqueous solvent or any acid normally used for hydrolysis of nitrile to ester may be employed such as HCl in an excess of alcohol such as methanol, ethanol, propanol etc. The reaction may be carried out at a temperature in the range of 0 °C to reflux temperature of the solvent used, preferably at a temperature in the range of 25 °C to reflux temperature of the solvent used. The duration of the reaction may range from 0.25 to 48 hrs.

5      Route 19: The reaction of a compound of formula (IVg) where R<sup>3</sup> is as defined earlier excluding hydrogen and all other symbols are as defined earlier with a compound of formula (IVc) where R represents substituted or unsubstituted groups selected from alkyl,  
10     aryl, aralkyl, heteroaryl or heteroaralkyl and L<sup>2</sup> is a halogen atom to yield compound of general formula (I) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined earlier (by a rhodium carbenoid mediated insertion reaction) may be carried out in the presence of rhodium (II) salts such as rhodium (II) acetate. The reaction may be  
15     carried out in the presence of solvents such as benzene, toluene, dioxane, ether, THF and the like or a combination thereof or when practicable in the presence of ROH as solvent at any temperature providing a convenient rate of formation of the required product, generally at an elevated temperature, such as reflux temperature of the solvent. The inert atmosphere may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The  
20     duration of the reaction may range from 0.5 to 24 h, preferably from 0.5 to 6 h.


In yet another embodiment of the present invention the compound of general formula (I), where Y represents O or S or NR<sup>6</sup> group where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, 25     carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups; X represents NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO- where m and p are as defined earlier; G is O or S and Z represents oxygen atom; R<sup>1</sup>, R<sup>2</sup>, R<sup>3</sup>, A, n and Ar are as defined earlier, can be prepared by any of the following routes shown in Scheme-III below.



Scheme-III

Route 20: The reaction of compound of formula (Va) where all symbols are as defined earlier with compound of formula (Vb) where L<sup>1</sup> is a leaving group such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like, and all other symbols are as defined earlier to produce a compound of the formula (I) defined above may be carried out in the presence of aprotic solvents such as THF, DMF, DMSO, DME and the like; organic base like triethyl amine, lutidine, collidine and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of a base such as K<sub>2</sub>CO<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub>, NaH, KH and the like or mixtures thereof. Acetone may be used as solvent when Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub> is used as a base. The reaction temperature may range from 0 °C – 120 °C, preferably at a temperature in the range of 25 °C – 100 °C. The duration of the reaction may range from 1 to 96 hours, preferably from 2 to 24 hours.

Route 21: The reaction of a compound of general formula (IIIc) where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



wherein Q represents O or S and all other symbols are as defined earlier, because of the keto-enol tautomerism, enol form reacts with reacts with compound of general formula (III<sup>d</sup>) where L<sup>1</sup> is a leaving group such as halogen atom, *p*-toluenesulfonate, 5 methanesulfonate, trifluoromethanesulfonate and the like, and all other symbols are as defined earlier to produce a compound of general formula (I) where all symbols are as defined above may be carried out in the presence of solvents such as DMSO, DMF, DME, THF, dioxane, ether, acetone and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, argon, 10 He and the like. The reaction may be effected in the presence of a base such as alkalis like sodium hydroxide or potassium hydroxide; alkali metal carbonates such as sodium carbonate or potassium carbonate; alkali metal hydrides such as sodium hydride or potassium hydride; organometallic bases like n-BuLi, TMEDA (N,N,N',N'-tetramethylethylenediamine), LDA; alkali metal amides like sodamide, organic base like 15 triethyl amine, lutidine, collidine or mixtures thereof. The amount of base may range from 1 to 5 equivalents, based on the amount of the compound of formula (III<sup>c</sup>), preferably the amount of base ranges from 1 to 3 equivalents. Phase transfer catalysts such as tetraalkylammonium halide or sulphonates or hydroxide may be added. Additives such as alkali metal halides like LiBr may be added. The reaction may be carried out at a 20 temperature in the range of 0 °C – 150 °C, preferably at a temperature in the range of 15 °C – 100 °C. The duration of the reaction may range from 0.25 to 72 hours, preferably from 0.25 to 24 hours.

Route 22: The reaction of compound of formula (Vc) where L<sup>1</sup> represents a leaving group 25 such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like, and all other symbols are as defined earlier with compound of formula (III<sup>f</sup>)

where all symbols are as defined earlier to produce a compound of the formula (I) defined above may be carried out in the presence of aprotic solvents such as THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like.


- 5 The reaction may be effected in the presence of a base such as K<sub>2</sub>CO<sub>3</sub>, Na<sub>2</sub>CO<sub>3</sub> or NaH, KH, triethyl amine and the like or mixtures thereof. Acetone may be used as solvent when Na<sub>2</sub>CO<sub>3</sub> or K<sub>2</sub>CO<sub>3</sub> is used as a base. The reaction temperature may range from 0 °C – 120 °C, preferably at a temperature in the range of 25 °C – 100 °C. The duration of the reaction may range from 1 to 72 hours, preferably from 2 to 24 hours.

10

- Route 23: The reaction of compound of general formula (IIIh) where A is as defined earlier and Hal represents halogen atom with the compound of formula (IIIi) where all symbols are as defined earlier to yield compound of general formula (I) where all symbols are as defined above may be carried out in the presence of a base such as alkali metal hydrides like NaH or KH; organolithiums such as TMEDA, LDA and the like; alkoxides such as NaOMe, NaOEt, *t*-BuOK<sup>+</sup> and the like or mixtures thereof. The reaction may be carried out in the presence of solvents such as THF, dioxane, DMF, DMSO, DME and the like or mixtures thereof. The reaction temperature may range from -78 °C to 120 °C, preferably at a temperature in the range of -10 °C to 80 °C. The reaction is more effective under anhydrous conditions.

- 15  
20  
25  
30  
35  
40  
45  
50  
55  
60  
65  
70  
75  
80  
85  
90  
95  
100  
105  
110  
115  
120  
125  
130  
135  
140  
145  
150  
155  
160  
165  
170  
175  
180  
185  
190  
195  
200  
205  
210  
215  
220  
225  
230  
235  
240  
245  
250  
255  
260  
265  
270  
275  
280  
285  
290  
295  
300  
305  
310  
315  
320  
325  
330  
335  
340  
345  
350  
355  
360  
365  
370  
375  
380  
385  
390  
395  
400  
405  
410  
415  
420  
425  
430  
435  
440  
445  
450  
455  
460  
465  
470  
475  
480  
485  
490  
495  
500  
505  
510  
515  
520  
525  
530  
535  
540  
545  
550  
555  
560  
565  
570  
575  
580  
585  
590  
595  
600  
605  
610  
615  
620  
625  
630  
635  
640  
645  
650  
655  
660  
665  
670  
675  
680  
685  
690  
695  
700  
705  
710  
715  
720  
725  
730  
735  
740  
745  
750  
755  
760  
765  
770  
775  
780  
785  
790  
795  
800  
805  
810  
815  
820  
825  
830  
835  
840  
845  
850  
855  
860  
865  
870  
875  
880  
885  
890  
895  
900  
905  
910  
915  
920  
925  
930  
935  
940  
945  
950  
955  
960  
965  
970  
975  
980  
985  
990  
995  
1000  
1005  
1010  
1015  
1020  
1025  
1030  
1035  
1040  
1045  
1050  
1055  
1060  
1065  
1070  
1075  
1080  
1085  
1090  
1095  
1100  
1105  
1110  
1115  
1120  
1125  
1130  
1135  
1140  
1145  
1150  
1155  
1160  
1165  
1170  
1175  
1180  
1185  
1190  
1195  
1200  
1205  
1210  
1215  
1220  
1225  
1230  
1235  
1240  
1245  
1250  
1255  
1260  
1265  
1270  
1275  
1280  
1285  
1290  
1295  
1300  
1305  
1310  
1315  
1320  
1325  
1330  
1335  
1340  
1345  
1350  
1355  
1360  
1365  
1370  
1375  
1380  
1385  
1390  
1395  
1400  
1405  
1410  
1415  
1420  
1425  
1430  
1435  
1440  
1445  
1450  
1455  
1460  
1465  
1470  
1475  
1480  
1485  
1490  
1495  
1500  
1505  
1510  
1515  
1520  
1525  
1530  
1535  
1540  
1545  
1550  
1555  
1560  
1565  
1570  
1575  
1580  
1585  
1590  
1595  
1600  
1605  
1610  
1615  
1620  
1625  
1630  
1635  
1640  
1645  
1650  
1655  
1660  
1665  
1670  
1675  
1680  
1685  
1690  
1695  
1700  
1705  
1710  
1715  
1720  
1725  
1730  
1735  
1740  
1745  
1750  
1755  
1760  
1765  
1770  
1775  
1780  
1785  
1790  
1795  
1800  
1805  
1810  
1815  
1820  
1825  
1830  
1835  
1840  
1845  
1850  
1855  
1860  
1865  
1870  
1875  
1880  
1885  
1890  
1895  
1900  
1905  
1910  
1915  
1920  
1925  
1930  
1935  
1940  
1945  
1950  
1955  
1960  
1965  
1970  
1975  
1980  
1985  
1990  
1995  
2000  
2005  
2010  
2015  
2020  
2025  
2030  
2035  
2040  
2045  
2050  
2055  
2060  
2065  
2070  
2075  
2080  
2085  
2090  
2095  
2100  
2105  
2110  
2115  
2120  
2125  
2130  
2135  
2140  
2145  
2150  
2155  
2160  
2165  
2170  
2175  
2180  
2185  
2190  
2195  
2200  
2205  
2210  
2215  
2220  
2225  
2230  
2235  
2240  
2245  
2250  
2255  
2260  
2265  
2270  
2275  
2280  
2285  
2290  
2295  
2300  
2305  
2310  
2315  
2320  
2325  
2330  
2335  
2340  
2345  
2350  
2355  
2360  
2365  
2370  
2375  
2380  
2385  
2390  
2395  
2400  
2405  
2410  
2415  
2420  
2425  
2430  
2435  
2440  
2445  
2450  
2455  
2460  
2465  
2470  
2475  
2480  
2485  
2490  
2495  
2500  
2505  
2510  
2515  
2520  
2525  
2530  
2535  
2540  
2545  
2550  
2555  
2560  
2565  
2570  
2575  
2580  
2585  
2590  
2595  
2600  
2605  
2610  
2615  
2620  
2625  
2630  
2635  
2640  
2645  
2650  
2655  
2660  
2665  
2670  
2675  
2680  
2685  
2690  
2695  
2700  
2705  
2710  
2715  
2720  
2725  
2730  
2735  
2740  
2745  
2750  
2755  
2760  
2765  
2770  
2775  
2780  
2785  
2790  
2795  
2800  
2805  
2810  
2815  
2820  
2825  
2830  
2835  
2840  
2845  
2850  
2855  
2860  
2865  
2870  
2875  
2880  
2885  
2890  
2895  
2900  
2905  
2910  
2915  
2920  
2925  
2930  
2935  
2940  
2945  
2950  
2955  
2960  
2965  
2970  
2975  
2980  
2985  
2990  
2995  
3000  
3005  
3010  
3015  
3020  
3025  
3030  
3035  
3040  
3045  
3050  
3055  
3060  
3065  
3070  
3075  
3080  
3085  
3090  
3095  
3100  
3105  
3110  
3115  
3120  
3125  
3130  
3135  
3140  
3145  
3150  
3155  
3160  
3165  
3170  
3175  
3180  
3185  
3190  
3195  
3200  
3205  
3210  
3215  
3220  
3225  
3230  
3235  
3240  
3245  
3250  
3255  
3260  
3265  
3270  
3275  
3280  
3285  
3290  
3295  
3300  
3305  
3310  
3315  
3320  
3325  
3330  
3335  
3340  
3345  
3350  
3355  
3360  
3365  
3370  
3375  
3380  
3385  
3390  
3395  
3400  
3405  
3410  
3415  
3420  
3425  
3430  
3435  
3440  
3445  
3450  
3455  
3460  
3465  
3470  
3475  
3480  
3485  
3490  
3495  
3500  
3505  
3510  
3515  
3520  
3525  
3530  
3535  
3540  
3545  
3550  
3555  
3560  
3565  
3570  
3575  
3580  
3585  
3590  
3595  
3600  
3605  
3610  
3615  
3620  
3625  
3630  
3635  
3640  
3645  
3650  
3655  
3660  
3665  
3670  
3675  
3680  
3685  
3690  
3695  
3700  
3705  
3710  
3715  
3720  
3725  
3730  
3735  
3740  
3745  
3750  
3755  
3760  
3765  
3770  
3775  
3780  
3785  
3790  
3795  
3800  
3805  
3810  
3815  
3820  
3825  
3830  
3835  
3840  
3845  
3850  
3855  
3860  
3865  
3870  
3875  
3880  
3885  
3890  
3895  
3900  
3905  
3910  
3915  
3920  
3925  
3930  
3935  
3940  
3945  
3950  
3955  
3960  
3965  
3970  
3975  
3980  
3985  
3990  
3995  
4000  
4005  
4010  
4015  
4020  
4025  
4030  
4035  
4040  
4045  
4050  
4055  
4060  
4065  
4070  
4075  
4080  
4085  
4090  
4095  
4100  
4105  
4110  
4115  
4120  
4125  
4130  
4135  
4140  
4145  
4150  
4155  
4160  
4165  
4170  
4175  
4180  
4185  
4190  
4195  
4200  
4205  
4210  
4215  
4220  
4225  
4230  
4235  
4240  
4245  
4250  
4255  
4260  
4265  
4270  
4275  
4280  
4285  
4290  
4295  
4300  
4305  
4310  
4315  
4320  
4325  
4330  
4335  
4340  
4345  
4350  
4355  
4360  
4365  
4370  
4375  
4380  
4385  
4390  
4395  
4400  
4405  
4410  
4415  
4420  
4425  
4430  
4435  
4440  
4445  
4450  
4455  
4460  
4465  
4470  
4475  
4480  
4485  
4490  
4495  
4500  
4505  
4510  
4515  
4520  
4525  
4530  
4535  
4540  
4545  
4550  
4555  
4560  
4565  
4570  
4575  
4580  
4585  
4590  
4595  
4600  
4605  
4610  
4615  
4620  
4625  
4630  
4635  
4640  
4645  
4650  
4655  
4660  
4665  
4670  
4675  
4680  
4685  
4690  
4695  
4700  
4705  
4710  
4715  
4720  
4725  
4730  
4735  
4740  
4745  
4750  
4755  
4760  
4765  
4770  
4775  
4780  
4785  
4790  
4795  
4800  
4805  
4810  
4815  
4820  
4825  
4830  
4835  
4840  
4845  
4850  
4855  
4860  
4865  
4870  
4875  
4880  
4885  
4890  
4895  
4900  
4905  
4910  
4915  
4920  
4925  
4930  
4935  
4940  
4945  
4950  
4955  
4960  
4965  
4970  
4975  
4980  
4985  
4990  
4995  
5000  
5005  
5010  
5015  
5020  
5025  
5030  
5035  
5040  
5045  
5050  
5055  
5060  
5065  
5070  
5075  
5080  
5085  
5090  
5095  
5100  
5105  
5110  
5115  
5120  
5125  
5130  
5135  
5140  
5145  
5150  
5155  
5160  
5165  
5170  
5175  
5180  
5185  
5190  
5195  
5200  
5205  
5210  
5215  
5220  
5225  
5230  
5235  
5240  
5245  
5250  
5255  
5260  
5265  
5270  
5275  
5280  
5285  
5290  
5295  
5300  
5305  
5310  
5315  
5320  
5325  
5330  
5335  
5340  
5345  
5350  
5355  
5360  
5365  
5370  
5375  
5380  
5385  
5390  
5395  
5400  
5405  
5410  
5415  
5420  
5425  
5430  
5435  
5440  
5445  
5450  
5455  
5460  
5465  
5470  
5475  
5480  
5485  
5490  
5495  
5500  
5505  
5510  
5515  
5520  
5525  
5530  
5535  
5540  
5545  
5550  
5555  
5560  
5565  
5570  
5575  
5580  
5585  
5590  
5595  
5600  
5605  
5610  
5615  
5620  
5625  
5630  
5635  
5640  
5645  
5650  
5655  
5660  
5665  
5670  
5675  
5680  
5685  
5690  
5695  
5700  
5705  
5710  
5715  
5720  
5725  
5730  
5735  
5740  
5745  
5750  
5755  
5760  
5765  
5770  
5775  
5780  
5785  
5790  
5795  
5800  
5805  
5810  
5815  
5820  
5825  
5830  
5835  
5840  
5845  
5850  
5855  
5860  
5865  
5870  
5875  
5880  
5885  
5890  
5895  
5900  
5905  
5910  
5915  
5920  
5925  
5930  
5935  
5940  
5945  
5950  
5955  
5960  
5965  
5970  
5975  
5980  
5985  
5990  
5995  
6000  
6005  
6010  
6015  
6020  
6025  
6030  
6035  
6040  
6045  
6050  
6055  
6060  
6065  
6070  
6075  
6080  
6085  
6090  
6095  
6100  
6105  
6110  
6115  
6120  
6125  
6130  
6135  
6140  
6145  
6150  
6155  
6160  
6165  
6170  
6175  
6180  
6185  
6190  
6195  
6200  
6205  
6210  
6215  
6220  
6225  
6230  
6235  
6240  
6245  
6250  
6255  
6260  
6265  
6270  
6275  
6280  
6285  
6290  
6295  
6300  
6305  
6310  
6315  
6320  
6325  
6330  
6335  
6340  
6345  
6350  
6355  
6360  
6365  
6370  
6375  
6380  
6385  
6390  
6395  
6400  
6405  
6410  
6415  
6420  
6425  
6430  
6435  
6440  
6445  
6450  
6455  
6460  
6465  
6470  
6475  
6480  
6485  
6490  
6495  
6500  
6505  
6510  
6515  
6520  
6525  
6530  
6535  
6540  
6545  
6550  
6555  
6560  
6565  
6570  
6575  
6580  
6585  
6590  
6595  
6600  
6605  
6610  
6615  
6620  
6625  
6630  
6635  
6640  
6645  
6650  
6655  
6660  
6665  
6670  
6675  
6680  
6685  
6690  
6695  
6700  
6705  
6710  
6715  
6720  
6725  
6730  
6735  
6740  
6745  
6750  
6755  
6760  
6765  
6770  
6775  
6780  
6785  
6790  
6795  
6800  
6805  
6810  
6815  
6820  
6825  
6830  
6835  
6840  
6845  
6850  
6855  
6860  
6865  
6870  
6875  
6880  
6885  
6890  
6895  
6900  
6905  
6910  
6915  
6920  
6925  
6930  
6935  
6940  
6945  
6950  
6955  
6960  
6965  
6970  
6975  
6980  
6985  
6990  
6995  
7000  
7005  
7010  
7015  
7020  
7025  
7030  
7035  
7040  
7045  
7050  
7055  
7060  
7065  
7070  
7075  
7080  
7085  
7090  
7095  
7100  
7105  
7110  
7115  
7120  
7125  
7130  
7135  
7140  
7145  
7150  
7155  
7160  
7165  
7170  
7175  
7180  
7185  
7190  
7195  
7200  
7205  
7210  
7215  
7220  
7225  
7230  
7235  
7240  
7245  
7250  
7255  
7260  
7265  
7270  
7275  
7280  
7285  
7290  
7295  
7300  
7305  
7310  
7315  
7320  
7325  
7330  
7335  
7340  
7345  
7350  
7355  
7360  
7365  
7370  
7375  
7380  
7385  
7390  
7395  
7400  
7405  
7410  
7415  
7420  
7425  
7430  
7435  
7440  
7445  
7450  
7455  
7460  
7465  
7470  
7475  
7480  
7485  
7490  
7495  
7500  
7505  
7510  
7515  
7520  
7525  
7530  
7535  
7540  
7545  
7550  
7555  
7560  
7565  
7570  
7575  
7580  
7585  
7590  
7595  
7600  
7605  
7610  
7615  
7620  
7625  
7630  
7635  
7640  
7645  
7650  
7655  
7660  
7665  
7670  
7675  
7680  
7685  
7690  
7695  
7700  
7705  
7710  
7715  
7720  
7725  
7730  
7735  
7740  
7745  
7750  
7755  
7760  
7765  
7770  
7775  
7780  
7785  
7790  
7795  
7800  
7805  
7810  
7815  
7820  
7825  
7830  
7835  
7840  
7845  
7850  
7855  
7860  
7865  
7870  
7875  
7880  
7885  
7890  
7895  
7900  
7905  
7910  
7915  
7920  
7925  
7930  
7935  
7940  
7945  
7950  
7955  
7960  
7965  
7970  
7975  
7980  
7985  
7990  
7995  
8000  
8005  
8010  
8015  
8020  
8025  
8030  
8035  
8040  
8045  
8050  
8055  
8060  
8065  
8070  
8075  
8080  
8085  
8090  
8095  
8100  
8105  
8110  
8115  
8120  
8125  
8130  
8135  
8140  
8145  
8150  
8155  
8160  
8165  
8170  
8175  
8180  
8185  
8190  
8195  
8200  
8205  
8210  
8215  
8220  
8225  
8230  
8235  
8240  
8245  
8250  
8255  
8260  
8265  
8270  
8275  
8280  
8285  
8290  
8295  
8300  
8305  
8310  
8315  
8320  
8325  
8330  
8335  
8340  
8345  
8350  
8355  
8360  
8365  
8370  
8375  
8380  
8385  
8390  
8395  
8400  
8405  
8410  
8415  
8420  
8425  
8430  
8435  
8440  
8445  
8450  
8455  
8460  
8465  
8470  
8475  
8480  
8485  
8490  
8495  
8500  
8505  
8510  
8515  
8520  
8525  
8530  
8535  
8540  
8545  
8550  
8555  
8560  
8565  
8570  
8575  
8580  
8585  
8590  
8595  
8600  
8605  
8610  
8615  
8620  
8625  
8630  
8635  
8640  
8645  
8650  
8655  
8660  
8665  
8670  
8675  
8680  
8685  
8690  
8695  
8700  
8705  
8710  
8715  
8720  
8725  
8730  
8735  
8740  
8745  
8750  
8755  
8760  
8765  
8770  
8775  
8780  
8785  
8790  
8795  
8800  
8805  
8810  
8815  
8820  
8825  
8830  
8835  
8840  
8845  
8850  
8855  
8860  
8865  
8870  
8875  
8880  
8885  
8890  
8895  
8900  
8905  
8910  
8915  
8920  
8925  
8930  
8935  
8940  
8945  
8950  
8955  
8960  
8965  
8970  
8975  
8980  
8985  
8990  
8995  
9000  
9005  
9010  
9015  
9020  
9025  
9030  
9035  
9040  
9045

pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



wherein Q represents O or S and all other symbols are as defined earlier, because of the keto-enol tautomerism, enol form reacts with reacts with compound of general formula

- 5 (III<sup>m</sup>) where all symbols are as defined earlier to afford compound of general formula (I) where all symbols are as defined earlier may be carried out using suitable coupling agents such as EDCI (N-ethyl-N'-(3-dimethylaminopropyl)carbodiimide hydrochloride), dicyclohexyl urea, triarylphosphine/ dialkylazadicarboxylate such as PPh<sub>3</sub> / DEAD or DIAD and the like. The reaction may be carried out in the presence of solvents such as
- 10 THF, DME, CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, toluene, acetonitrile, carbon tetrachloride and the like. The inert atmosphere may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of DMAP, HOBt and they may be used in the range of 0.05 to 2 equivalents, preferably 0.25 to 1 equivalents. The reaction temperature may be in the range of -20 °C to 100 °C, preferably at a temperature in the
- 15 range of 0 °C to 80 °C. The duration of the reaction may range from 0.5 to 48 hours, preferably from 6 to 18 hours.

- Route 26: The conversion of compound of formula (IVf) where all symbols are as defined earlier to a compound of formula (I) may be carried out either in the presence of base or acid and the selection of base or acid is not critical. Any base normally used for hydrolysis of nitrile to acid may be employed, metal hydroxides such as NaOH or KOH in an aqueous solvent, or any acid normally used for hydrolysis of nitrile to ester may be employed such as HCl in an excess of alcohol such as methanol, ethanol, propanol etc. The reaction may be carried out at a temperature in the range of 0 °C to reflux temperature of the solvent used, preferably at a temperature in the range of 25 °C to reflux temperature of the solvent used. The duration of the reaction may range from 0.25 to 48 hrs.

Route 27: The reaction of compound of general formula (IIIj) where A, G and n are as defined earlier with a compound of general formula (IIIf) where all symbols are as defined earlier may be carried out using suitable coupling agents such as EDCI, dicyclohexyl urea, 5 triarylphosphine/ dialkylazadicarboxylate such as PPh<sub>3</sub> / DEAD or DIAD and the like. The reaction may be carried out in the presence of solvents such as THF, DME, CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, toluene, acetonitrile, carbon tetrachloride and the like. The inert atmosphere may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of DMAP, HOBr and they may be used in the range of 0.05 to 2 10 equivalents, preferably 0.25 to 1 equivalents. The reaction temperature may be in the range of -20 °C to 100 °C, preferably at a temperature in the range of 0 °C to 80 °C. The duration of the reaction may range from 0.5 to 48 hours, preferably from 6 to 18 hours. The above condensation may also be made using mixed anhydride methodology as described in Route 24.

15


The compound of formula (I) where R<sup>3</sup> represents hydrogen atom may be prepared by hydrolysing, using conventional methods, a compound of formula (I) where R<sup>3</sup> represents all groups defined earlier excluding hydrogen. The hydrolysis may be carried out in the presence of a base such as Na<sub>2</sub>CO<sub>3</sub>, K<sub>2</sub>CO<sub>3</sub>, NaOH, KOH, LiOH and the like 20 and a suitable solvent such as methanol, ethanol, dioxane, water and the like or mixtures thereof. THF is used as solubilizing agent wherever necessary. The reaction may be carried out at a temperature in the range of 20 °C to reflux temperature of the solvent, preferably at 25 °C to reflux temperature. The reaction time may range from 1 to 48 h, preferably from 1 to 12 h.

25

The compound of general formula (I) where Z represents oxygen and R<sup>3</sup> represents hydrogen or lower alkyl group may be converted to compound of formula (I), where Z represents NR<sup>4</sup> by reaction with appropriate amines of the formula NHR<sup>3</sup>R<sup>4</sup>, where R<sup>3</sup> and R<sup>4</sup> are as defined earlier to yield a compound of formula (I) where Z represents NR<sup>4</sup> and 30 all other symbols are as defined earlier. Alternatively, the compound of formula (I) where ZR<sup>3</sup> represents OH may be converted to acid halide, preferably ZR<sup>3</sup> = Cl, by reacting with appropriate reagents such as oxalyl chloride, thionyl chloride and the like, followed by treatment with amines of the formula NHR<sup>3</sup>R<sup>4</sup> where R<sup>3</sup> and R<sup>4</sup> are as defined earlier. Alternatively, mixed anhydrides may be prepared from compound of formula (I) where

ZR<sup>3</sup> represents OH and all other symbols are as defined earlier by treating with acid halides such acetyl chloride, acetyl bromide, pivaloyl chloride, dichlorobenzoyl chloride and the like. The reaction may be carried out in the presence of pyridine, triethylamine, diisopropyl ethylamine and the like. Coupling reagents such as DCC/DMAP, DCC/HOBt, 5 EDCI/HOBt, ethylchloroformate, isobutylchloroformate can also be used to activate the acid. Solvents such as halogenated hydrocarbons like CHCl<sub>3</sub> or CH<sub>2</sub>Cl<sub>2</sub>; hydrocarbons such as benzene, toluene, xylene and the like may be used. The reaction may be carried out at a temperature in the range of -40 °C to 40 °C, preferably at a temperature in the range of 0 °C to room temperature. The acid halide or mixed anhydride or activated acid 10 obtained by coupling reagents described above thus prepared may further be treated with appropriate amines of the formula NHR<sup>3</sup>R<sup>4</sup> where R<sup>3</sup> and R<sup>4</sup> are as defined earlier to yield a compound of formula (I) where Z represents NR<sup>4</sup> and all other symbols are as defined earlier.


15 In still another embodiment of the present invention the novel intermediate of formula (IIIf)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable 20 solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alcoxycarbonyl, 25 aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl or heteroaralkyl groups; Z represents oxygen or NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, arakanoyl, heterocycl, heteroaryl 30 or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or

nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, 5 aralkanoyl, heterocycl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted 10 aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4 is provided.

In yet another embodiment of the present invention, the compound of formula (IIIIf) where X represents NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-, where p is 0, 15 m is 0-4, R<sup>5</sup> is as defined above; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup> all other symbols are as defined above may be prepared by any of the following the processes described in scheme-IV below :

**Scheme-IV**

20 **Route 28 :** The reduction of compound of the formula (IIIIf-1) where all symbols are as defined above to yield compound of the general formula (IIIIf) where R<sup>5</sup> represents hydrogen; and all other symbols are as defined above may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C, and the like. Mixtures of catalysts may be used. The reaction may also be carried out in the presence of solvents 25 such as dioxane, acetic acid, ethyl acetate, alcohol such as methanol, ethanol and the like

or mixture thereof. A pressure between atmospheric pressure and 40 to 80 psi may be employed. The catalyst may be preferably 5 - 10% Pd/C and the amount of catalyst used may range from 5 - 100% w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium or samarium in alcohol or sodium amalgam in 5 alcohol, preferably methanol. When R<sup>1</sup> and R<sup>2</sup> represent double bond, the hydrogenation may be carried out in the presence of metal catalysts containing chiral ligands to obtain a compound of formula (IIIIf) in optically active form. The metal catalyst may contain Rhodium, Ruthenium, Indium and the like. The chiral ligands may preferably be chiral phosphines such as optically pure enantiomers of 2,3-bis(diphenylphosphino)butane, 2,3-10 isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino)butane and the like. Any suitable chiral catalyst may be employed which would give required optical purity of the product (I) (Ref: Principles of Asymmetric Synthesis, Tetrahedron Series Vol 14, pp311-316, Ed. Baldwin J. E.).

15 Route 29 : The reaction of compound of formula (IIIIf-2) with compound of formula (IIIIf-3) to give a compound of formula (IIIIf) where R<sup>5</sup> represents alkyl group and all other symbols are as defined above may be carried out in two steps the first step being the imine formation, followed by reduction. Formation of imine may be carried out in solvents such as MeOH, EtOH, i-PrOH and the like. The reaction may be effected in the presence of a 20 promoter such as NaOAc, KOAc and the like or the mixtures thereof. The temperature of reaction may range from room temperature to the reflux temperature of the solvent used. The reaction time may be 2 h to 24 h, preferably in the range 2 h to 12 h.

The imine can also be obtained by the reaction of a compound of general formula (IIIIf-2) with a compound of formula (IIIIf-3) using solvents such as CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, 25 chlorobenzene, benzene, THF, in the presence of catalyst such as p-toluenesulfonic acid, methanesulfonic acid, TFA, TfOH, BF<sub>3</sub>-OEt<sub>2</sub> and the like. The reaction may also be carried out in presence of activated molecular sieves. The temperature of the reaction may range from 10 °C to 100 °C, preferably at a temperature in the range from 10 °C to 60 °C. The reaction time may be 1 h to 48 h.

30 The imine product thus obtained above may be reduced by using Na(CN)BH<sub>3</sub>-HCl (ref: Hutchins, R. O. et al. *J. Org. Chem.* 1983, 48, 3433), NaBH<sub>4</sub>, H<sub>2</sub>-Pd]/C, H<sub>2</sub>-Pt/C, H<sub>2</sub>-Rh/C and the like in solvents such as methanol, ethanol and the like.

Route30 : The conversion of compound of formula (IIIIf-4) to a compound of formula

(IIIf) where R<sup>5</sup> represents hydrogen, and all other symbols are as defined above may be carried out in two steps the first step being the imine formation, followed by reduction. Formation of imine may be carried out in solvents such as MeOH, EtOH, i-PrOH and the like using hydroxylamine hydrochloride. The reaction may be effected in the presence of a promoter such as NaOAc, KOAc and the like or the mixtures thereof. The temperature of reaction may range from room temperature to the reflux temperature of the solvent used. The reaction time may be 2 h to 24 h, preferably in the range 2 h to 12 h.

The imine product thus obtained above may be reduced by using Na(CN)BH<sub>3</sub>-HCl (ref: Hutchins, R. O. et al. *J. Org. Chem.* 1983, 48, 3433), NaBH<sub>4</sub>, H<sub>2</sub>-Pd]/C, H<sub>2</sub>-Pt/C, H<sub>2</sub>-Rh/C and the like in solvents such as methanol, ethanol and the like.


Alternatively, the conversion of compound of formula (IIIf-4) to a compound of formula (IIIf) where R<sup>5</sup> represents hydrogen, and all other symbols are as defined above may be carried out using TiCl<sub>3</sub> as reagent and a reducing agent such as NaCNBH<sub>3</sub>, or Na<sub>2</sub>BH<sub>4</sub>. The coactivators like ammonium acetate can be used. The reaction may be carried out in the presence of solvents such as methanol, ethanol water and the like. The temperature of reaction may range from -20 °C to the reflux temperature of the solvent used. The reaction time may be 1 h to 48.

The compound of formula (IIIf-4) where all symbols are as defined earlier can be converted to corresponding methane sulfonate, p-toluene sulfonate, trifluoromethane sulfonate and the like. The intermediates thus obtained are then subjected to hydrogenation following the condition as described in route 7 and route 15 to yield compound of formula (IIIf) where all symbols are as defined above.

Route 31 : The reduction of compound of the formula (IIIf-5) to yield compound of the general formula (IIIf) where R<sup>5</sup> represents hydrogen and all other symbols are as defined above may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C, Raney nickel and the like. Mixtures of catalysts may be used. The reaction may also be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be preferably 5-10% Pd/C and the amount of catalyst used may range from 1-50 % w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium, iron, tin, samarium in alcohol or sodium amalgam in alcohol, preferably methanol or ethanol. The hydrogenation may be carried out in the presence of metal catalysts containing chiral ligands to obtain a compound of formula

(III<sup>f</sup>) in optically active form. The metal catalyst may contain Rhodium, Ruthenium, Indium and the like. The chiral ligands may preferably be chiral phosphines such as optically pure enantiomers of 2,3-bis(diphenylphosphino)butane, 2,3-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino) butane and the like. (Ref : Principles of 5 Asymmetric Synthesis, Tet. Org. Chem. Series Vol 14, pp311-316, Ed. Baldwin J. E.).

In yet another embodiment of the present invention, the compound of formula (III<sup>f</sup>) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy; X represents NHR<sup>5</sup>, Y represents O, S, 10 NR<sup>6</sup> or CHR<sup>7</sup>, Z is as defined above excluding NH and all other symbols are as defined above may be prepared by diazotizing the compound of formula (III<sup>f</sup>-6) to a compound of formula (III<sup>f</sup>-7) and reducing the compound of formula (III<sup>f</sup>-7) to yield compound of formula (III<sup>f</sup>). The reaction shown in scheme-V below :



15


Scheme-V

The diazotization of the compound of the formula (III<sup>f</sup>-6) where Z is as defined above excluding NH and all other symbols are as defined above to obtain compound of formula (III<sup>f</sup>-7) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as 20 defined earlier may be carried out using diazotizing agent such as sodium nitrite, isoamyl nitrite, potassium nitrite, ammonium nitrite and the like under aqueous acidic conditions using acids such as sulfuric acid, HCl, acetic acid and the like, in an organic solvent such as alcohols such as methanol, ethanol, propanol and the like; 1,4-dioxane, THF, acetone and the like. Etherifying the residue obtained using alkyl sulfates such as diethyl sulphate, 25 dimethylsulphate and the like or alkyl halides such as ethyl iodide, methyliodide and the like, in solvents such as hydrocarbons like toluene, benzene and the like or DMF, DMSO,

methyl isobutyl ketone (MIBK) and the like, in the presence of alkali bases such as sodium carbonate, potassium carbonate, sodium methoxide, sodium hydride, potassium hydride and the like.

The reduction of compound of the formula (III<sup>f</sup>-7) to yield a compound of the general formula (III<sup>f</sup>) where R<sup>5</sup> represents hydrogen atom and all other symbols are as defined earlier may be carried out in the presence of gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C, Raney nickel and the like. Mixtures of catalysts may be used. The reaction may also be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be preferably 5-10 % Pd/C and the amount of catalyst used may range from 1-50 % w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium, iron, tin, samarium in alcohol or sodium amalgam in alcohol, preferably methanol. The hydrogenation may also be carried out using ammonium formate, cyclohex-1,4-diene type of hydrogen donor under pd/c conditions using solvents such as methanol, ethanol, ethyl acetate and the like.

In yet another embodiment of the present invention, the compound of formula (III<sup>f</sup>) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy; X represents NHR<sup>5</sup>, Z is as defined above excluding NH and all other symbols are as defined above may be prepared by diazotizing and reducing the compound of formula (III<sup>f</sup>-6) to a compound of formula (III<sup>f</sup>-8) and etherifying the compound of formula (III<sup>f</sup>-8) to yield compound of formula (III<sup>f</sup>). The reaction shown in scheme-VI below :




Scheme-VI

The diazotization of the compound of the formula (III<sup>f</sup>-6) where all symbols are as defined above to obtain compound of formula (III<sup>f</sup>-8) may be carried out using diazotizing agent such as sodium nitrite, isoamyl nitrite, potassium nitrite, ammonium nitrite and the

like under aqueous acidic conditions using acids such as sulfuric acid, HCl, acetic acid and the like, in an organic solvent such as alcohols such as methanol, ethanol, propanol and the like; 1,4-dioxane, THF, acetone and the like. Reducing the residue obtained using gaseous hydrogen and a catalyst such as Pd/C, Rh/C, Pt/C, Raney nickel and the like. Mixtures of 5 catalysts may be used. The reduction may also be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be preferably 5-10 % Pd/C and the amount of catalyst used may range from 1-50 % w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium, iron, tin, samarium 10 in alcohol or sodium amalgam in alcohol, preferably methanol. The hydrogenation may also be carried out using ammonium formate, cyclohex-1,4-diene type of hydrogen donor under pd/c conditions using solvents such as methanol, ethanol, ethyl acetate and the like.

The Etherification of compound of formula (III<sup>f</sup>-8) to yield compound of formula (III<sup>f</sup>) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, 15 aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined earlier may be carried out using alkyl sulfates such as diethyl sulphate, dimethylsulphate and the like or alkyl halides such as ethyl iodide, methyliodide and the like, in solvents such as hydrocarbons like toluene, benzene and the like or DMF, DMSO, methyl isobutyl ketone (MIBK) and the like, in the presence of alkali bases such as sodium carbonate, 20 potassium carbonate, sodium methoxide, sodium hydride, potassium hydride and the like.

In yet another embodiment of the present invention, the compound of formula (III<sup>f</sup>) where R<sup>2</sup> represents hydroxy or substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy; X represents NHR<sup>5</sup>, Z is as 25 defined above excluding NH and all other symbols are as defined above may be prepared by following the process described in scheme-VII below :



Scheme-VII

The reaction of a compound of the general formula (IIIb) where all symbols are as defined above with a compound of formula (IIIf-9) where  $\text{R}^{12}$  represents ( $\text{C}_1\text{-C}_6$ )alkyl group to yield compound of formula (IIIf-10) may be carried out in the presence of a base such as metal hydride like  $\text{NaH}$  or  $\text{KH}$ ; organolithiums such as  $\text{CH}_3\text{Li}$ ,  $\text{BuLi}$  and the like; alkoxides such as  $\text{NaOMe}$ ,  $\text{NaOEt}$ ,  $t\text{-BuO}^-\text{K}^+$  and the like or mixtures thereof. The reaction may be carried out in the presence of solvents such as diethyl ether, THF, dioxane, DMF, DMSO, DME, dimethyl acetamide and the like or mixtures thereof. HMPA may be used as cosolvent. The reaction temperature may range from  $-78^\circ\text{C}$  to  $50^\circ\text{C}$ , preferably at a temperature in the range of  $-10^\circ\text{C}$  to  $30^\circ\text{C}$ .

The reduction of compound of the formula (IIIf-10) to yield a compound of the formula (IIIf-2) may be carried out in the presence of gaseous hydrogen and a catalyst such as  $\text{Pd/C}$ ,  $\text{Rh/C}$ ,  $\text{Pt/C}$ , Raney nickel and the like. Mixtures of catalysts may be used. The reaction may also be conducted in the presence of solvents such as dioxane, acetic acid, ethyl acetate and the like. A pressure between atmospheric pressure and 80 psi may be employed. The catalyst may be preferably 5-10 %  $\text{Pd/C}$  and the amount of catalyst used may range from 1-50 % w/w. The reaction may also be carried out by employing metal solvent reduction such as magnesium, iron, tin, samarium in alcohol or sodium amalgam in alcohol, preferably methanol followed by an acidic work up. The hydrogenation may be carried out in the presence of metal catalysts containing chiral ligands to obtain a compound of formula (I) in optically active form. The metal catalyst may contain Rhodium, Ruthenium, Indium and the like. The chiral ligands may preferably be chiral phosphines such as optically pure enantiomers of 2,3-


bis(diphenylphosphino)butane, 2,3-isopropylidene-2,3-dihydroxy-1,4-bis(diphenylphosphino) butane and the like.

The reaction of a compound of general formula (III<sup>f</sup>-2) with a compound of formula (III<sup>f</sup>-3) where R<sup>5</sup> is as defined above to yield compound of formula (III<sup>f</sup>) may be carried out using solvents such as CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, chlorobenzene, benzene, THF, in the presence of catalyst such as p-toluenesulfonic acid, methanesulfonic acid, TFA, TfOH, BF<sub>3</sub>-OEt<sub>2</sub> and the like. The reaction may also be carried out using activated molecular sieves. The temperature of the reaction may range from 10 °C to 100 °C, preferably at a temperature in the range from 10 °C to 60 °C. The imine product initially produced may be reduced using Na(CN)BH<sub>3</sub>-HCl (ref: Hutchins, R. O. et al. J. Org. Chem. 1983, vol. 48, 3433-3428), H<sub>2</sub>-Pd/C, H<sub>2</sub>-Pt/C, H<sub>2</sub>-Ph/C and the like in solvents such as methanol, ethanol and the like.

Alternatively, the reaction of compound of formula (III<sup>f</sup>-2) to yield compound of formula (III<sup>f</sup>) where R<sup>5</sup> represents hydrogen, m is 1, and all other symbols are as defined above may be carried out using substituted or unsubstituted hydroxyl amine followed by treating with TiCl<sub>3</sub> as reagent and a reducing agent such as NaCNBH<sub>3</sub>, or NaBH<sub>4</sub>. The coactivators like ammonium acetate can be used. The reaction may be carried out in the presence of solvents such as methanol, ethanol, water and the like or mixtures thereof. The temperature of reaction may range from -20 °C to the reflux temperature of the solvent used. The reaction time may be 1 h to 48.

Alternatively, the reaction of compound of formula (III<sup>f</sup>-2) to yield compound of formula (III<sup>f</sup>) where R<sup>5</sup> represents hydrogen, m is 1, and all other symbols are as defined above may be carried out using NH<sub>3</sub>/methanol, NH<sub>3</sub>/ethanol or NH<sub>3</sub>/isopropanol in presence of Pd/C, Ra-Ni and the like as catalyst and atmospheric pressure to 80 psi pressure of hydrogen gas. The reaction temperature may range from room temperature to 60 °C. The duration of reaction may range from 2 h to 48.


In still another embodiment of the present invention the novel intermediate of formula (III<sup>d</sup>)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their

polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $L^1$  is a leaving group such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate;  $R^1$  represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups;  $R^2$  represents 5 hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups;  $R^3$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, 10 cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl or heteroaralkyl groups;  $Z$  represents oxygen or  $NR^4$ , where  $R^4$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups or  $R^3$  and  $R^4$  together may form a 15 substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen;  $Ar$  represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group;  $X$  represents  $O$ ,  $NHR^5$ ,  $-CO(CH_2)_pNR^5(CH_2)_m-$ ,  $-(CH_2)_pO-$ ,  $-(CH_2)_pNR^5CO-$ ; where  $R^5$  represents 20 hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups;  $Y$  represents  $O$ ,  $S$ ,  $NR^6$  or  $CHR^7$ ; where  $R^6$  represents hydrogen or 25 substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups;  $R^7$  represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group  $R^1$ ;  $n$  is an integer in the range of 1-4;  $m$  and  $p$  are integers ranging from 0-4 is provided.

In yet another embodiment of the present invention, the compound of formula (IIId) where  $X$  represents  $-CO(CH_2)_pNR^5(CH_2)_m-$ ,  $-(CH_2)_pNR^5CO-$ ; all symbols are as 30 defined above may be prepared by a process which comprises, reacting the compound of formula (IIIe)



where X represents  $\text{NHR}^5$  and all other symbols are as defined above with compound of formula (IIId-1)




where  $\text{L}^1$  and n are as defined above and  $\text{L}^2$  represents halogen atom.

5

The reaction of compound of formula (IIIe) with compound of formula (IIId-1) where may be carried out in the presence of solvents such as DCM, DCE, THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as  $\text{N}_2$ , Ar, He and the like.

- 10 The reaction may be effected in the presence of a base such as triethyl amine, lutidine, collidine and the like or mixtures thereof. The reaction temperature may range from -20 °C – 120 °C. The duration of the reaction may range from 1 to 48 hours, preferably from 2 to 12 hours.

- 15 In still another embodiment of the present invention the novel intermediate of formula (IIId)




their derivatives, their analogs, their tautomeric forms, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $\text{L}^1$  is a


- 20 leaving group such as halogen, p-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate;  $\text{R}^1$  represents hydrogen;  $\text{R}^2$  represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, 25 alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups;  $\text{R}^3$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen or  $\text{NR}^4$ , where  $\text{R}^4$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, 30 heterocyclyl, heteroaryl or heteroaralkyl groups or  $\text{R}^3$  and  $\text{R}^4$  together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms

selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, 5 hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted 10 aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; n is an integer in the range of 1-4; m and p are integers ranging from 0-4 is provided.

In yet another embodiment of the present invention, the compound of formula (IIId) where X represents -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; all symbols 15 are as defined above may be prepared by a process which comprises, reacting the compound of formula (IIIIf)



where X represents NHR<sup>5</sup> and all other symbols are as defined above with compound of formula (IIId-1)




where L<sup>1</sup> and n are as defined above and L<sup>2</sup> represents halogen atom.

The reaction of compound of formula (IIIIf) with compound of formula (IIId-1) 25 where may be carried out in the presence of solvents such as DCM, DCE, THF, DMF, DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as N<sub>2</sub>, Ar, He and the like. The reaction may be effected in the presence of a base such as triethyl amine, lutidine, collidine and the like or mixtures thereof. The reaction temperature may range from -20 °C – 120 °C. The duration of the reaction may range from 1 to 48 hours, preferably from 2 to 30 12 hours.

In still another embodiment of the present invention the novel intermediate


of formula (IIId)




their derivatives, their analogs, their tautomeric forms, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $\text{L}^1$  is a leaving group such as halogen, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate;  $\text{R}^1$  represents hydrogen;  $\text{R}^2$  represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxy carbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups;  $\text{R}^3$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen or  $\text{NR}^4$ , where  $\text{R}^4$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups or  $\text{R}^3$  and  $\text{R}^4$  together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; n is an integer in the range of 1-4; m and p are integers ranging from 0-4 is provided.

In yet another embodiment of the present invention, the compound of formula (IIId) where X represents -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; all symbols are as defined above may be prepared by a process which comprises, reacting the

compound of formula (IIIf)




where X represents  $\text{NHR}^5$  and all other symbols are as defined above with compound of formula (IIId-1)




where  $\text{L}^1$  and n are as defined above and  $\text{L}^2$  represents halogen atom.

The reaction of compound of formula (IIIf) with compound of formula (IIId-1) where may be carried out in the presence of solvents such as DCM, DCE, THF, DMF, 10 DMSO, DME and the like or mixtures thereof. The reaction may be carried out in an inert atmosphere that may be maintained by using inert gases such as  $\text{N}_2$ , Ar, He and the like. The reaction may be effected in the presence of a base such as triethyl amine, lutidine, collidine and the like or mixtures thereof. The reaction temperature may range from -20 °C 15 – 120 °C. The duration of the reaction may range from 1 to 48 hours, preferably from 2 to 12 hours.

In still another embodiment of the present invention the novel intermediate of formula (IIIa)




20 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O,  $\text{NHR}^5$ ,  $-\text{CO}(\text{CH}_2)_p\text{NR}^5(\text{CH}_2)_m-$ ,  $(\text{CH}_2)_p\text{O}$ ,  $-(\text{CH}_2)_p\text{NR}^5\text{CO}-$ ; where  $\text{R}^5$  represents hydrogen 25 or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; n is an integer in the range of 1-4; m and p are integers ranging from 0-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives is provided.

In still another embodiment of the present invention the novel intermediate of  
20 formula (IVb)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $L^1$  is a leaving group such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like;  $R^1$  represents hydrogen atom,


halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen or NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, 5 divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, (CH<sub>2</sub>)<sub>p</sub>O, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or 10 imidazolopyrimidine of the formula given below :



where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, 25 aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino,


aryl amino, aralkyl amino, amino alkyl, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkoxy alkyl, aryloxy alkyl, aralkoxy alkyl, alkylthio, thio alkyl, alkoxy carbonyl amino, aryloxy carbonyl amino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents 5 hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxy alkyl, amino alkyl, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkoxy alkyl, aryloxy alkyl, aralkoxy alkyl, alkylthio, thio alkyl groups, carboxylic acid or its derivatives, 10 or sulfonic acid or its derivatives is provided.

In still another embodiment of the present invention the novel intermediate of formula (IVf)




15 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, 20 alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxy alkyl, alkoxy carbonyl, aryloxy carbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic, or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, (CH<sub>2</sub>)<sub>n</sub>O, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted 25 groups selected from alkyl, aryl, aralkyl, hydroxy alkyl, carboxy alkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxy alkyl, carboxy alkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, 30 heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4; n is an integer in the range of 1-

4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, 5 aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or 10 sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, 15 aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives is provided.

In still another embodiment of the present invention the novel intermediate of formula (IVg)



20 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen or NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted 25

groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional 5 heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, (CH<sub>2</sub>)<sub>p</sub>O, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its 10 derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl 15 group; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, 20 aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or 25 sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl,

cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, 5 or sulfonic acid or its derivatives is provided.

It is appreciated that in any of the above mentioned reactions, any reactive group in the substrate molecule may be protected according to conventional chemical practice. Suitable protecting groups in any of the above mentioned reactions are tertiarybutyldimethylsilyl, methoxymethyl, triphenyl methyl, benzyloxycarbonyl, THP etc, 10 to protect hydroxyl or phenolic hydroxy group; N-Poc, Boc, N-Cbz, N-Fmoc, benzophenoneimine etc, for protection of amino or anilino group, acetal protection for aldehyde, ketal protection for ketone and the like. The methods of formation and removal of such protecting groups are those conventional methods appropriate to the molecule being protected.

15

The pharmaceutically acceptable salts are prepared by reacting the compound of formula (I) with 1 to 4 equivalents of a base such as sodium hydroxide, sodium methoxide, sodium hydride, potassium hydroxide, potassium t-butoxide, calcium hydroxide, magnesium hydroxide and the like, in solvents like ether, THF, methanol, t-butanol, 20 dioxane, isopropanol, ethanol, toluene etc. Mixtures of solvents may be used. Organic bases like lysine, arginine, diethanolamine, choline, guanidine, adamentyl amine and their derivatives etc. may also be used. Alternatively, acid addition salts wherever applicable are prepared by treatment with acids such as hydrochloric acid, hydrobromic acid, nitric acid, sulfuric acid, phosphoric acid, p-toluenesulphonic acid, methanesulfonic acid, acetic acid, citric acid, maleic acid, salicylic acid, hydroxynaphthoic acid, ascorbic acid, palmitic acid, succinic acid, benzoic acid, benzenesulfonic acid, tartaric acid and the like in solvents like ethyl acetate, ether, alcohols, acetone, THF, dioxane and the like. Mixtures of 25 solvents may also be used.

The stereoisomers of the compounds forming part of this invention may be 30 prepared by using reactants in their single enantiomeric form in the process wherever possible or by conducting the reaction in the presence of reagents or catalysts in their single enantiomer form or by resolving the mixture of stereoisomers by conventional methods. Some of the preferred methods include use of microbial resolution, resolving the diastereomeric salts formed with chiral acids such as mandelic acid, camphorsulfonic acid,

- tartaric acid, lactic acid, and the like wherever applicable or chiral bases such as brucine, cinchona alkaloids and their derivatives and the like. Commonly used methods are compiled by Jaques et al in "Enantiomers, Racemates and Resolution" (Wiley Interscience, 1981). More specifically the compound of formula (I) where ZR<sup>3</sup> represents
- 5 OH may be converted to a 1:1 mixture of diastereomeric amides by treating with chiral amines, aminoacids, aminoalcohols derived from aminoacids; conventional reaction conditions may be employed to convert acid into an amide; the diastereomers may be separated either by fractional crystallization or chromatography and the stereoisomers of compound of formula (I) may be prepared by hydrolyzing the pure diastereomeric amide.
10. Various polymorphs of a compound of general formula (I) forming part of this invention may be prepared by crystallization of compound of formula (I) under different conditions. For example, using different solvents commonly used or their mixtures for recrystallization; crystallizations at different temperatures; various modes of cooling, ranging from very fast to very slow cooling during crystallizations. Polymorphs may also
- 15 be obtained by heating or melting the compound followed by gradual or fast cooling. The presence of polymorphs may be determined by solid probe NMR spectroscopy, IR spectroscopy, differential scanning calorimetry, powder X-ray diffraction or such other techniques.

The present invention provides a pharmaceutical composition, containing the

20 compounds of the general formula (I) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates in combination with the usual pharmaceutically employed carriers, diluents and the like are useful for the treatment and / or prophylaxis of diseases such as hypertension, coronary heart disease,

25 atherosclerosis, stroke, peripheral vascular diseases and related disorders. These compounds are useful for the treatment of hyperlipidemia, hyperglycemia, familial hypercholesterolemia, hypertriglyceridemia, lowering of atherogenic lipoproteins, VLDL and LDL. The compounds of the present invention can be used for the treatment of certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome,

30 hypertensive nephrosclerosis, nephropathy. The compounds of general formula (I) are also useful for the treatment / prophylaxis of insulin resistance (type II diabetes), leptin resistance, impaired glucose tolerance, dyslipidemia, disorders related to syndrome X such as hypertension, obesity, insulin resistance, coronary heart disease, and other cardiovascular disorders. These compounds may also be useful as aldose reductase

inhibitors, for improving cognitive functions in dementia, treating diabetic complications, disorders related to endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), inflammatory bowel diseases, osteoporosis, myotonic dystrophy, pancreatitis, retinopathy, arteriosclerosis, xanthoma, inflammation and for the treatment of cancer. The 5 compounds of the present invention are also useful in the treatment and / or prophylaxis of the above said diseases in combination / concomitant with one or more HMG CoA reductase inhibitors, hypolipidemic / hypolipoproteinemic agents such as fibrac acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol or their combination. The compounds of the present invention in combination with HMG CoA reductase inhibitors, 10 hypolipidemic / hypolipoproteinemic agents can be administered together or within such a period to act synergistically. The HMG CoA reductase inhibitors may be selected from those used for the treatment or prevention of hyperlipidemia such as lovastatin, pravastatin, simvastatin, fluvastatin, atorvastatin, cerivastatin and their analogs thereof. Suitable fibrac acid derivative may be gemfibrozil, clofibrate, fenofibrate, ciprofibrate, 15 benzafibrate and their analogs thereof.

The present invention also provides a pharmaceutical composition, containing the compounds of the general formula (I) as defined above, their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts or their pharmaceutically acceptable solvates and one or more HMG CoA 20 reductase inhibitors, hypolipidemic / hypolipoproteinemic agents such as fibrac acid derivatives, nicotinic acid, cholestyramine, colestipol, probucol in combination with the usual pharmaceutically employed carriers, diluents and the like.

The pharmaceutical composition may be in the forms normally employed, such as tablets, capsules, powders, syrups, solutions, suspensions and the like, may contain 25 flavorants, sweeteners etc. in suitable solid or liquid carriers or diluents, or in suitable sterile media to form injectable solutions or suspensions. Such compositions typically contain from 1 to 20 %, preferably 1 to 10 % by weight of active compound, the remainder of the composition being pharmaceutically acceptable carriers, diluents or solvents.

Suitable pharmaceutically acceptable carriers include solid fillers or diluents and 30 sterile aqueous or organic solutions. The active ingredient will be present in such pharmaceutical compositions in the amounts sufficient to provide the desired dosage in the range as described above. Thus, for oral administration, the compound of formula (I) can be combined with a suitable solid or liquid carrier or diluent to form capsules, tablets, powders, syrups, solutions, suspensions and the like. The pharmaceutical compositions,

may, if desired, contain additional components such as flavourants, sweeteners, excipients and the like. For parenteral administration, the compound formula (I) can be combined with sterile aqueous or organic media to form injectable solutions or suspensions. For example, solutions in sesame or peanut oil, aqueous propylene glycol and the like can be used, as well as aqueous solutions of water-soluble pharmaceutically-acceptable acid addition salts or salts with base of the compounds. Aqueous solutions with the active ingredient dissolved in polyhydroxylated castor oil may also be used for injectable solutions. The injectable solutions prepared in this manner can then be administered intravenously, intraperitoneally, subcutaneously, or intramuscularly, with intramuscular administration being preferred in humans.

For nasal administration, the preparation may contain the compound of formula (I), of the present invention dissolved or suspended in a liquid carrier, in particular an aqueous carrier, for aerosol application. The carrier may contain additives such as solubilizing agents, such as propylene glycol, surfactants, absorption enhancers such as lecithin (phosphatidylcholine) or cyclodextrin or preservatives such as parabenes.

Tablets, dragees or capsules having talc and / or a carbohydrate carried binder or the like are particularly suitable for any oral application. Preferably, carriers for tablets, dragees or capsules include lactose, corn starch and / or potato starch. A syrup or elixir can be used in cases where a sweetened vehicle can be employed.

A typical tablet production method is exemplified below :

Tablet Production Example :

a) 1)	Active ingredient	30 g
2)	Lactose	95 g
3)	Corn starch	30 g
25	4) Carboxymethyl cellulose	44 g
	5) Magnesium stearate	1 g

200 g for 1000 tablets

The ingredients 1 to 3 are uniformly blended with water and granulated after drying under reduced pressure. The ingredient 4 and 5 are mixed well with the granules and compressed by a tabletting machine to prepare 1000 tablets each containing 30 mg of active ingredient.

b) 1) Active ingredient                    30 g

2)	Calcium phosphate	90 g
3)	Lactose	40 g
4)	Corn starch	35 g
5)	Polyvinyl pyrrolidone	3.5 g
5	6) Magnesium stearate	1.5 g

200 g for 1000 tablets


The ingredients 1-4 are uniformly moistened with an aqueous solution of 5 and granulated after drying under reduced pressure. Ingredient 6 is added and granules are  
10 compressed by a tabletting machine to prepare 1000 tablets containing 30 mg of ingredient 1.

The compound of the formula (I) as defined above are clinically administered to mammals, including man, via either oral, nasal, pulmonary, transdermal or parenteral,  
15 rectal, depot, subcutaneous, intravenous, intraurethral, intramuscular, intranasal, ophthalmic solution or an ointment. Administration by the oral route is preferred, being more convenient and avoiding the possible pain and irritation of injection. However, in circumstances where the patient cannot swallow the medication, or absorption following oral administration is impaired, as by disease or other abnormality, it is essential that the  
20 drug be administered parenterally. By either route, the dosage is in the range of about 0.01 to about 100 mg / kg body weight of the subject per day or preferably about 0.01 to about 30 mg / kg body weight per day administered singly or as a divided dose. However, the optimum dosage for the individual subject being treated will be determined by the person responsible for treatment, generally smaller doses being administered initially and  
25 thereafter increments made to determine the most suitable dosage.

The invention is explained in detail in the examples given below which are provided by way of illustration only and therefore should not be construed to limit the scope of the invention.

### 30 Preparation 1

#### Ethyl 2-bromopentanoate




Red phosphorous (455 mg, 14.7 mmol) was added to valeric acid (15 g, 14.7 mmol) followed by drop wise addition of bromine (15 mL, 294 mmol) at room temperature. After complete addition, the reaction mixture was heated to 100 °C for 6 h. The excess bromine was then removed using water aspirator at the same temperature. Ethanol (25 mL) was 5 added to the residue and refluxed for overnight. The reaction mixture was cooled to room temperature and poured into water (45 mL) when oil separated. The oil was washed with water, saturated sodium bicarbonate and water, dried ( $\text{Na}_2\text{SO}_4$ ) and distilled under reduced pressure to obtain the title compound (26.2 g, 85%) as colorless oil.

<sup>1</sup>H NMR ( $\text{CDCl}_3$ ):  $\delta$  0.94 (t,  $J = 7.3$  Hz, 3H), 1.29 (t,  $J = 7.1$  Hz, 3H), 1.35-1.56 (m, 2H),  
10 1.90-2.13 (m, 2H), 4.15-4.29 (m, 3H).

### Preparation 2

#### Ethyl 2-(4-aminophenylsulfanyl)pentanoate




To a cooled solution of 4-aminothiophenol (5.40 g, 43.2 mmol) in *N,N*-dimethylformamide (30 mL) sodium hydride (60% oil coated, 1.9 g, 47.5 mmol) was 15 added portion wise. After stirring at room temperature for 30 min ethyl 2-bromopentanoate (14.44 g, 69.1 mmol), obtained in preparation 1, in *N,N*-dimethylformamide (25 mL) was added to the above reaction mixture at 0 °C with vigorous stirring. The stirring was continued at room temperature for further 48 h. The 20 reaction mixture was diluted with ethyl acetate (400 mL) and washed the organic layer successively with water (300 mL) and brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography using 10% ethyl acetate in pet ether to afford the title compound (6.04 g, 55.3%) as yellow oil.

<sup>1</sup>H NMR ( $\text{CDCl}_3$ ):  $\delta$  0.90 (t,  $J = 7.0$  Hz, 3H), 1.24 (t,  $J = 7.1$  Hz, 3H), 1.30-1.50 (m, 2H),  
25 1.55-1.91 (m, 2H), 3.42 (dd,  $J = 8.1$  and 6.6 Hz, 1H), 4.09 (q,  $J = 7.1$  Hz, 2H), 6.60 (d,  $J = 8.8$  Hz, 2H), 7.26 (d,  $J = 8.3$  Hz, 2H).

### Preparation 3

#### Ethyl 2-(4-heptylaminophenylsulfanyl)pentanoate




30 The title compound (586 mg, 14.25%) was obtained as light brown colored liquid from ethyl 2-(4-aminophenylsulfanyl)pentanoate (2.96 g, 11.7 mmol) obtained in preparation

2, heptyl bromide (2 mL, 12.9 mmol) and sodium hydride (60% oil coated, 516 mg, 12.9 mmol) by following the similar procedure as described in preparation 2.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.92-1.00 (m, 6H), 1.21 (t, J = 7.1 Hz, 3H), 1.30-1.88 (m, 14H), 3.10 (t, J = 7.1 Hz, 2H), 3.41 (dd, J = 8.3 and 6.8 Hz, 1H), 4.10 (q, J = 7.2 Hz, 2H), 6.52 (d, J = 5 8.8 Hz, 2H), 7.29 (d, J = 8.3 Hz, 2H).

#### Preparation 4

##### Ethyl 2-[4-chloromethyl(heptyl)carboxamidophenylsulfanyl]pentanoate




To a cooled solution of ethyl 2-(4-heptylaminophenylsulfanyl)pentanoate (586 mg, 1.66 mmol), obtained in preparation 3, in dichloromethane (10 mL) triethyl amine (0.58 mL, 4.17 mmol) was added drop wise. After stirring at room temperature for 15 min chloroacetyl chloride (0.3 mL, 3.77 mmol) was added at 0 °C and the stirring was continued at room temperature for further 12 h. The reaction mixture was diluted with dichloromethane (10 mL) and washed the organic layer successively with water (10 mL) and brine, dried over anhydrous sodium sulfate and concentrated. The residue was purified by column chromatography using 8% ethyl acetate in pet ether to afford the title compound (597 mg, 84%) as oil.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.88 (t, J = 6.1 Hz, 3H), 0.98 (t, J = 7.3 Hz, 3H), 1.15-1.60 (m, 15H), 1.71-2.03 (m, 2H), 3.65-3.88 (m, 5H), 4.17 (q, J = 7.2 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H), 7.52 (d, J = 8.3 Hz, 2H).

#### Preparation 5

##### Ethyl (2S)-3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate



25

##### Step-i:

4-Hydroxybenzaldehyde (100 g), potassium carbonate (226 g) and dimethylformamide (500 ml) were taken in a reaction flask and stirred for 15 minutes. Benzylchloride (114 g) was then added at room temperature and the reaction mass was stirred at the same temperature for a period of 8-10 h. The progress of the reaction was monitored with TLC.

After completion of the reaction, the reaction mixture was dumped into ice water and extracted with toluene. The combined organic extracts were washed with 10 % aq. sodium hydroxide solution followed by water. The solvent was removed under reduced pressure and the resulting residue was triturated with pet. ether to afford 4-benzyloxybenzaldehyde  
5 (160 -165 g, 93-95 %).

Step-ii:

4-Benzyloxybenzaldehyde obtained in step (i) above, was added to a solution of sodium ethoxide (64 g) in absolute ethanol followed by the addition of ethylchloroacetate (87 g) over a period of 30-45 minutes, maintaining ambient temperature. The reaction mixture  
10 was stirred at the same temperature for 3-5 h. The progress of the reaction was monitored with TLC. After completion of the reaction, the reaction mixture was dumped into ice water and stirred for 5-10 minutes. The solid thus obtained was filtered, washed with water and dried to afford ethyl-2,3-epoxy-3-(4-benzyloxyphenyl)propionate (126-129 g, 90-92 %).

15 Step-iii:

A mixture of ethyl-2,3-epoxy-3-(4-benzyloxyphenyl)propionate (125 g) obtained in step (ii) above, 5 % Pd/C catalyst (12.5 g) and 1,4-dioxane (750 ml) was hydrogenated at room temperature at 5-10 psi of hydrogen pressure for a period of 10-15 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the catalyst was filtered  
20 and the solvent was removed under reduced pressure to afford racemic ethyl 2-hydroxy-3-(4-benzyloxyphenyl)propionate (100-105 g, 80-83 %).

Step-iv:

A mixture of racemic ethyl 2-hydroxy-3-(4-benzyloxyphenyl)propionate (100 g) obtained in step (iii) above and 10 % aq. sodium hydroxide solution (500 ml) was stirred at room  
25 temperature for a period of 1-2 h. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was acidified with dil. hydrochloric acid at 15-20 °C and the solid thus obtained was filtered and washed with water to afford racemic 2-hydroxy-3-(4-benzyloxyphenyl)propionic acid (72-77 g, 80-85 %).

To a solution of racemic 2-hydroxy-3-(4-benzyloxyphenyl)propionic acid (75 g) obtained  
30 according to the procedure described above in ethylacetate (1.1 L) was added R(+)- $\alpha$ -methylbenzylamine (33 g) and the mixture was stirred at room temperature for a period of 2-4 h. The solid thus obtained was filtered and the acid was regenerated after acidification to afford S(-)-2-hydroxy-3-(4-benzyloxyphenyl)propionic acid of the formula (11), (33-35 g, 44-47%). The R(+)- $\alpha$ -hydroxy acid obtained from the mother liquor was racemised and

mixed with subsequent batches for resolution. The overall yield obtained by several such reprocesses was ~90-95 %.

Step-v:


To a slurry of sodium hydride (60 % suspension in oil, 13 g) and dimethyl formamide (70 ml) was added a solution of S(-)-2-hydroxy-3-(4-benzyloxyphenyl)propionic acid (35 g) obtained in step (iv) above, in dimethylformamide (105 ml) at 5-10 °C over a period of 15-30 minutes. The temperature was allowed to attain room temperature and maintained at the same temperature for 1-3 hours. Ethyl iodide (62 g) was added slowly by maintaining the temperature at 25-30 °C over a period of 2-3 hours. The progress of the reaction was monitored by TLC. After completion of the reaction, the reaction mixture was dumped into ice water and extracted with toluene. The combined organic extracts were washed with water and the solvent was removed under reduced pressure to afford S(-)-ethyl 2-ethoxy-3-(4-benzyloxyphenyl)propionate (41-42 g, 98-99 %).

Step-vi:


A mixture of S(-)-ethyl 2-ethoxy-3-(4-benzyloxyphenyl)propionate (40 g) obtained in step (v) above, 5 % Pd/C catalyst (8 g) and tetrahydrofuran (120 ml) was subjected to hydrogenation at room temperature and 50-60 psi of hydrogen pressure for a period of 8-12 hours. After completion of the reaction, the catalyst was filtered off and the solvent was removed under reduced pressure to afford S(-)-ethyl 2-ethoxy-3-(4-hydroxyphenyl)propionate (28-29 g, 97-98 %).

Step-vii:

Ethyl (2S)-3-(4-hydroxyphenyl)-2-ethoxypropanoate obtained in step vi above (18 g, 75.63 mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub> (31.14 g, 225.65 mmol) were brought to reflux temperature in dry acetone (180 mL). 1,2-Dibromoethane (32.58 mL, 377.45 mmol) was added to the reaction mixture at reflux temperature and refluxed for 48 h. Solid K<sub>2</sub>CO<sub>3</sub> was filtered off and the filtrate was concentrated under vacuum. The residue was dissolved in ethyl acetate and washed with water, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was chromatographed on silica gel using 10% ethyl acetate in pet ether to yield the title compound (12.5 g, 47.9%) as liquid and the starting material was recovered (6 g), mp 170-173 °C.



<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.18 (t, J = 6.8 Hz, 3H), 1.25 (t, J = 6.8 Hz, 3H), 2.96 (d, J = 6.8 Hz, 2H), 3.28-3.47 (m, 1H), 3.51-3.88 (m, 3H), 3.98 (t, J = 6.6 Hz, 1H), 4.18 (q, J = 7.1 Hz, 2H), 4.28 (t, J = 6.3 Hz, 2H), 6.84 (d, J = 8.8 Hz, 2H), 7.1 (d, J = 8.3 Hz, 2H).

**Preparation 6****2-Ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoic acid****Step i:**

- 5 A solution of triethyl-2-ethoxyphosphonoacetate prepared (5.61 g, 20.89 mmol) in dry tetrahydrofuran (20 mL) was added slowly to a stirred ice cooled suspension of sodium hydride (60 % dispersion of oil) (1 g, 42 mmol) in dry tetrahydrofuran (10 mL), under a nitrogen atmosphere. The mixture was stirred at 0 °C for 30 min. prior to the addition of a 4-(2-bromoethoxy)benzaldehyde (4.0 g, 17.4 mmol) in dry tetrahydrofuran (30 mL). The 10 mixture was allowed to warm up to room temperature and stirred at that temperature for further 20 h. The solvent was evaporated, water (100 mL) was added and extracted with ethyl acetate (2 x 75 mL). The combined organic extracts were washed with water (50 mL), brine (50 mL), dried ( $\text{Na}_2\text{SO}_4$ ), filtered and the solvent was evaporated under reduced pressure. The residue was chromatographed over silica gel using a mixture of 15 ethyl acetate and pet. ether (2 : 8) as an eluent to afford ethyl (E/Z)-3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropenoate (4.0 g, 66 %) as an oil in 45 : 55 ratio of E:Z isomers (as measured by  $^1\text{H}$  NMR).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 200 MHz) :  $\delta$  1.17 and 1.42 ( 6H, *E* and *Z* triplets, isomeric - $\text{OCH}_2\text{CH}_3$  and  $\text{OCH}_2\text{CH}_3$ ), 3.62 - 3.72 (complex, 2H), 3.90 - 4.28 (complex, 2H), 4.30 - 4.37 (complex, 4H), 6.09 (s, 0.45H, olefinic proton of *E* isomers), 6.85 and 6.92 (2H, d and d, *J* = 8.67 Hz and 8.7 Hz), 6.98 (s, 0.55H, *Z* isomer of olefinic proton ), 7.16 and 7.78 (d and d, combined 2H, *J* = 8.63 Hz and 8.72 Hz).

**Step ii.**

- Ethyl (E/Z)-3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropenoate obtained in step i. above 25 (5.0 g, 14.5 mmol) and  $\text{H}_2$  / 10 % Pd-C (4 g) in dioxane (50 ml) was stirred at 25 °C under 60 psi hydrogen pressure for 24 h. The catalyst was filtered and the solvent was evaporated under reduced pressure. The residue was chromatographed over silica gel using a mixture of ethyl acetate and pet. ether (2 : 8) as an eluent to afford ethyl 3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate (4.0 g, 80 %) as a colorless oil.

$^1\text{H}$  NMR ( $\text{CDCl}_3$ , 200 MHz) :  $\delta$  1.12 - 1.30 (complex, 6H), 2.95 (d, *J* = 6.64 Hz, 2H), 3.25 - 3.45 (complex, 1H), 3.56 - 3.68 (complex, 3H), 3.96 (t, *J* = 6.65 Hz, 1H), 4.16 (q, *J* = 7.1 Hz, 2H), 4.27 (t, *J* = 6.3 Hz, 2H), 6.81 (d, *J* = 8.67 Hz, 2H), 7.16 (d, *J* = 8.63 Hz,

2H).

**Step iii.**


- Method A:** Ethyl 3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate obtained in step ii. above (1.7 g, 4.93 mmol) was taken in potassium hydroxide solution (1.1 g, 19.71 mmol in 5 18 mL of water) and stirred at room temperature for 24 h. Then the reaction mixture was heated to 80-85 °C for 4-5 days. The reaction mixture was cooled to 0 °C and acidified with 2N HCl solution to pH ~2 and extracted with ethyl acetate (3 x 50 mL). The combined organic extracts were washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated to dryness. The residue was purified by column chromatography on silica gel using 25% pet 10 ether in ethyl acetate to afford the title compound (0.93 g, 74%).

- Method B:** To a solution of ethyl 3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate obtained in step ii. above (2.5 g, 7.25 mmol) in methanol (40 mL) was added a solution of sodium carbonate (3.84 g, 36.2 mmol) in water (20 mL), and stirred the reaction mixture for 24 h at room temperature. Methanol was removed under reduced pressure and the 15 residue was diluted with water (50 mL) and extracted with ethyl acetate (2 x 50 mL) to remove impurities, if any. The aqueous layer was cooled to 0 °C and acidified with 2N HCl solution to pH~2 and extracted with ethyl acetate (2 x 200 mL). The organic extracts were washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated to dryness to give the crude intermediate (2.2 g, 96%).
- 20 The crude residue (2.2 g) was dissolved in potassium hydroxide solution (1.56 g in 20 mL of water) and the reaction mixture was stirred at room temperature for 96 h. The reaction mixture was cooled to 0 °C and acidified with 2N HCl solution to pH ~2 and extracted with ethyl acetate (3 x 100 mL). The combined organic extracts were washed with brine, dried ( $\text{Na}_2\text{SO}_4$ ) and evaporated to dryness. The residue was purified by column 25 chromatography on silica gel using 25% pet ether in ethyl acetate to afford the title compound (1.5 g, 81%).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.19 (t,  $J = 7.1$  Hz, 3H), 2.88-3.18 (m, 2H), 3.39-3.70 (m, 2H), 3.93-4.25 (m, 5H), 6.86 (d,  $J = 8.8$  Hz, 2H), 7.17 (d,  $J = 8.8$  Hz, 2H).

**Preparation 7**

- 30 **Ethyl 2-ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoate**




To a cooled solution of 2-ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoic acid obtained

in preparation 6 (0.92 g, 3.62 mmol) in ethanol (10 mL), conc. H<sub>2</sub>SO<sub>4</sub> (1 mL) was added slowly and the reaction mixture was refluxed for 6 h. Ethanol was removed under reduced pressure. The residue was taken in ethyl acetate (100 mL), washed with saturated sodium bicarbonate solution, water, brine and dried over Na<sub>2</sub>SO<sub>4</sub>, and concentrated. The residue 5 was purified on silica gel column using 10% ethyl acetate in pet ether to afford the title compound (0.72 g, 70.5%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.16 (t, J = 6.8 Hz, 3H), 1.22 (t, J = 6.8 Hz, 3H), 2.95 (d, J = 6.3 Hz, 2H), 3.27-3.42 (m, 1H), 3.51-3.70 (m, 1H), 3.92-4.08 (m, 5H), 4.16 (q, J = 7.2 Hz, 2H), 6.83 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.8 Hz, 2H).

## 10 Preparation 8

### (2S)-2-Ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoic acid




The title compound (0.72 g, 49%) was prepared from ethyl (2S)-3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate obtained in preparation 5 (2 g, 5.8 mmol) by 15 following similar procedure as described in preparation 6, method B.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.17 (t, J = 7.1 Hz, 3H), 2.90-3.15 (m, 2H), 3.39-3.70 (m, 2H), 3.95 (t, J = 4.1 Hz, 2H), 3.99-4.19 (m, 3H), 6.84 (d, J = 8.3 Hz, 2H), 7.16 (d, J = 8.8 Hz, 2H).

## Preparation 9

### Ethyl (2S)-2-ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoate



20 The title compound (0.37 g, 48%) was prepared from (2S)-2-ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoic acid obtained in preparation 8 (0.7 g, 2.76 mmol) by following the similar procedure as described in preparation 7.

[α]<sub>D</sub><sup>25</sup> = -17.8° (c = 0.5, CHCl<sub>3</sub>).

25 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.16 (t, J = 6.8 Hz, 3H), 1.23 (t, J = 7.3 Hz, 3H), 2.95 (d, J = 6.4 Hz, 2H), 3.26-3.43 (m, 1H), 3.51-3.69 (m, 1H), 3.92-4.10 (m, 5H), 4.17 (q, J = 7.2 Hz, 2H), 6.84 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H).

**Preparation 10****4-Aminobenzoyl-1-methyl-3-propyl-1*H*-pyrazole-5-carboxamide****Step i.**

5 Sodium (11.5 g, 500 mmol) was added to ethanol (130 mL) in portions at room temperature with vigorous stirring. After sodium got dissolved, the solution was cooled to 0 °C. Methyl propyl ketone (53.0 mL, 500 mmol) was added dropwise and the stirring was continued for further 15 – 20 min. Diethyl oxalate (68.0 mL, 500 mmol) was added dropwise to the resulting solution at 0 °C and the stirring was continued for another 15  
10 min at 0 °C. The reaction mixture was then allowed to attain room temperature and the stirring was continued for further 12 h at this temperature. The reaction mixture was then kept in refrigerator for 24 h. The solvent was removed under vacuum at room temperature. The resulting residue was diluted with dil. hydrochloric acid on an ice bath and extracted the aqueous layer with diethyl ether (4 x 50 mL). The combined ether extracts were  
15 washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated under vacuum. The crude mass was chromatographed on silica gel using 3 % ethyl acetate in pet. ether as eluent to yield ethyl 2,4-dioxoheptanoate (60.0 g, 64.5 %).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 14.45 (broad s, D<sub>2</sub>O exchangeable, 1H), 6.33 (s, 1H), 4.32 (q, J = 7.10 Hz, 2H), 2.44 (t, J = 7.40 Hz, 2H), 1.72 – 1.57 (m, 2H), 1.35 (t, J = 7.30 Hz, 3H),  
20 0.94 (t, J = 7.40 Hz, 3H).

**Step ii.**

To a stirred mixture of ethyl 2,4-dioxoheptanoate (28.0 g, 150 mmol) obtained in step i. above, acetic acid (225 mL) and methoxy ethanol (225 mL), hydrazine hydrochloride (31.6 g, 300 mmol) was added and heated to 105 °C for 3 h. Acetic acid and methoxy ethanol were removed under vacuum at 90 °C. The residue was taken in water and extracted three times with ethyl acetate. The combined organic layers were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to obtain solids suspended in liquid. The filtrate was evaporated to yield Ethyl 3-propyl-1*H*-5-pyrazole carboxylate (16.0 g, 58.4 %) as liquid.  
25

30 <sup>1</sup>H NMR (2A) (CDCl<sub>3</sub>): δ 6.57 (s, 1H), 4.34 (q, J = 7.10 Hz, 2H), 2.65 (t, J = 7.50 Hz, 2H),

1.71 – 1.59 (m, 2H), 1.33 (t, J = 7.20 Hz, 3H), 0.92 (t, J = 7.30 Hz, 3H).

**Step iii.**

Dimethyl sulfate (6.0 g, 48.35 mmol) was added to the pyrazole ester obtained in step ii. above (16.0 g, 88 mmol) and the reaction mixture was heated at 160 °C for 2 h. The

5 reaction mixture was cooled to ~ 90 °C and 5N sodium hydroxide solution (64 mL) was added and the reaction mixture was stirred at 80 – 90 °C for 30 min. The reaction mixture was cooled in an ice bath and was acidified to pH 4 with 2N hydrochloric acid resulting precipitation of the product. The precipitate was filtered, washed with cold water and dried under vacuum to yield 1-Methyl-3-propyl-1H-5-pyrazole carboxylic acid (12.0 g, 81 %).

10  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  6.70 (s, 1H), 4.14 (s, 3H), 2.64 (t, J = 7.60 Hz, 2H), 1.72 – 1.61 (m, 2H), 0.95 (t, J = 7.30 Hz, 3H).

**Step iv.**

Nitrating agent was prepared by adding 90 % nitric acid (7.18 mL) to concentrated sulphuric acid (13.8 mL) at 75-78 °C. 1-Methyl-3-propyl-1H-5-pyrazole carboxylic acid (11.5 g, 68.4 mmol) obtained in step iii. above was added to the nitrating agent portion wise with stirring so that the temperature is maintained at ~ 85 °C. After the complete addition, the mixture was heated at 100 °C for 2 h. The reaction mixture was cooled and poured into crushed ice. The suspension was filtered cold (10 °C) and the solids were washed with ice cold brine and dried to yield 1-Methyl-4-nitro-3-propyl-1H-5-pyrazole carboxylic acid (5.0 g, 34 %).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ) :  $\delta$  6.90 (broad s,  $\text{D}_2\text{O}$  exchangeable, 1H), 4.20 (s, 3H), 2.90 (t, J = 7.60 Hz, 2H), 1.79-1.64 (m, 2H), 1.02 (t, J = 7.40 Hz, 3H).

**Step v.**

Thionyl chloride (7.2 mL, 98 mmol) was added to 1-methyl-4-nitro-3-propyl-1H-5-pyrazole carboxylic acid obtained in step iv. (3.3 g, 15.5 mmol) and refluxed for 3.5 h. The excess thionyl chloride was removed from the reaction mixture under vacuum and the residue was taken in dry acetone (20 mL). Ammonia gas was passed through this solution till pH reached 8-9. The precipitate formed was filtered. The filtrate was concentrated and then dissolved in ethyl acetate. The organic phase was washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to yield 1-Methyl-4-nitro-3-propyl-1H-5-pyrazole carboxamide as a fluffy material (3.1 g, 94 %).

$^1\text{H}$  NMR ( $\text{CDCl}_3$ ) :  $\delta$  7.50 (broad s,  $\text{D}_2\text{O}$  exchangeable, 1H), 6.08 (broad s,  $\text{D}_2\text{O}$  exchangeable, 1H), 4.05 (s, 3H), 2.86 (t, J = 7.70 Hz, 2H), 1.75-1.60 (m, 2H), 0.98 (t, J = 7.30 Hz, 3H).

**Step vi.**

To a solution of 1-methyl-4-nitro-3-propyl-1*H*-5-pyrazole carboxamide obtained in step v. (3.2 g, 15.0 mmol) in methanol (30 mL), Raney nickel (450 mg) was added and hydrogenated by passing hydrogen gas at 50 psi for 10 h. The reaction mixture was 5 filtered through celite bed and washed with methanol. The filtrate and washings were combined, concentrated, purified by silica gel column chromatography using ethyl acetate-pet. ether (1 : 1) as eluent to yield 4-amino-1-methyl-3-propyl-1*H*-5-pyrazole carboxamide (2.0 g, 73 %).

<sup>1</sup>H NMR (CDCl<sub>3</sub>) : δ 7.05 (broad s, D<sub>2</sub>O exchangeable, 2H), 4.07 (s, 3H), 2.75 (broad s, D<sub>2</sub>O exchangeable, 2H), 2.51 (t, J = 7.60 Hz, 2H), 1.69 – 1.50 (m, 2H), 0.95 (t, J = 7.30 Hz, 3H).

**Step vii.**

To a solution of 4-amino-1-methyl-3-propyl-1*H*-5-pyrazole carboxamide obtained in step vi. above (550 mg, 3.0 mmol) in dichloromethane (8 mL) triethyl amine (0.92 mL, 6.6 mmol) was added at 0 °C and the reaction mixture was stirred for 15 min. Benzoyl chloride (0.39 mL, 3.32 mmol) was added drop wise at 0 °C and the stirring was continued for further 1 h at the same temperature. The reaction mixture was diluted with dichloromethane and washed successively with water and brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to give the title compound (680 mg, 70%) as a solid, mp 140 °C.

20 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.92 (t, J = 7.6 Hz, 3H), 1.50-1.75 (m, 2H), 2.51 (t, J = 7.6 Hz, 2H), 3.95 (s, 3H), 7.35-7.65 (m, 3H), 7.91 (d, J = 7.5 Hz, 2H).

**Preparation 11****1-Methyl-5-phenyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one**


25 To a stirred solution of potassium *tert*-butoxide (440 mg, 4.4 mmol) in *t*-butanol (10 mL) 4-aminobenzoyl-1-methyl-3-propyl-1*H*-pyrazole-5-carboxamide (1.0 g, 3.67 mmol), obtained in the preparation 10, was added portion wise and the reaction mixture was refluxed for 6 h. The solvent was removed under vacuum and the resulting residue was diluted with water and acidified with dil. HCl to pH~5 at 0 °C. The resulting white 30 precipitate was filtered, washed with water and dried to afford the title compound (700

mg, 74.7%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.02 (t, J = 7.3 Hz, 3H), 1.79-2.10 (m, 2H), 2.93 (t, J = 7.5 Hz, 2H), 4.27 (s, 3H), 7.51 (br s, 3H), 8.10-8.17 (m, 2H).

#### Preparation 12

##### 5 1-Methyl-3-propyl-5-cyclopropyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-one




Cyclopropane carboxylic acid (600 mg, 6.97 mmol) was refluxed in thionyl chloride (1.01 mL, 1.64 mmol) for 2 h. Excess thionyl chloride was distilled off and the acid chloride was cooled to 0 °C. In another set up, to a solution of 4-amino-1-methyl-3-propyl-1*H*-5-pyrazole carboxamide (prepared as disclosed in our US application No. 09/507,373) (1.0 g, 5.49 mmol) in xylene (10 mL), cyclopropane carboxylic acid (5 mL) was added and cooled in ice bath. Triethyl amine was added to the above mixture and stirred for 20 min. This mixture was then added to acid chloride at 0 °C and stirred at room temperature for 1 h. The reaction mixture was refluxed for 48 h and the solvents were removed under reduced pressure. The residue was diluted with water and extracted with ethyl acetate (3 x 60 mL). The combined organic layers were washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude compound was purified by silica gel column chromatography using 30% ethyl acetate in pet ether to yield the title compound (1.22 g, 45%) as a white solid, mp 228-230 °C.

10      20      1H NMR (CDCl<sub>3</sub>): δ 0.98 (t, J = 7.3 Hz, 3H), 1.01-1.25 (m, 4H), 1.72-1.99 (m, 3H), 2.82 (t, J = 7.6 Hz, 2H), 4.23 (s, 3H), 11.05 (br s, 1H, D<sub>2</sub>O exchangeable).

#### Preparation 13

##### Ethyl 2-(4-nitrophenoxy)pentanoate




25 To a solution of 4-nitrophenol (11.08 g, 79.7 mmol) in *N,N*-dimethylformamide (70 mL) anhydrous K<sub>2</sub>CO<sub>3</sub> (28.1 g, 203.8 mmol) was added and stirred for 30 min at room temperature. Ethyl 2-bromopentanoate obtained in preparation 1 (20.0 g, 95.7 mmol) in

*N,N*-dimethylformamide (25 mL) was added to the above reaction mixture with vigorous stirring. The stirring was continued at room temperature for further 18 h. The reaction mixture was diluted with ethyl acetate (400 mL) and washed the organic layer successively with water (3 x 300 mL) and brine, dried over anhydrous sodium sulfate and concentrated to afford the title compound (23.0 g, 92%) as a gummy mass.

5       $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  0.99 (t,  $J = 7.6$  Hz, 3H), 1.25 (t,  $J = 7.1$  Hz, 3H), 1.42-1.64 (m, 2H), 1.92-2.04 (m, 2H), 4.22 (q,  $J = 7.2$  Hz, 2H), 4.71 (t,  $J = 6.1$  Hz, 1H), 6.92 (d,  $J = 9.3$  Hz, 2H), 8.18 (d,  $J = 9.3$  Hz, 2H).

#### Preparation 14

10     Ethyl 2-(4-aminophenoxy)pentanoate




To a solution of ethyl 2-(4-nitrophenoxy)pentanoate obtained in preparation 13 (22.5 g, 84.3 mmol) in dioxane (65 mL), 10 % Pd-C (5.63 g) was added and hydrogenated by passing hydrogen gas at 40 psi at room temperature for 5 h. The reaction mixture was 15 filtered through celite bed and washed with dioxane. The filtrate and washings were combined, concentrated, and purified by silica gel column chromatography using 20% ethyl acetate in pet ether as eluent to yield the title compound (14.0 g, 70%).

15      $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  0.94 (t,  $J = 7.1$  Hz, 3H), 1.22 (t,  $J = 7.1$  Hz, 3H), 1.40-1.62 (m, 2H), 1.78-1.96 (m, 2H), 4.17 (q,  $J = 7.1$  Hz, 2H), 4.45 (t,  $J = 6.3$  Hz, 1H), 6.5 (d,  $J = 6.8$  Hz, 2H), 6.73 (d,  $J = 6.3$  Hz, 2H).


#### Preparation 15

Ethyl 6-[4-(1-ethoxycarbonylbutoxy)anilino]hexanoate




The title compound (1.55 g, 48.5%) was obtained as a liquid from ethyl 2-(4-aminophenoxy)pentanoate (2.0 g, 8.4 mmol) obtained in preparation 14 by reacting with ethyl 6-bromohexanoate (2.26 g, 10.1 mmol) using anhydrous potassium carbonate (3.5 g, 25.31 mmol) at room temperature for 48 h by following the similar procedure as described in preparation 13.

14      $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  0.97 (t,  $J = 7.3$  Hz, 3H), 1.25 (t,  $J = 7.3$  Hz, 6H), 1.36-1.76 (m, 8H), 1.80-1.96 (m, 2H), 2.31 (t,  $J = 7.3$  Hz, 2H), 3.06 (t,  $J = 6.8$  Hz, 2H), 4.07-4.26 (m, 4H), 4.46 (t,  $J = 6.4$  Hz, 1H), 6.52 (d,  $J = 6.8$  Hz, 2H), 6.77 (d,  $J = 6.3$  Hz, 2H).

**Preparation 16****Ethyl 6-chloromethyl[4-(1-ethoxycarbonylbutoxy)phenyl]carboxamido-hexanoate**

The title compound (1.45 g, 78%) was obtained from ethyl 6-[4-(1-ethoxycarbonylbutoxy)anilino]hexanoate (1.55 g, 4.1 mmol) obtained in preparation 15 by reacting with chloroacetyl chloride (0.47 mL, 6.13 mmol) using dichloromethane (18 mL) in presence of triethyl amine (1.7 mL, 12.27 mmol) at room temperature for 16 h by following the similar procedure as described in preparation 4.


<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 3H), 1.24 (t, J = 7.1 Hz, 3H), 1.25-1.41 (m, 3H), 1.40-1.70 (m, 8H), 1.86-2.09 (m, 2H), 2.27 (t, J = 7.6 Hz, 2H), 3.66 (t, J = 7.3 Hz, 2H), 3.78 (s, 2H), 4.11 (q, J = 7.1 Hz, 2H), 4.25 (q, J = 6.8 Hz, 2H), 4.61 (t, J = 6.8 Hz, 1H), 6.90 (d, J = 8.8 Hz, 2H), 7.10 (d, J = 8.8 Hz, 2H).

**Preparation 17****Ethyl 2-ethoxy-3-[4-nitrophenyl]propaneate**


To an ice-cold slurry of sodium hydride (60% oil coated, 5.3 g, 132.5 mmol), a solution of the Wittig salt (triethyl 2-ethoxyphosphonoacetate) (23.16 g, 86.1 mmol), (prepared as disclosed in our US patent No. 6,054,453), in THF (150 mL) was slowly added drop wise with vigorous stirring. The reaction temperature was brought to room temperature and heated until the reaction mixture became clear. The reaction mixture was cooled to 0 °C and a solution of *p*-nitrobenzaldehyde (10.0 g, 66.2 mmol) in THF (150 mL) was added drop wise and stirred at room temperature for overnight. THF was then removed and the residue was taken in ethyl acetate, and washed successively with water and brine, dried over anhydrous sodium sulfate and concentrated. The residue was chromatographed using 5% ethyl acetate in pet ether to afford the title compound as E and Z isomers (15.1 g, 86%) as bright yellow liquid.

**Z isomer:** <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.16 (t, J = 7.2 Hz, 3H), 1.46 (t, J = 7.0 Hz, 3H), 3.99 (q, J = 7.0 Hz, 2H), 4.19 (q, J = 7.1 Hz, 2H), 6.04 (s, 1H), 7.34 (d, J = 8.7 Hz, 2H), 8.15 (d, J = 8.6 Hz, 2H).


**E isomer:** <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.35-1.47 (m, 6H), 4.12 (q, J = 7.0 Hz, 2H), 4.34 (q, J = 7.2 Hz, 2H), 6.92 (s, 1H), 7.92 (d, J = 8.8 Hz, 2H), 8.22 (d, J = 8.7 Hz, 2H).

**Preparation 18****Ethyl 2-ethoxy-3-[4-aminophenyl]propanoate**

- 5 The title compound (3.2 g, 55%) was synthesized by hydrogenating ethyl 2-ethoxy-3-[4-nitrophenyl]propane obtained in preparation 17 (6.5 g, 24.4 mmol) by passing hydrogen gas at 60 psi, taken in dioxane (65 mL), in presence of 10% Pd-C (2.6 g) at room temperature for 36 h by following the same procedure as described in preparation 14.
- 10  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.17 (t,  $J = 6.1$  Hz, 3H), 1.23 (t,  $J = 6.1$  Hz, 3H), 2.91 (d,  $J = 6.7$  Hz, 2H), 3.28-3.44 (m, 1H), 3.52-3.68 (m, 1H), 3.95 (t,  $J = 6.8$  Hz, 1H), 4.17 (q,  $J = 7.1$  Hz, 2H), 6.62 (d,  $J = 8.1$  Hz, 2H), 7.04 (d,  $J = 8.2$  Hz, 2H).

**Preparation 19****Ethyl 2-ethoxy-3-[4-(4-fluorobenzylamino)phenyl]propanoate**


- 15 The title compound (100 mg, 14%) was obtained as yellow colored liquid from ethyl 2-ethoxy-3-[4-aminophenyl]propanoate (500 mg, 2.11 mmol) obtained in preparation 18, 1-bromomethyl-4-fluorobenzene (438 mg, 2.32 mmol) and anhydrous potassium carbonate (873 mg, 6.33 mmol) at room temperature for 18 h by following the similar procedure as described in preparation 13.
- 20  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.16 (t,  $J = 6.9$  Hz, 3H), 1.21 (t,  $J = 7.1$  Hz, 3H), 2.89 (d,  $J = 6.8$  Hz, 2H), 3.28-3.43 (m, 1H), 3.50-3.66 (m, 1H), 3.94 (t,  $J = 6.6$  Hz, 1H), 4.15 (q,  $J = 7.3$  Hz, 2H), 4.27 (s, 2H), 6.54 (d,  $J = 8.3$  Hz, 2H), 6.94-7.09 (m, 4H), 7.32 (dd,  $J = 8.3$  and 5.4 Hz, 2H).

**Preparation 20****Ethyl 3-[4-chloromethyl(4-fluorobenzyl)carboxamidophenyl]-2-ethoxypropanoate**

The title compound (355 mg, 74%) was obtained as straw yellow colored liquid from ethyl

- 5 2-ethoxy-3-[4-(4-fluorobenzylamino)phenyl]propanoate (390 mg, 1.13 mmol) obtained in preparation 19, chloroacetyl chloride (0.09 mL, 1.36 mmol) and dichloromethane in presence of triethyl amine (0.39 mL, 2.83 mmol) at room temperature for 16 h by following the similar procedure as described in preparation 4.

10  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  1.14 (t,  $J = 6.9$  Hz, 3H), 1.24 (t,  $J = 7.3$  Hz, 3H), 2.95-3.06 (m, 2H), 3.25-3.42 (m, 1H), 3.55-3.70 (m, 1H), 3.83 (s, 2H), 3.94 (dd,  $J = 7.6$  and 5.6 Hz, 1H), 4.16 (q,  $J = 7.0$  Hz, 2H), 4.84 (s, 2H), 6.80-7.00 (m, 4H), 7.15 (dd,  $J = 8.3$  and 5.9 Hz, 2H), 7.25 (d,  $J = 8.3$  Hz, 2H).


**Preparation 21****Ethyl 2-[4-{4-(4-ethoxycarbonylphenyl)butylamino}phenoxy]pentanoate**

- 15 The title compound (1.35 g, 36.4%) was obtained as a liquid from ethyl 2-(4-aminophenoxy)pentanoate (2.0 g, 8.4 mmol), obtained in preparation 14, by reacting with ethyl 4-(4-bromobutyl)benzoate (2.65 g, 9.82 mmol) using anhydrous potassium carbonate (3.5 g, 25.31 mmol) at room temperature for 60 h following a similar procedure as described in the preparation 13.


20  $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  0.97 (t,  $J = 7.3$  Hz, 3H), 1.25 (t,  $J = 7.1$  Hz, 3H), 1.39 (t,  $J = 7.3$  Hz, 3H), 1.40-1.96 (m, 8H), 2.71 (t,  $J = 7.1$  Hz, 2H), 3.08 (t,  $J = 6.6$  Hz, 2H), 4.20 (t,  $J = 7.1$  Hz, 2H), 4.37 (q,  $J = 7.5$  Hz, 2H), 4.47 (t,  $J = 7.1$  Hz, 1H), 6.52 (d,  $J = 8.8$  Hz, 2H), 6.77 (d,  $J = 8.8$  Hz, 2H), 7.25 (d,  $J = 8.3$  Hz, 2H), 7.97 (d,  $J = 8.3$  Hz, 2H).

**Preparation 22**

Ethyl 2-[4-chloromethyl{4-(4-ethoxycarbonylphenyl)butyl}carboxamido-phenoxy]pentanoate



- 5 The title compound (1.4 g, 88%) was obtained from ethyl 2-[4-(4-ethoxycarbonylphenyl)butylamino]phenoxy]pentanoate (1.35 g, 3.07 mmol), obtained in preparation 21, by reacting with chloroacetyl chloride (0.28 mL, 3.68 mmol) using dichloromethane (20 mL) in presence of triethyl amine (1.08 mL, 7.67 mmol) at room temperature for 40 h by following the similar procedure as described in preparation 4.
- 10 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 3H), 1.24 (t, J = 7.3 Hz, 3H), 1.38 (t, J = 7.3 Hz, 3H), 1.48-1.70 (m, 6H), 1.82-2.05 (m, 2H), 2.66 (t, J = 6.8 Hz, 2H), 3.68 (t, J = 6.8 Hz, 2H), 3.77 (s, 2H), 4.24 (t, J = 7.0 Hz, 2H), 4.36 (q, J = 7.1 Hz, 2H), 4.60 (t, J = 6.1 Hz, 1H), 6.88 (d, J = 8.8 Hz, 2H), 7.05 (d, J = 8.8 Hz, 2H), 7.19 (d, J = 8.3 Hz, 2H), 7.93 (d, J = 7.8 Hz, 2H).
- 15 **Preparation 23**

**5-Ethyl-1-methyl-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one**


- To 4-amino-1-methyl-3-propyl-1H-5-pyrazole carboxamide obtained in step vi. preparation 10 (1.3 g, 7.1 mmol) in xylene (10.5 mL), propionic acid (10.5 mL) was added 20 and cooled in ice bath. Triethyl amine (2.2 mL, 15.7 mmol) was added to the reaction mixture and stirred for 15 min. Propionyl chloride was added and stirred at the same temperature for 30 min. The reaction mixture was refluxed for 36 h and the solvent was removed under vacuum. The resulting residue was diluted with water and extracted with ethyl acetate (3 X 10 mL). The combined organic extracts were washed with water, brine, 25 dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The crude compound was purified by silica gel column

chromatography using 30 % ethyl acetate in pet. ether as eluent to yield the title compound (560 mg, 36 %).

<sup>1</sup>H NMR ( $\text{CDCl}_3$ ):  $\delta$  11.1 (broad s,  $\text{D}_2\text{O}$  exchangeable, 1H), 4.23 (s, 3H), 2.89 – 2.69 (m, 4H), 1.85 – 1.71 (m, 2H), 1.37 (t,  $J$  = 7.50 Hz, 3H), 0.98 (t,  $J$  = 7.40 Hz, 3H).

## 5 Preparation 24.

### 1,5-Dimethyl-3-propyl-6,7-dihydro-1H-pyrazolo[4,3-d]pyrimidin-7-one




The title compound (360 mg, 36 %) was obtained as fluffy solid from 4-amino-1-methyl-3-propyl-1H-5-pyrazole carboxamide (950 mg, 5.2 mmol) obtained in step vi preparation 10, acetyl chloride (450 mg, 5.74 mmol), triethyl amine (1.15 g, 11.48 mmol) and acetic acid (7.5 mL) by refluxing in xylene (7.5 mL) for 72 h following a similar procedure as described in preparation 23.

<sup>1</sup>H NMR ( $\text{CDCl}_3$ ):  $\delta$  11.18 (broad s,  $\text{D}_2\text{O}$  exchangeable, 1H), 4.23 (s, 3H), 2.84 (t,  $J = 7.60$  Hz, 2H), 2.51 (s, 3H), 1.84–1.75 (m, 2H), 0.98 (t,  $J = 7.30$  Hz, 3H).

15

### Example 1

Ethyl 2-[4-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)methyl(heptyl)carboxamido]phenylsulfanyl]pentanoate




20 A mixture of 5-ethyl-1-methyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]-pyrimidin-7-one obtained in preparation 23 (236 mg, 1.07 mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub> (444 mg, 3.21 mmol) in dry *N,N*-dimethylformamide (4 mL) was stirred under argon atmosphere for 30 min at room temperature. Ethyl 2-[4-chloromethyl(heptyl)carboxamidophenylsulfanyl]pentanoate (597 mg, 1.39 mmol), obtained in preparation 4, dissolved in dry *N,N*-dimethylformamide (3 mL) was added drop wise to the above reaction mixture at 0 °C. The reaction mixture was stirred at room temperature for 48 h. The reaction mixture was diluted with ethyl acetate (25 mL), washed with water (3 x 15 mL), brine (20 mL), dried

( $\text{Na}_2\text{SO}_4$ ) and concentrated. The residue was column chromatographed using 10% ethyl acetate in pet ether to afford the title compound (527 mg, 81%).

- $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  0.85 (t,  $J = 6.4$  Hz, 3H), 0.96 (t,  $J = 7.6$  Hz, 3H), 0.99 (t,  $J = 7.6$  Hz, 3H), 1.15-1.62 (m, 20H), 1.70-1.90 (m, 2H), 2.84-3.00 (m, 4H), 3.63-3.79 (m, 3H), 4.10-4.22 (m, 5H), 4.82 (s, 2H), 7.26 (d,  $J = 8.3$  Hz, 2H), 7.54 (d,  $J = 8.3$  Hz, 2H).

**Example 2**

**2-[4-(5-Ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl-heptyl)carboxamido]phenylsulfanyl]pentanoic acid**




- To a solution of ethyl 2-[4-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl-heptyl)carboxamido]phenylsulfanyl]pentanoate (527 mg, 0.86 mmol), obtained in example 1, in methanol (5 mL) sodium carbonate (457 mg, 4.31 mmol) in water (5 mL) was added and stirred at room temperature for 12 h. Methanol was removed from the reaction mixture under reduced pressure and the resulting aqueous layer was acidified with 2N HCl at 0 °C to pH~2. The aqueous layer was extracted with ethyl acetate, dried ( $\text{Na}_2\text{SO}_4$ ) and concentrated. The residue was chromatographed using 60% ethyl acetate in pet ether as eluent to afford the title compound (27 mg, 5.4%), mp 84-86 °C.

- $^1\text{H}$  NMR ( $\text{CDCl}_3$ ):  $\delta$  0.87 (t,  $J = 6.4$  Hz, 3H), 1.01 (t,  $J = 7.3$  Hz, 6H), 1.20-1.42 (m, 11H), 1.45-1.68 (m, 3H), 1.74-1.95 (m, 2H), 2.84-3.00 (m, 6H), 3.63-3.84 (m, 4H), 4.15 (s, 3H), 4.79 (s, 2H), 7.27 (d,  $J = 8.8$  Hz, 2H), 7.59 (d,  $J = 8.3$  Hz, 2H).

**Example 3**

**Ethyl 2(S)-2-ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate**



A mixture of 5-ethyl-1-methyl-3-propyl-6,7-dihydro-1*H*-pyrazolo-[4,3-d]pyrimidin-7-one obtained in preparation 23 (40.0 g, 180 mmol) and anhydrous K<sub>2</sub>CO<sub>3</sub> (75.2 g, 544 mmol) in dry *N,N*-dimethylformamide (200 mL) was stirred under argon atmosphere for 30 min at room temperature. Ethyl (2*S*)-3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate (3.9 g, 11.3 mmol), obtained in preparation 5, dissolved in dry *N,N*-dimethylformamide (7 mL) was added drop wise to the above mixture at room temperature. The reaction mixture was stirred at room temperature for 24 h. The reaction mixture was diluted with ethyl acetate (1 L), washed with water (3 x 400 mL), brine (200 mL), dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. The residue was column chromatographed using 10% ethyl acetate in pet ether to afford the title compound (14.36 g, 16.4%), mp 59-60 °C.

[α]<sub>D</sub><sup>25</sup> = -11.0° (c = 1.0, CH<sub>3</sub>OH).


<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 3H), 1.17 (t, J = 6.6 Hz, 3H), 1.23 (t, J = 6.8 Hz, 3H), 1.36 (t, J = 7.3 Hz, 3H), 1.74-1.93 (m, 2H), 2.87-3.03 (m, 6H), 3.26-3.47 (m, 1H), 3.51-3.88 (m, 1H), 3.97 (t, J = 6.6 Hz, 1H), 4.14 (s, 3H), 4.16 (q, J = 7.3 Hz, 2H), 4.38 (t, J = 4.7 Hz, 2H), 4.91 (t, J = 4.7 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H).

#### Example 4

Methyl 2(*S*)-2-ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate (A)

&

2(*S*)-2-Ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoic acid (B)



To a solution of ethyl 2(*S*)-2-ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate (5.0 g, 10.33 mmol), obtained in example 3, in methanol (250 mL) sodium carbonate (5.47 g, 51.65 mmol) in water (25 mL) was added and stirred at room temperature for 24 h. Methanol was removed from the reaction mixture under vacuum and the resulting aqueous layer was extracted with ethyl acetate which was washed with water, brine, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated to get a *trans* esterified product i.e., the corresponding methyl ester (4A) of the free acid (1.44 g,

29.7%), mp 68-70 °C. The aqueous layer was acidified with 2N HCl at low temperature to pH~2. The solids were filtered and washed with cold water, dried under vacuum overnight to yield the title compound (4B) (2.9 g, 59.9%), mp 138-140 °C.

4A:  $[\alpha]_D^{25} = -9.0^\circ$  ( $c = 0.5$ , CH<sub>3</sub>OH).


5     <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  1.01 (t,  $J = 7.3$  Hz, 3H), 1.17 (t,  $J = 7.1$  Hz, 3H), 1.23 (t,  $J = 7.6$  Hz, 3H), 1.77-1.95 (m, 2H), 2.87-3.03 (m, 6H), 3.27-3.43 (m, 1H), 3.54-3.69 (m, 1H), 3.72 (s, 3H), 4.01 (t,  $J = 6.6$  Hz, 1H), 4.16 (s, 3H), 4.40 (t,  $J = 4.7$  Hz, 2H), 4.92 (t,  $J = 4.7$  Hz, 2H), 6.88 (d,  $J = 8.3$  Hz, 2H), 7.17 (d,  $J = 8.3$  Hz, 2H).

4B:  $[\alpha]_D^{25} = -18.6^\circ$  ( $c = 0.5$ , CH<sub>3</sub>OH).

10    <sup>1</sup>H NMR (CDCl<sub>3</sub>):  $\delta$  0.99 (t,  $J = 7.3$  Hz, 3H), 1.18 (t,  $J = 6.8$  Hz, 3H), 1.36 (t,  $J = 7.6$  Hz, 3H), 1.77-1.95 (m, 2H), 2.82-3.16 (m, 6H), 3.40-3.65 (m, 2H), 4.00-4.12 (m, 1H), 4.14 (s, 3H), 4.39 (t,  $J = 4.4$  Hz, 2H), 4.92 (t,  $J = 4.7$  Hz, 2H), 6.87 (d,  $J = 8.8$  Hz, 2H), 7.18 (d,  $J = 8.8$  Hz, 2H).

#### Example 5

15    Ethyl 2(S)-3-[4-{2-(1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoate



- Method A: The title compound (2.26 g, 15%) was obtained as white solid by condensing 1,5-dimethyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one (prepared as disclosed in our US application No. 09/507,373) (6.6 g, 32 mmol) with ethyl (2S)-3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate (3.9 g, 11.3 mmol), obtained in preparation 5, in dry *N,N*-dimethylformamide (80 mL) in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> (11.05 g, 80.1 mmol) at room temperature by following the similar procedure as described in example 3, mp 84-86 °C.
- Method B: To a cooled solution of triphenyl phosphine (1.78 g, 6.8 mmol) in dry THF (5 mL) DIAD (1.35 mL, 6.8 mmol) was added drop wise and stirred for 15 min. 1,5-Dimethyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one (0.7 g, 3.4 mmol) in THF (25 mL) was added drop wise to the above reaction mixture at 0 °C. The reaction mixture was stirred for 10 min at room temperature. The reaction mixture was cooled and


a solution of ethyl (2*S*)-2-ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoate (1.054 g, 3.79 mmol), obtained in preparation 9, in THF (10 mL) was added to the reaction mixture slowly. The reaction mixture was allowed to stir at room temperature for 3 days. THF was removed under reduced pressure and the residue was purified by column chromatography

5 using 15% ethyl acetate in pet ether to get the title compound (0.8 g, 50%).

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 3H), 1.17 (t, J = 6.8 Hz, 3H), 1.23 (t, J = 6.8 Hz, 3H), 1.72-1.84 (m, 2H), 2.70 (s, 3H), 2.92-3.02 (m, 4H), 3.25-3.42 (m, 1H), 3.52-3.70 (m, 1H), 3.97 (t, J = 6.6 Hz, 1H), 4.15 (s, 3H), 4.17 (q, J = 6.6 Hz, 2H), 4.39 (t, J = 4.7 Hz, 2H), 4.91 (t, J = 4.4 Hz, 2H), 6.87 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H).

10 **Example 6**

**2(*S*)-3-[4-{2-(1,5-Dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy}ethoxy}phenyl]-2-ethoxypropanoic acid**




The title compound (0.3 g, 40%) was obtained as white solid from ethyl 2(*S*)-3-[4-{2-(1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}-phenyl]-2-ethoxypropanoate (0.8 g, 1.7 mmol) obtained in example 5 by hydrolyzing in methanol-water (2:1, 30 mL) using sodium carbonate (0.9 g, 8.5 mmol) at room temperature for 48 h following a similar procedure as described in example 2, mp 148-150 °C.

[α]<sub>D</sub><sup>25</sup> = -7.6° (c = 0.5, CHCl<sub>3</sub>).  
 20 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 3H), 1.20 (t, J = 7.0 Hz, 3H), 1.75-1.93 (m, 2H), 2.69 (s, 3H), 2.17-3.10 (m, 4H), 3.45-3.65 (m, 2H), 4.06 (dd, J = 7.0 and 4.7 Hz, 1H), 4.14 (s, 3H), 4.39 (t, J = 4.6 Hz, 2H), 4.91 (t, J = 5.1 Hz, 2H), 6.88 (d, J = 8.6 Hz, 2H), 7.18 (d, J = 8.6 Hz, 2H).

**Example 7**

**Ethyl 2-ethoxy-3-[4-{2-(1-methyl-5-phenyl-3-propyl-1*H*-pyrazolo-[4,3-d]pyrimidin-7-yloxy}ethoxy]phenyl]propanoate**




- 5 The title compound (480 mg, 96.7%) was obtained as white solid by condensing 1-methyl-5-phenyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one, obtained in preparation 11, (250 mg, 0.93 mmol) with ethyl 3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate obtained in step ii. Preparation 6 (386 mg, 1.12 mmol) was taken in dry *N,N*-dimethylformamide (10 mL) in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> (386 mg, 2.79 mmol) at room temperature for 12 h following the similar procedure as described in example 1, mp 80-82 °C.
- 10

15 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.04 (t, J = 7.3 Hz, 3H), 1.17 (t, J = 7.1 Hz, 3H), 1.23 (t, J = 6.8 Hz, 3H), 1.84-2.01 (m, 2H), 2.92-3.09 (m, 4H), 3.28-3.44 (m, 1H), 3.52-3.70 (m, 1H), 3.97 (t, J = 6.6 Hz, 1H), 4.17 (q, J = 7.1 Hz, 2H), 4.19 (s, 3H), 4.45 (t, J = 4.7 Hz, 2H), 5.05 (t, J = 4.6 Hz, 2H), 6.88 (d, J = 8.8 Hz, 2H), 7.18 (d, J = 8.8 Hz, 2H), 7.40-7.55 (m, 3H), 8.42-8.55 (m, 2H).

**Example 8**

**3-[4-{2-(1-Methyl-5-phenyl-3-propyl-1*H*-pyrazolo-[4,3-d]pyrimidin-7-yloxy}ethoxy]phenyl]-2-ethoxypropanoic acid**




- 20 The title compound (149 mg, 63%) obtained as a white solid from ethyl 2-ethoxy-3-[4-{2-(1-methyl-5-phenyl-3-propyl-1*H*-pyrazolo-[4,3-d]pyrimidin-7-yloxy)-ethoxy}phenyl]propanoate (253 mg, 0.47 mmol) obtained in example 7 by hydrolyzing in methanol-water (3:2, 8 mL) using sodium carbonate (252 mg, 2.37 mmol) at room temperature for 24 h following the similar procedure as described in example 2, mp 124-126 °C.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.04 (t, J = 7.3 Hz, 3H), 1.19 (t, J = 7.0 Hz, 3H), 1.84-2.01 (m, 2H), 2.92-3.17 (m, 4H), 3.42-3.69 (m, 2H), 4.06 (t, J = 5.6 Hz, 1H), 4.19 (s, 3H), 4.47 (t, J = 4.7 Hz, 2H), 5.06 (t, J = 4.8 Hz, 2H), 6.89 (d, J = 8.8 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H), 7.39-7.56 (m, 3H), 8.48 (d, J = 8.3 Hz, 2H).

5   **Example 9**

Ethyl (2*S*)-3-[4-{2-(5-cyclopropyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoate




The title compound (230 g, 38%) was obtained by condensing 1-methyl-3-propyl-5-cyclopropyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-one (200 mg, 0.86 mmol) obtained in preparation 12 with ethyl (2*S*)-3-[4-(2-bromoethoxy)phenyl]-2-ethoxypropanoate (357 mg, 1.03 mmol) obtained in preparation 5 in dry *N,N*-dimethylformamide (8 mL) in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> (357 mg, 2.58 mmol) at room temperature for 24 h following the similar procedure as described in example 3.

15   <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.01 (t, J = 7.3 Hz, 3H), 1.05-1.31 (m, 10H), 1.71-1.93 (m, 2H), 2.17-2.31 (m, 1H), 2.87-3.05 (m, 4H), 3.28-3.43 (m, 1H), 3.51-3.68 (m, 1H), 3.97 (t, J = 7.3 Hz, 1H), 4.12 (s, 3H), 4.17 (q, J = 7.1 Hz, 2H), 4.36 (t, J = 4.4 Hz, 2H), 4.83 (t, J = 4.4 Hz, 2H), 6.86 (d, J = 8.3 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H).

**Example 10**

20   (2*S*)-3-[4-{2-(5-Cyclopropyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoic acid



The title compound (145 mg, 81%) was obtained as a white solid from ethyl (2*S*)-3-[4-{2-(5-cyclopropyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoate (190 mg, 0.38 mmol) obtained in example 9 by


hydrolyzing in methanol-water (5:2, 7 mL) using sodium carbonate (203 mg, 1.9 mmol) at room temperature for 18 h following the similar procedure as described in example 2, mp 118-120 °C.

$[\alpha]_D^{25} = -14.0^\circ$  ( $c = 0.5$ , CH<sub>3</sub>OH).

- <sup>1</sup>H NMR ( $\text{CDCl}_3$ ):  $\delta$  0.93-1.13 (m, 7H), 1.18 (t,  $J$  = 7.1 Hz, 3H), 1.72-1.93 (m, 2H), 2.17-2.31 (m, 1H), 2.93 (t,  $J$  = 7.6 Hz, 2H), 2.96-3.14 (m, 2H), 3.40-3.68 (m, 2H), 4.02-4.08 (m, 1H), 4.10 (s, 3H), 4.35 (t,  $J$  = 4.6 Hz, 2H), 4.83 (t,  $J$  = 4.6 Hz, 2H), 6.85 (d,  $J$  = 8.3 Hz, 2H), 7.17 (d,  $J$  = 8.3 Hz, 2H).

### Example 11

- 10 Ethyl 6-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl{4-(1-ethyloxycarbonylbutoxy)phenyl}carboxamido]hexanoate




The title compound (400 mg, 55%) was obtained by condensing 5-ethyl-1-methyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]-pyrimidin-7-one obtained in preparation 23 (250 mg, 1.14 mmol) with ethyl 6-chloromethyl[4-(1-ethyloxycarbonylbutoxy)phenyl]carboxamido hexanoate, obtained in preparation 16, in dry *N,N*-dimethylformamide (10 mL) in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> (470 mg, 3.41 mmol) at room temperature for 96 h following a similar procedure as described in example 1.

- <sup>1</sup>H NMR ( $\text{CDCl}_3$ ):  $\delta$  1.00 (t,  $J = 7.3$  Hz, 6H), 1.23 (t,  $J = 7.1$  Hz, 3H), 1.24-1.38 (m, 10H), 1.43-1.70 (m, 4H), 1.75-2.00 (m, 4H), 2.26 (t,  $J = 7.6$  Hz, 2H), 2.82-2.98 (m, 4H), 3.67 (t,  $J = 7.3$  Hz, 2H), 4.09 (q,  $J = 7.2$  Hz, 2H), 4.17 (q,  $J = 7.3$  Hz, 2H), 4.19 (s, 3H), 4.63 (t,  $J = 5.8$  Hz, 1H), 4.81 (s, 2H), 6.95 (d,  $J = 8.8$  Hz, 2H), 7.22 (d,  $J = 8.8$  Hz, 2H).

**Example 12**


**6-[4-(1-Carboxybutoxy)phenyl(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxyethyl)carboxamido]hexanoic acid**



- 5 The title compound (200 mg, 73%) was obtained from ethyl 6-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxyethyl{4-(1-ethyloxycarbonyl-butoxy)phenyl}carboxamido]hexanoate (300 mg, 0.47 mmol), obtained in example 11, by hydrolyzing in methanol-water using sodium carbonate (248 mg, 2.35 mmol) at room temperature for 18 h following a similar procedure as described in example 2.
- 10 <sup>1</sup>H NMR ( $\text{CDCl}_3$ ):  $\delta$  0.98 (t,  $J = 7.3$  Hz, 3H), 1.02 (t,  $J = 7.3$  Hz, 3H), 1.22-1.42 (m, 7H), 1.43-1.88 (m, 6H), 1.92-2.11 (m, 2H), 2.31 (t,  $J = 6.8$  Hz, 2H), 2.80-2.99 (m, 4H), 3.58-3.77 (m, 2H), 4.17 (s, 3H), 4.63 (t,  $J = 5.9$  Hz, 1H), 4.77 (d,  $J = 5.2$  Hz, 1H), 4.91 (d,  $J = 4.8$  Hz, 1H), 6.98 (d,  $J = 8.8$  Hz, 2H), 7.21 (d,  $J = 8.8$  Hz, 2H).

**Example 13**

- 15 Bis-arginine salt of 6-[4-(1-carboxybutoxy)phenyl(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxyethyl)carboxamido]hexanoic acid




- To a solution of 6-[4-(1-carboxybutoxy)phenyl(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxyethyl)carboxamido]hexanoic acid obtained in example 12 (72 mg, 0.123 mmol) in ethanol (2 mL) was added arginine (43 mg, 0.246 mmol) dissolved in ethanol (1 mL) and stirred the reaction mixture at room temperature for 18 h.

Ethanol was then distilled off under vacuum, flushed with toluene (3 x 3 mL), dried under high vacuum to yield the title compound as a hygroscopic solid (110 mg, 96%), mp 158-160 °C.

<sup>1</sup>H NMR (CD<sub>3</sub>OD): δ 0.80-1.03 (m, 6H), 1.22-1.90 (m, 17H), 2.15 (t, J = 6.8 Hz, 2H), 5 2.83-2.99 (m, 2H), 3.10-3.37 (m, 8H), 3.41-3.75 (m, 6H), 4.16 (s, 3H), 4.63-4.92 (m, 5H), 7.02 (d, J = 8.8 Hz, 2H), 7.21 (d, J = 9.2 Hz, 2H).

**Example 14**

**3-[4-{2-(1,5-Dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoic acid**



10

To a cooled solution of triphenyl phosphine (420 mg, 1.6 mmol) in dry THF (4 mL) DIAD (0.32 mL, 1.6 mmol) was added drop wise and stirred for 15 min. 1,5-Dimethyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one (165 mg, 0.8 mmol) in THF (6 mL) was added drop wise to the above reaction mixture at 0 °C. The reaction mixture was stirred 15 for 10 min at room temperature and cooled. To this ethyl 2-ethoxy-3-[4-(2-hydroxyethoxy)phenyl]propanoate (248 mg, 0.881 mmol), obtained in preparation 7, in THF (5 mL) was added slowly. The reaction mixture was allowed to stir at room temperature for 4 days. THF was removed under reduced pressure and the residue was purified by column chromatography using 10% ethyl acetate in pet ether to get the 20 corresponding ester of the title compound.

To a solution of compound obtained above in methanol (4 mL) lithium hydroxide (44 mg, 1.05 mmol) in water (1 mL) was added and stirred at room temperature for 18 h. Methanol was removed from the reaction mixture under reduced pressure and the resulting aqueous layer was acidified with 2N HCl at 0 °C to pH~2. The aqueous layer was extracted with 25 ethyl acetate, dried (Na<sub>2</sub>SO<sub>4</sub>) and concentrated. Column chromatography of the residue, using 60% ethyl acetate in pet ether as eluent, afforded the title compound (50 mg), mp 142-144 °C.


<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.98 (t, J = 7.3 Hz, 3H), 1.18 (t, J = 7.1 Hz, 3H), 1.73-1.92 (m, 2H), 2.68 (s, 3H), 2.90 (t, J = 7.6 Hz, 2H), 2.98-3.15 (m, 2H), 3.43-3.68 (m, 2H), 4.06 (dd, J =

7.1 and 4.7 Hz, 1H), 4.13 (s, 3H), 4.37 (t, J = 4.4 Hz, 2H), 4.90 (t, J = 4.0 Hz, 2H), 6.86 (d, J = 8.8 Hz, 2H), 7.17 (d, J = 8.3 Hz, 2H).

**Example 15**

3-[4-{2-(5-Ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)

- 5 ethoxy}phenyl]-2-ethoxypropanoic acid




The title compound (65 mg, 9%) was prepared from 5-ethyl-1-methyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one (0.35 g, 1.6 mmol) following the similar procedure as described in the example 14, mp 140-142 °C.

- 10 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 3H), 1.20 (t, J = 7.1 Hz, 3H), 1.37 (t, J = 7.6 Hz, 3H), 1.75-1.91 (m, 2H), 2.86-3.10 (m, 6H), 3.42-3.68 (m, 2H), 4.06 (dd, J = 7.3 and 4.4 Hz, 1H), 4.14 (s, 3H), 4.40 (t, J = 4.4 Hz, 2H), 4.93 (t, J = 4.9 Hz, 2H), 6.88 (d, J = 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H).

**Example 16**

- 15 Ethyl 3-[4-{1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl(4-fluorobenzyl)carboxamido}phenyl]-2-ethoxypropanoate




- 20 The title compound (170 mg, 47%) was obtained as white solid by condensing 1,5-dimethyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one obtained in preparation 24 (125 mg, 0.606 mmol) with ethyl 3-[4-chloromethyl(4-fluorobenzyl)carboxamidophenyl]-2-ethoxypropanoate obtained in preparation 20 in dry *N,N*-dimethylformamide (7 mL) in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> (251 mg, 1.82 mmol) at room temperature for 24 h following a similar procedure as described in example

1, mp 86-88 °C.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 3H), 1.15 (t, J = 6.8 Hz, 3H), 1.23 (t, J = 7.1 Hz, 3H), 1.87-1.94 (m, 2H), 2.61 (s, 3H), 2.94 (t, J = 7.5 Hz, 2H), 3.00-3.09 (m, 2H), 3.30-3.44 (m, 1H), 3.55-3.73 (m, 1H), 3.97-4.27 (m, 6H), 4.82 (s, 2H), 4.85 (s, 2H), 6.95 (t, J = 8.5 Hz, 2H), 7.08 (d, J = 8.3 Hz, 2H), 7.12-7.34 (m, 4H).

**Example 17**


**3-[4-{1,5-Dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl(4-fluorobenzyl)carboxamido}phenyl]-2-ethoxypropanoic acid**



- 10 The title compound (59 mg, 86%) obtained as white solid from Ethyl 3-[4-{1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl(4-fluorobenzyl)carboxamido}phenyl]-2-ethoxypropanoate (72 mg, 122 μmol) obtained in example 16 by hydrolyzing in methanol-water (3:1, 4 mL) using sodium carbonate (64 mg, 0.61 mmol) at room temperature for 18 h by following a similar procedure as described in example 2.
- 15 <sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 0.99 (t, J = 7.3 Hz, 3H), 1.15 (t, J = 7.3 Hz, 3H), 1.72-1.88 (m, 2H), 2.60 (s, 3H), 2.94 (t, J = 7.1 Hz, 2H), 3.01-3.17 (m, 2H), 3.35-3.73 (m, 2H), 4.03-4.21 (m, 4H), 4.78 (s, 2H), 4.86 (s, 2H), 6.87 (d, J = 8.3 Hz, 1H), 6.96 (t, J = 8.8 Hz, 2H), 7.05-7.38 (m, 5H).

**Example 18**

- 20 Ethyl 2-(4-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl{4-(4-ethyloxycarbonylphenyl)butyl}carboxamido]phenoxy) pentanoate




The title compound (530 mg, 86%) was obtained by condensing 5-ethyl-1-methyl-3-propyl-6,7-dihydro-1*H*-pyrazolo[4,3-d]pyrimidin-7-one obtained in preparation 23 (193 mg, 0.88 mmol) with ethyl 2-[4-chloromethyl{4-(4-ethoxycarbonylphenyl)butyl}carboxamidophenoxy] pentanoate (530 mg, 1.03 mmol), obtained in preparation 22, in dry *N,N*-dimethylformamide (8 mL) in the presence of anhydrous K<sub>2</sub>CO<sub>3</sub> (358 mg, 2.59 mmol) at room temperature for 48 h following a similar procedure as described in example 1.

<sup>1</sup>H NMR (CDCl<sub>3</sub>): δ 1.00 (t, J = 7.3 Hz, 6H), 1.27 (t, J = 7.1 Hz, 3H), 1.32-1.44 (m, 6H), 1.47-1.72 (m, 6H), 1.77-2.02 (m, 4H), 2.65 (t, J = 6.8 Hz, 2H), 2.81-2.94 (m, 4H), 3.70 (t, J = 6.4 Hz, 2H), 4.19 (s, 3H), 4.25 (q, J = 7.3 Hz, 2H), 4.36 (q, J = 7.3 Hz, 2H), 4.62 (t, J = 6.1 Hz, 1H), 4.80 (s, 2H), 6.93 (d, J = 8.8 Hz, 2H), 7.17 (d, J = 7.8 Hz, 2H), 7.19 (d, J = 8.8 Hz, 2H), 7.92 (d, J = 7.8 Hz, 2H).

### 15 Example 19

#### 2-[4-{4-(4-Carboxyphenyl)butyl}(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl)carboxamido]phenoxy]pentanoic acid



The title compound (81 mg, 88%) obtained as white solid from ethyl 2-(4-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl{4-(4-ethyloxycarbonylphenyl)butyl}carboxamido]phenoxy)pentanoate (100 mg, 142  $\mu$ mol), obtained in example 18, by hydrolyzing in methanol-water using sodium carbonate (76 mg, 0.71 mmol) at room temperature for 18 h by following a similar procedure as described in example 2, mp 178-180 °C.

<sup>1</sup>H NMR (CD<sub>3</sub>OD+DMSO-d<sub>6</sub>):  $\delta$  1.06-1.11 (m, 6H), 1.45 (t, J = 7.5 Hz, 3H), 1.62-2.18 (m, 10H), 2.74-3.12 (m, 6H), 3.89 (t, J = 5.4 Hz, 2H), 4.30 (s, 3H), 4.90 (br s, 1H), 5.06 (s, 2H), 7.16 (d, J = 8.6 Hz, 2H), 7.36 (d, J = 8.1 Hz, 2H), 7.46 (d, J = 8.6 Hz, 2H), 8.00 (d, J = 8.1 Hz, 2H).

The compounds of the present invention lowered random blood sugar level, triglyceride, total cholesterol, LDL, VLDL and increased HDL. This was demonstrated by *in vitro* as well as *in vivo* animal experiments.

15

#### Demonstration of Efficacy of Compounds

A) In vitro:

a) Determination of hPPAR $\alpha$  activity

Ligand binding domain of hPPAR $\alpha$  was fused to DNA binding domain of Yeast transcription factor GAL4 in eucaryotic expression vector. Using superfect (Qiagen, Germany) as transfecting reagent HEK-293 cells were transfected with this plasmid and a reporter plasmid harboring the luciferase gene driven by a GAL4 specific promoter. Compound was added at different concentrations after 42 hrs of transfection and incubated overnight. Luciferase activity as a function of compound binding/activation capacity of PPAR $\alpha$  was measured using Packard Luclite kit (Packard, USA) in Top Count (Ivan Sadowski, Brendan Bell, Peter Broag and Melvyn Hollis. Gene 1992, 118 : 137 -141; Superfect Transfection Reagent Handbook. February 1997. Qiagen, Germany).

b) Determination of hPPAR $\gamma$  activity

Ligand binding domain of hPPAR $\gamma$ 1 was fused to DNA binding domain of Yeast transcription factor GAL4 in eucaryotic expression vector. Using Lipofectamine (Gibco BRL, USA) as transfecting reagent HEK-293 cells were transfected with this plasmid and a reporter plasmid harboring the luciferase gene driven by a GAL4 specific promoter. Compound was added at 1  $\mu$ M concentration after 48 hrs of transfection and incubated overnight. Luciferase activity as a function of drug binding/activation capacity of

PPAR $\gamma$ 1 was measured using Packard Luclite kit (Packard, USA) in Packard Top Count (Ivan Sadowski, Brendan Bell, Peter Broag and Melvyn Hollis. Gene 1992, 118 : 137 – 141; Guide to Eukaryotic Transfections with Cationic Lipid Reagents. Life Technologies, GIBCO BRL, USA).

5

Example No.	Concentration	PPAR $\alpha$	PPAR $\gamma$	Concentration
2	50 $\mu$ M	2.7	1 $\mu$ M	1.4
4b	50 $\mu$ M	5.1	1 $\mu$ M	6.9

c) Determination of HMG CoA reductase inhibition activity

Liver microsome bound reductase was prepared from 2% cholestyramine fed rats at mid-dark cycle. Spectrophotometric assays were carried out in 100 mM KH<sub>2</sub>PO<sub>4</sub>, 4 mM DTT, 0.2 mM NADPH, 0.3 mM HMG CoA and 125  $\mu$ g of liver microsomal enzyme. Total reaction mixture volume was kept as 1 ml. Reaction was started by addition of HMG CoA. Reaction mixture was incubated at 37 °C for 30 min and decrease in absorbance at 340 nm was recorded. Reaction mixture without substrate was used as blank (Goldstein, J. L and Brown, M. S. Progress in understanding the LDL receptor and HMG CoA reductase, two membrane proteins that regulate the plasma cholesterol. *J. Lipid Res* 1984, 25 : 1450 – 1461). The test compounds inhibited the HMG CoA reductase enzyme.

B) In vivo

a) Efficacy in genetic models

Mutation in colonies of laboratory animals and different sensitivities to dietary regimens have made the development of animal models with non-insulin dependent diabetes and hyperlipidemia associated with obesity and insulin resistance possible. Genetic models such as db/db and ob/ob (Diabetes, (1982) 31(1) : 1- 6) mice and zucker fa/fa rats have been developed by the various laboratories for understanding the pathophysiology of disease and testing the efficacy of new antidiabetic compounds (Diabetes, (1983) 32: 830-838 ; Annu. Rep. Sankyo Res. Lab. (1994). 46 : 1-57). The homozygous animals, C57 BL/KsJ-db/db mice developed by Jackson Laboratory, US, are obese, hyperglycemic, hyperinsulinemic and insulin resistant (J. Clin. Invest., (1990) 85 : 962-967), whereas heterozygous are lean and normoglycemic. In db/db model, mouse progressively develops insulinopenia with age, a feature commonly observed in late stages of human type II diabetes when blood sugar levels are insufficiently controlled. The state of pancreas and its course vary according to the models. Since this model resembles that

of type II diabetes mellitus, the compounds of the present invention were tested for blood sugar and triglycerides lowering activities.

Male C57BL/KsJ-db/db mice of 8 to 14 weeks age, having body weight range of 35 to 60 grams, bred at Dr. Reddy's Research Foundation (DRF) animal house, were used 5 in the experiment. The mice were provided with standard feed (National Institute of Nutrition (NIN), Hyderabad, India) and acidified water, *ad libitum*. The animals having more than 350 mg / dl blood sugar were used for testing. The number of animals in each group was 4.

Test compounds were suspended on 0.25 % carboxymethyl cellulose and 10 administered to test group at a dose of 0.1 mg to 30 mg / kg through oral gavage daily for 6 days. The control group received vehicle (dose 10 ml / kg). On 6th day the blood samples were collected one hour after administration of test compounds / vehicle for assessing the biological activity.

The random blood sugar and triglyceride levels were measured by collecting blood 15 (100 µl) through orbital sinus, using heparinised capillary in tubes containing EDTA which was centrifuged to obtain plasma. The plasma glucose and triglyceride levels were measured spectrometrically, by glucose oxidase and glycerol-3-PO<sub>4</sub> oxidase/peroxidase enzyme (Dr. Reddy's Lab. Diagnostic Division Kits, Hyderabad, India) methods respectively.

20 The blood sugar and triglycerides lowering activities of the test compound was calculated according to the formula.

No adverse effects were observed for any of the mentioned compounds of invention in the above test.

Compound	Dose (mg / kg)	Reduction in Blood Glucose Level (%)	Triglyceride Lowering (%)
Example 4a	10	48	69
Example 4b	10	56	17
Example 5	3	61	51

25 The ob/ob mice were obtained at 5 weeks of age from Bomholtgard, Denmark and were used at 8 weeks of age. Zucker fa/fa fatty rats were obtained from IffaCredo, France at 10 weeks of age and were used at 13 weeks of age. The animals were maintained under 12 hour light and dark cycle at 25 ± 1 °C. Animals were given standard laboratory chow (NIN, Hyderabad, India) and water, *ad libitum* (Fujiwara, T., Yoshioka, S., Yoshioka, T., 30 Ushiyama, I and Horikoshi, H. Characterization of new oral antidiabetic agent CS-045.

Studies in KK and ob/ob mice and Zucker fatty rats. *Diabetes* 1988, 37 : 1549 – 1558).

The test compounds were administered at 0.1 to 30 mg/kg/day dose for 9 days. The control animals received the vehicle (0.25 % carboxymethylcellulose, dose 10 ml/kg) through oral gavage.

5       The blood samples were collected in fed state 1 hour after drug administration on 0 and 9 day of treatment. The blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for triglyceride, glucose, free fatty acid, total cholesterol and insulin estimations. Measurement of plasma triglyceride, glucose, total cholesterol were done using 10 commercial kits (Dr. Reddy's Laboratory, Diagnostic Division, India). The plasma free fatty acid was measured using a commercial kit from Boehringer Mannheim, Germany. The plasma insulin was measured using a RIA kit (BARC, India). The reduction of various parameters examined are calculated according to the formula given below.

In ob/ob mice oral glucose tolerance test was performed after 9 days treatment. 15 Mice were fasted for 5 hrs and challenged with 3 gm/kg of glucose orally. The blood samples were collected at 0, 15, 30, 60 and 120 min for estimation of plasma glucose levels.

20      The experimental results from the db/db mice, ob/ob mice, Zucker fa/fa rats suggest that the novel compounds of the present invention also possess therapeutic utility as a prophylactic or regular treatment for diabetes, obesity, cardiovascular disorders such as hypertension, hyperlipidaemia and other diseases; as it is known from the literature that such diseases are interrelated to each other.

Blood glucose level and triglycerides are also lowered at doses greater than 10 mg/kg. Normally, the quantum of reduction is dose dependent and plateaus at certain 25 dose.

b) Plasma triglyceride and Cholesterol lowering activity in hypercholesterolemic rat models

Male Sprague Dawley rats (NIN stock) were bred in DRF animal house. Animals were maintained under 12 hour light and dark cycle at  $25 \pm 1^{\circ}\text{C}$ . Rats of 180 - 200 gram 30 body weight range were used for the experiment. Animals were made hypercholesterolemic by feeding 2% cholesterol and 1% sodium cholate mixed with standard laboratory chow [National Institute of Nutrition (NIN), Hyderabad, India] for 6 days. Throughout the experimental period the animals were maintained on the same diet (Petit, D., Bonnefis, M. T., Rey, C and Infante, R. Effects of ciprofibrate on liver lipids

and lipoprotein synthesis in normal and hyperlipidemic rats. *Atherosclerosis* 1988, 74 : 215 – 225).

The test compounds were administered orally at a dose 0.1 to 30 mg/kg/day for 3 days. Control group was treated with vehicle alone (0.25 % Carboxymethylcellulose; dose 5 10 ml/kg).

The blood samples were collected in fed state 1 hour after drug administration on 0 and 3 day of compound treatment. The blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for total cholesterol, HDL and triglyceride estimations. 10 Measurement of plasma triglyceride, total cholesterol and HDL were done using commercial kits (Dr. Reddy's Laboratory, Diagnostic Division, India). LDL and VLDL cholesterol were calculated from the data obtained for total cholesterol, HDL and triglyceride. The reduction of various parameters examined are calculated according to the formula.

15       c)     Plasma triglyceride and total cholesterol lowering activity in Swiss albino mice and Guinea pigs

Male Swiss albino mice (SAM) and male Guinea pigs were obtained from NIN and housed in DRF animal house. All these animals were maintained under 12 hour light and dark cycle at  $25 \pm 1^{\circ}\text{C}$ . Animals were given standard laboratory chow (NIN, Hyderabad, 20 India) and water, *ad libitum*. SAM of 20 - 25 g body weight range and Guinea pigs of 500 - 700 g body weight range were used (Oliver, P., Plancke, M. O., Marzin, D., Clavey, V., Sauzieres, J and Fruchart, J. C. Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. *Atherosclerosis*. 1988. 70 : 107 – 114).

25       The test compounds were administered orally to Swiss albino mice at 0.3 to 30 mg/kg/day dose for 6 days. Control mice were treated with vehicle (0.25% Carboxymethylcellulose; dose 10 ml/kg). The test compounds were administered orally to Guinea pigs at 0.3 to 30 mg/kg/day dose for 6 days. Control animals were treated with vehicle (0.25% Carboxymethylcellulose; dose 5 ml/kg).

30       The blood samples were collected in fed state 1 hour after drug administration on 0 and 6 day of treatment. The blood was collected from the retro-orbital sinus through heparinised capillary in EDTA containing tubes. After centrifugation, plasma sample was separated for triglyceride and total cholesterol (Wieland, O. Methods of Enzymatic analysis. Bergermeyer, H. O., Ed., 1963. 211 - 214; Trinder, P. *Ann. Clin. Biochem* 1969,

6 : 24 – 27). Measurement of plasma triglyceride, total cholesterol and HDL were done using commercial kits (Dr. Reddy's Diagnostic Division, Hyderabad, India).

Compound	Dose (mg / kg)	Triglyceride Lowering (%)
8	10	61
7	3	43
10	3	42

c) **Body weight reducing effect in cholesterol fed hamsters :**

5 Male Syrian Hamsters were procured from NIN, Hyderabad, India. Animals were housed at DRF animal house under 12 hour light and dark cycle at  $25 \pm 1^{\circ}\text{C}$  with free access to food and water. Animals were maintained with 1 % cholesterol containing standard laboratory chow (NIN) from the day of treatment.

10 The test compounds were administered orally at 1 to 30 mg/kg/day dose for 15 days. Control group animals were treated with vehicle (Mill Q water, dose 10 ml/kg/day). Body weights were measured on every 3<sup>rd</sup> day.

**Formulae for calculation :**

1. Percent reduction in Blood sugar / triglycerides / total cholesterol were calculated  
15 according to the formula :

$$\text{Percent reduction (\%)} = \left[ 1 - \frac{\text{TT} / \text{OT}}{\text{TC} / \text{OC}} \right] \times 100$$

OC = Zero day control group value

OT = Zero day treated group value

TC = Test day control group value

20 TT = Test day treated group value

2. LDL and VLDL cholesterol levels were calculated according to the formula :


$$\text{LDL cholesterol in mg/dl} = [\text{Total cholesterol} - \text{HDL cholesterol} - \frac{\text{Triglyceride}}{5}] \text{ mg/dl}$$

$$\text{VLDL cholesterol in mg/dl} = [\text{Total cholesterol} - \text{HDL cholesterol} - \text{LDL cholesterol}]$$


25 mg/dl.

We claim:

1. Novel alkyl carboxylic acids of compound of the general formula (I)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their  
 5 polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable  
 solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, alkanoyl,  
 acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy,  
 halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl,  
 cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy,  
 10 heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl,  
 alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; R<sup>3</sup>  
 represents hydrogen or substituted or unsubstituted groups selected from alkyl,  
 cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents  
 oxygen or NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted groups  
 15 selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl,  
 heterocyclyl, heteroaryl or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together form a substituted  
 or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen  
 atom and which can optionally contain one or two additional heteroatoms selected from  
 oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or  
 20 fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents  
 O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents  
 hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl;  
 hydroxyalkyl, carboxyalkyl, alkanoyl, alkanoyloxy, aroyl, aralkanoyl, heterocyclyl,  
 heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y  
 25 represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or  
 unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl,  
 alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents  
 hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group  
 or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-  
 30 4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or  
 imidazolopyrimidine of the formula given below :



where  $R^8$  and  $R^9$ ,  $R^{10}$  when attached to carbon atom are same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives;  $R^9$  and  $R^{10}$  when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives.

2. A compound according to claim 1, wherein when the groups represented by  $R^2$  are substituted, the substituents are selected from halogen, hydroxy, nitro or unsubstituted or substituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, alkanoyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, arylamino, aminoalkyl, aryloxy, aralkoxy, alkoxy carbonyl, alkylamino, alkoxyalkyl, aryloxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives or sulfonic acid or its derivatives.
- 25 3. A compound according to claims 1 to 2 wherein Ar represents substituted or unsubstituted groups selected from divalent phenylene, naphthylene, pyrrolyl, pyridyl,


quinolinyl, benzofuryl, dihydrobenzofuryl, benzopyranyl, dihydrobenzopyranyl, indolyl, indolinyl, azaindolyl, azaindinolyl, pyrazolyl, benzothiazolyl or benzoxazolyl groups.

4. A compound according to claim 1, which is selected from:
- 5 Ethyl 2-[4-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)methyl(heptyl)carboxamido]phenylsulfanyl]pentanoate or its salts in its single enantiomeric form or as a racemate;
- 2-[4-(5-Ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)methyl(heptyl)carboxamido]phenylsulfanyl]pentanoic acid or its salts in its single enantiomeric form or as a racemate;
- 10 10 Ethyl 2-ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate or its salts in its single enantiomeric form or as a racemate;
- Methyl 2-ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate or its salts in its single enantiomeric form or as a racemate;
- 15 15 2-Ethoxy-3-[4-{2-(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoic acid or its salts in its single enantiomeric form or as a racemate;
- 20 Ethyl 3-[4-{2-(1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoate or its salts in its single enantiomeric form or as a racemate;
- 3-[4-{2-(1,5-Dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)-ethoxy}phenyl]-2-ethoxypropanoic acid or its salts in its single enantiomeric form or as a racemate;
- 25 Ethyl 2-ethoxy-3-[4-{2-(1-methyl-5-phenyl-3-propyl-1*H*-pyrazolo-[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]propanoate or its salts in its single enantiomeric form or as a racemate;
- 3-[4-{2-(1-Methyl-5-phenyl-3-propyl-1*H*-pyrazolo-[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoic acid or its salts in its single enantiomeric form
- 30 30 or as a racemate;
- Ethyl 3-[4-{2-(5-cyclopropyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy)ethoxy}phenyl]-2-ethoxypropanoate or its salts in its single enantiomeric form or as a racemate;
- 3-[4-{2-(5-Cyclopropyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-

- yloxy)ethoxy}phenyl]-2-ethoxypropanoic acid or its salts in its single enantiomeric form or as a racemate;
- Ethyl 6-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl{4-(1-ethyloxycarbonylbutoxyl)phenyl}carboxamido]hexanoate or its salts in its single  
5 enantiomeric form or as a racemate;
- 6-[4-(1-Carboxybutoxy)phenyl(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl)carboxamido]hexanoic acid or its salts in its single enantiomeric form or as a racemate;
- Ethyl 3-[4-{1,5-dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl(4-fluorobenzyl)carboxamido}phenyl]-2-ethoxypropanoate or its salts in its single  
10 enantiomeric form or as a racemate;
- 3-[4-{1,5-Dimethyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl(4-fluorobenzyl)carboxamido}phenyl]-2-ethoxypropanoic acid or its salts in its single enantiomeric form or as a racemate;
- Ethyl 2-(4-[5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxy-methyl{4-(4-  
15 ethyloxycarbonylphenyl)butyl}carboxamido]phenoxy)pentanoate or its salts in its single enantiomeric form or as a racemate;
- 2-[4-{4-(4-Carboxyphenyl)butyl(5-ethyl-1-methyl-3-propyl-1*H*-pyrazolo[4,3-d]pyrimidin-7-yloxymethyl)carboxamido}phenoxy]pentanoic acid or its salts in its single enantiomeric  
20 form or as a racemate;
5. A compound according to claim 1 wherein the pharmaceutically acceptable salt is selected from the group consisting of Li, Na, K, Ca, Mg, Fe, Cu, Zn, Al, Mn; organic bases selected from N,N'-diacetylenediamine, betaine, caffeine, 2-diethylaminoethanol, 2-dimethylaminoethanol, N-ethylmorpholine, N-ethylpiperidine,  
25 glucamine, glucosamine, hydramine, isopropylamine, methylglucamine, morpholine, piperazine, piperidine, procaine, theobromine, glycinol, diethylamine, triethylamine, trimethylamine, tripropylamine, tromethamine, adamentyl amine, diethanolamine, meglumine, ethylenediamine, N,N'-diphenylethylenediamine, N,N'-dibenzylethylenediamine, N-benzyl phenylethylamine, choline, choline hydroxide,  
30 dicyclohexylamine, metformin, benzylamine, phenylethylamine, thiamine, aminopyrimidine, aminopyridine, purine or spermidine; chiral bases like alkylphenylamine or phenyl glycinol; salts of natural amino acids selected from glycine, alanine, valine, leucine, isoleucine, norleucine, tyrosine, cystine, cysteine, methionine, proline, hydroxy proline, histidine, ornithine, lysine, arginine, serine, threonine,


phenylalanine; unnatural amino acids selected from D-isomers or substituted amino acids; guanidine, substituted guanidine wherein the substituents are selected from nitro, amino, alkyl, alkenyl, alkynyl, ammonium or substituted ammonium salts. Salts include acid addition salts where appropriate which are, sulphates, nitrates, phosphates, perchlorates, 5 borates, hydrohalides, acetates, tartrates, maleates, citrates, succinates, palmoates, methanesulfonates, benzoates, salicylates, hydroxynaphthoates, benzenesulfonates, ascorbates, glycerophosphates or ketoglutarates.


6. A process for the preparation of compound of formula (I)



10


their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> and R<sup>7</sup> together represent a bond; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, 15 cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, arakanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or 20 (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents CHR<sup>7</sup>; where R<sup>7</sup> forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the 25 formula given below :






where  $R^8$  and  $R^9$ ,  $R^{10}$  when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, 5 aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alcoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or 10 sulfonic acid or its derivatives;  $R^9$  and  $R^{10}$  when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alcoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, 15 aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives, which comprises :

- a) reacting the compound of formula (IIIa)



where all symbols are as defined above with a compound of formula (IIIb)



20 where  $R^{11}$  represents  $(C_1-C_6)$ alkyl, R represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and all other symbols are as defined earlier to yield compound of general formula (I) where  $R^2$  represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined above ;

- b) reacting the compound of formula (IIIa)



where all symbols are as defined above with Wittig reagent to yield a compound of


formula (I) where all symbols are as defined above ; or

- c) reacting the compound of formula (IIIc)




where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given

5 below :




wherein Q represents O or S and all other symbols are as defined above with compound of general formula (IIId)




- 10 where  $\text{L}^1$  is a leaving group;  $\text{R}^1$  and  $\text{R}^7$  together represent a bond and all other symbols are as defined above to yield compound of formula (I) where all symbols are as defined above ; or

- d) reacting the compound of formula (IIIA)



- 15 where all symbols are as defined above with a compound of formula (IIIf)




where  $\text{R}^1$  represents hydrogen atom and all other symbols are as defined above ; or

- e) reacting the compound of formula (IIIf)




- 20 where  $\text{L}^1$  represents a leaving group and all other symbols are as defined above with compound of formula (IIIf)




where R<sup>1</sup> and R<sup>7</sup> together represent a bond and all other symbols are as defined above ; or

f) reaction of compound of general formula (IIIh)




5 A is as defined above and Hal represents halogen atom with compound of formula (IIIi)




where all symbols are as defined above ; or

g) reacting the of compound of general formula (IIIj)



10 where all symbols are as defined above with a compound of general formula (IIIf)




where all symbols are as defined above ; or

h) reacting the compound of formula (IIIk)



15 where all symbols are as defined above with a compound of formula (IIIl)



where R represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and where R<sup>3</sup> is as defined earlier excluding hydrogen to yield compound of general formula (I) where R<sup>2</sup> represents substituted or unsubstituted groups


20 selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined above

i) reacting the compound of formula (IIIc)




where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given


25 below :



wherein Q represents O or S and all other symbols are as defined above with compound of general formula (IIIIm)




- 5 where all symbols are as defined above ;  
 j) converting the compounds of formula (I) obtained in any of the processes described above into pharmaceutically acceptable salts or pharmaceutically acceptable solvates by conventional methods.  
 7. A process for the preparation of compound of formula (I)




- 10 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, 15 substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, 20 heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or

heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents CHR<sup>7</sup>; where R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




- 10 where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives, which comprises :
- 15 a) reducing the compound of the formula (IVa)
- 20
- 25



which represents a compound of formula (I) where R<sup>1</sup> and R<sup>7</sup> together represent a bond and Z represents oxygen atom and all other symbols are as defined above to yield a compound of the general formula (I) where R<sup>1</sup> and R<sup>5</sup> each represent hydrogen atom and

5 all other symbols are as defined above ; or

b) reacting the compound of formula (IVb)




where L<sup>1</sup> is a leaving group, R<sup>3</sup> is as defined earlier excluding hydrogen and all other symbols are as defined earlier with an alcohol of general formula (IVc),

10 R-OH (IVc)


where R represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and all other symbols are as defined earlier to yield compound of general formula (I) where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols

15 above ; or

c) reacting the compound of formula (IIIg)




where all symbols are as defined above with compound of formula (IIIf)




20 where all symbols are as defined above ; or

d) reacting the compound of general formula (IIIj)




where all symbols are as defined above with a compound of general formula (IIIe)



25 where all symbols are as defined above ; or

e) reacting the compound of formula (IVd),




which represents a compound of formula (I), when  $\text{R}^2$  represents hydroxy group and all other symbols are as defined above with a compound of formula (IVE)



- 5 where R represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and  $\text{L}^2$  is a halogen atom to yield compound of general formula (I) where  $\text{R}^2$  represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined above ; or  
f) reacting the compound of general formula (IIIh)




- 10 where Hal represents halogen atom and A is as defined earlier with the compound of formula (IIIi)




where all other symbols are as defined above ; or


- 15 g) reacting the compound of general formula (IIIC)



where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



- 20 wherein Q represents O or S and all other symbols are as defined above with compound of general formula (IIIm)




where symbols are as defined above ; or

- h) reacting the compound of the general formula (IIIa)



- 5 where all symbols are as defined above with a compound of formula (IIIe)




where  $\text{R}^1$  represents hydrogen atom and all other symbols are as defined above ; or


- i) reacting the compound of the general formula (IIIC)



- 10 where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




wherein Q represents O or S and all other symbols are as defined above with compound of general formula (IIId)



15


where  $\text{L}^1$  is a leaving group and all other symbols are as defined above ; or

- j) converting the compound of formula (IVf)



where all symbols are as defined above to a compound of formula (I) where all symbols are as defined above ; or

k) reacting the compound of formula (IVg)




- 5 where  $\text{R}^3$  is as defined above excluding hydrogen and all other symbols are as defined above with a compound of formula (IVc)




- where R represents substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, heteroaryl or heteroaralkyl and  $\text{L}^2$  is a halogen atom to yield compound of general formula  
 10 (I) where  $\text{R}^2$  represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined above ; or  
 l) converting the compounds of formula (I) obtained in any of the processes described above into pharmaceutically acceptable salts, or pharmaceutically acceptable solvates.

- 15 8. A process for the preparation of compound of formula (I)




- their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $\text{R}^1$  represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, 20 substituted or unsubstituted aralkyl groups;  $\text{R}^2$  represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups;  $\text{R}^3$  represents hydrogen 25 or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl or heteroaralkyl groups; Z represents oxygen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents  $\text{NHR}^5$ ,  $-\text{CO}(\text{CH}_2)_p\text{NR}^5(\text{CH}_2)_m-$ ,  $-(\text{CH}_2)_p\text{O}-$ ,  $-(\text{CH}_2)_p\text{NR}^5\text{CO}-$ ; where  $\text{R}^5$  represents hydrogen or substituted or unsubstituted 30 groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl,

- aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents O, S, NR<sup>6</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




- where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxy carbonylamino, aralkoxy carbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives, which comprises :

- a) reacting the compound of formula (Va)



- 25 where all symbols are as defined above with compound of formula (Vb)




where  $L^1$  is a leaving group and all other symbols are as defined above ; or


b) reacting the compound of general formula (IIIc)



- 5 where  $B$  represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




wherein  $Q$  represents O or S and all other symbols are as defined above with compound of general formula (IIId)




10

where  $L^1$  is a leaving group and all other symbols are as defined above ; or

c) reacting the compound of formula (Vc)



- 15 where  $L^1$  represents a leaving group and all other symbols are as defined above with compound of formula (IIIf)




where all symbols are as defined above ; or

d) reacting the compound of general formula (IIIh)




- 20 where  $A$  is as defined above and Hal represents halogen atom with the compound of

formula (IIIi)




where all symbols are as defined above ; or

e) reacting the compound of formula (Vd)



where all symbols are as defined above with a compound of general formula (IIIf)




where all symbols are as defined above ; or


f) reacting the compound of general formula (IIIC)



where B represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




15                    wherein Q represents O or S and all other symbols are as defined above with compound of general formula (IIIm)




where all symbols are as defined above ; or

g) converting the compound of formula (IVf)




where all symbols are as defined above to a compound of formula (I) where all symbols are as defined above ; or

- h) reacting the compound of general formula (IIIj)




5 where A, G and n are as defined above with a compound of general formula (IIIf)



where all symbols are as defined above ; or

- i) converting the compounds of formula (I) obtained in any of the processes 10 described above into pharmaceutically acceptable salts, or pharmaceutically acceptable solvates.


9. A process for the preparation of compound of formula (I)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their 15 polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, 20 heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; R<sup>3</sup> represents hydrogen; Z represents oxygen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents 25 hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl,


heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :

5





where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, 10 aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or 15 sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, 20 aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives, which comprises, hydrolysing a compound of formula (I) described in any of the claims 5, 6 and 7, wherein R<sup>3</sup> represents substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups and all other symbols are as defined above by conventional 25 methods.

10. A process for the preparation of compound of formula (I)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :






where  $R^8$  and  $R^9$ ,  $R^{10}$  when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, 5 aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or 10 sulfonic acid or its derivatives;  $R^9$  and  $R^{10}$  when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, 15 aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives, which comprises :


- a) reacting a compound of formula (I) where all symbols are as defined above and Y represent oxygen or  $ZR^3$  represents a halogen atom or  $COZR^3$  represents a mixed anhydride group with appropriate amines of the formula  $NHR^3R^4$ , where  $R^3$  and  $R^4$  are as 20 defined above and if desired;
- b) converting the compounds of formula (I) obtained above into pharmaceutically acceptable salts or pharmaceutically acceptable solvates by conventional methods.

11. An intermediate of formula (IIIa)



25 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O,  $NHR^5$ ,  $-CO(CH_2)_pNR^5(CH_2)_m-$ ,  $-(CH_2)_pO-$ ,  $-(CH_2)_pNR^5CO-$ ; where  $R^5$  represents 30 hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl,


hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



5


where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxy carbonylamino, aralkoxy carbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxy carbonyl, aryloxy carbonyl, aralkoxy carbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives.

10 12. An intermediate of formula (IVb)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable


solvates where  $L^2$  is a leaving group such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate and the like;  $R^1$  represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups;  $R^3$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, 5 cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups;  $Z$  represents oxygen or  $NR^4$ , where  $R^4$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups or  $R^3$  and  $R^4$  together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a 10 nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen;  $Ar$  represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group;  $G$  represents O or S;  $X$  represents O,  $NHR^5$ ,  $-CO(CH_2)_pNR^5(CH_2)_{m-}$ ,  $(CH_2)_pO$ ,  $-(CH_2)_pNR^5CO-$ ; where  $R^5$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, 15 aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or  $(C_1-C_{12})$ alkylcarboxylic acid and its derivatives;  $Y$  represents O, S,  $NR^6$  or  $CHR^7$ ; where  $R^6$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups;  $R^7$  represents hydrogen atom, halogen, 20 hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group  $R^1$ ;  $m$  and  $p$  are integers ranging from 0-4;  $n$  is an integer in the range of 1-4;  $A$  represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :



25 where  $R^8$  and  $R^9$ ,  $R^{10}$  when attached to carbon atom may be same or different and represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted


groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, 5 alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxycarbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, 10 heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives.

13. An intermediate of formula (IVf)




15 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic, or 20 heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, (CH<sub>2</sub>)<sub>p</sub>O, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or 25 substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted 30 groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups;

aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




- where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and  
 5 represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl,  
 10 alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl,  
 15 heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxy carbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives, or sulfonic acid or its derivatives.

14. An intermediate of formula (IVg)



- 20 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl or heteroaralkyl groups; Z  
 25 represents oxygen or NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted

groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional 5 heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; G represents O or S; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, (CH<sub>2</sub>)<sub>p</sub>O, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, 10 heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl 15 group; m and p are integers ranging from 0-4; n is an integer in the range of 1-4; A represents pyrazolopyrimidine or imidazolopyrimidine of the formula given below :




where R<sup>8</sup> and R<sup>9</sup>, R<sup>10</sup> when attached to carbon atom may be same or different and

represent hydrogen, halogen, hydroxy, nitro, cyano, formyl or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aryloxy, aralkyl,

20 aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, amino, alkanoylamino, monoalkylamino, dialkylamino, arylamino, aralkylamino, aminoalkyl, alcoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl, alkoxy carbonylamino, aryloxycarbonylamino, aralkoxycarbonylamino, carboxylic acid or its derivatives, or 25 sulfonic acid or its derivatives; R<sup>9</sup> and R<sup>10</sup> when attached to nitrogen atom represents hydrogen, hydroxy, formyl or substituted or unsubstituted groups selected from alkyl,

cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkanoyl, aroyl, alkanoyloxy, hydroxyalkyl, aminoalkyl, alkoxycarbonyl, aryloxycarbonyl, aralkoxycarbonyl, alkoxyalkyl, aryloxyalkyl, aralkoxyalkyl, alkylthio, thioalkyl groups, carboxylic acid or its derivatives,  
5 or sulfonic acid or its derivatives.


15. An intermediate of formula (IIIf)



their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where R<sup>1</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups; R<sup>2</sup> represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocyclyl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylamino carbonyl, arylaminocarbonyl groups; R<sup>3</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Z represents oxygen or NR<sup>4</sup>, where R<sup>4</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups or R<sup>3</sup> and R<sup>4</sup> together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl, heteroaralkyl groups or (C<sub>1</sub>-C<sub>12</sub>)alkylcarboxylic acid and its derivatives; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted


aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; m and p are integers ranging from 0-4.

16. A process for preparing the compound of formula (III<sup>f</sup>)




5 wherein all the symbols are as defined in claim 15, which comprises:

a. reducing a compound of formula (III<sup>f</sup>-1)




where all symbols are as defined in claim 15, in the presence of gaseous hydrogen and a catalyst selected from Pd/C, Rh/C, Pt/C or a mixture thereof. The reaction is carried out in  
10 the presence of a solvent selected from dioxane, acetic acid, ethyl acetate, alcohol like methanol or ethanol or a mixture thereof. A pressure between atmospheric pressure and 40 to 80 psi is employed. The catalyst used is preferably 5 - 10% Pd/C and the amount from 5 - 100% w/w. Alternatively the reaction can be carried out by employing metal solvent reduction selected from magnesium or samarium in alcohol or sodium amalgam in  
15 alcohol, preferably methanol to yield a compound of formula (III<sup>f</sup>)



where all symbols are as defined earlier


or

b. reacting a compound of formula (III<sup>f</sup>-2)



20


where all symbols are as defined earlier with a compound of formula (III<sup>f</sup>-3)



where R<sup>5</sup> represents alkyl group using a solvent selected from CH<sub>2</sub>Cl<sub>2</sub>, CHCl<sub>3</sub>, chlorobenzene, benzene, THF, in the presence of catalyst selected from p-toluenesulfonic acid, methanesulfonic acid, TFA, TfOH, BF<sub>3</sub>-OEt<sub>2</sub> or in the presence of activated molecular sieves at a temperature in the range of 10 °C to 100 °C, preferably at a 5 temperature in the range from 10 °C to 60 °C for a period in the range of 1 h to 48 h. The imine thus obtained is reduced in the presence of Na(CN)BH<sub>3</sub>-HCl to obtain the compound of formula (IIIIf) where R<sup>5</sup> represents alkyl group and all other symbols are as defined earlier.

Or


10 c. Conversion of the compound of formula (IIIIf-4)



where R<sup>5</sup> represents hydrogen and all other symbols as defined earlier, in the presence of a solvent selected from MeOH, EtOH or i-PrOH using hydroxylamine hydrochloride, in the presence or absence of a promoter selected from NaOAc, KOAc or a mixture thereof. The 15 reaction is carried out at a temperature in the range of room temperature to the reflux temperature of the solvent used for a period in the range of 2 h to 24 h, preferably in the range 2 h to 12 h. The imine product thus obtained above may be reduced by using Na(CN)BH<sub>3</sub>-HCl to obtain the compound of formula (IIIIf) wher R<sup>5</sup> represents hydrogen and all other symbols are as defined earlier.

20 Or

d. reducing the compound of formula (IIIIf-5)




to a compound of formula (IIIIf) where R<sup>5</sup> represents hydrogen and all other symbols are as defined earlier, in the presence of gaseous hydrogen and a catalyst selected from Pd/C, Rh/C, Pt/C or a mixture thereof. The reaction is carried out in the presence of a solvent selected from dioxane, acetic acid, ethyl acetate, alcohol like methanol or ethanol or a mixture thereof. A pressure between atmospheric pressure and 40 to 80 psi is employed. The catalyst used is preferably 5 - 10% Pd/C and the amount from 5 - 100% w/w. 25


Alternatively the reaction can be carried out by employing metal solvent reduction selected from magnesium or samarium in alcohol or sodium amalgam in alcohol, preferably methanol.

Or

- 5 e. i. diazotization of the compound of formula (IIIf-6)



where Z is as defined earlier excluding NH and all other symbols are as defined earlier to obtain compound of formula (IIIf-7)




- 10 where R<sup>2</sup> represents substituted or unsubstituted groups selected from alkoxy, aryloxy, aralkoxy, heteroaryloxy, heteroaralkoxy and all other symbols are as defined earlier is carried out using a diazotizing agent selected from sodium nitrite, isoamyl nitrite, potassium nitrite or ammonium nitrite under aqueous acidic conditions using an acid selected from sulfuric acid, HCl or acetic acid, in an organic solvent selected from an alcohol like methanol, ethanol or propanol; 1,4-dioxane, THF or acetone. Etherifying the residue obtained using an alkylating agent selected from alkyl sulfate like diethyl sulphate or dimethylsulphate; alkyl halide like ethyl iodide or methyl iodide, in a solvent selected from a hydrocarbon like toluene or benzene or DMF, DMSO or methyl isobutyl ketone (MIBK), in the presence of a alkali base selected from sodium carbonate, potassium carbonate, sodium methoxide, sodium hydride or potassium hydride.
- 15

- 20 ii. The compound of formula (IIIf-7) is converted to a compound of formula (IIIf) where R<sup>5</sup> represents hydrogen atom and all other symbols are as defined earlier in the presence of gaseous hydrogen and a catalyst selected from Pd/C, Rh/C, Pt/C or a mixture thereof. The reaction is carried out in the presence of a solvent selected from dioxane, acetic acid, ethyl acetate, alcohol like methanol or ethanol or a mixture thereof. A pressure between atmospheric pressure and 40 to 80 psi is employed. The catalyst used is preferably 5 - 10% Pd/C and the amount from 5. - 100% w/w. Alternatively the reaction can be carried out by employing metal solvent reduction selected from magnesium or
- 25


samarium in alcohol or sodium amalgam in alcohol, preferably methanol.

Or


- f. i. reacting a compound of formula (IIIb)



- 5 where all symbols are as defined earlier, with a compound of formula (IIIf-9)




where R<sup>12</sup> represents (C<sub>1</sub>-C<sub>6</sub>)alkyl group to yield compound of formula (IIIf-10)



- where Z is as defined earlier excluding NH and all symbols are as defined earlier, is  
 10 carried out in the presence of a base like a metal hydride like NaH or KH; organolithiums like CH<sub>3</sub>Li or BuLi; alkoxides like NaOMe, NaOEt or t-BuOK<sup>+</sup> or a mixture thereof. The reaction is carried out in the presence of a solvent selected from diethyl ether, THF, dioxane, DMF, DMSO, DME, dimethyl acetamide or a mixture thereof in the presence or absence of HMPA as a cosolvent at a temperature in the range of -78 °C to 50 °C,  
 15 preferably at a temperature in the range of -10 °C to 30 °C.


- ii. The compound of formula (IIIf-10) is reduced to compound of formula (IIIf-2)



- where all symbols are as defined earlier in the presence of gaseous hydrogen and a catalyst selected from Pd/C, Rh/C, Pt/C or a mixture thereof. The reaction is carried out in the  
 20 presence of a solvent selected from dioxane, acetic acid, ethyl acetate, alcohol like methanol or ethanol or a mixture thereof. A pressure between atmospheric pressure and to 80 psi is employed. The catalyst used is preferably 5 - 10% Pd/C and the amount from 5 -

50% w/w. Alternatively the reaction can be carried out by employing metal solvent reduction selected from magnesium, iron, tin or samarium in alcohol or sodium amalgam in alcohol, preferably methanol.


iii. reacting a compound of formula (IIIf-2)



IIIIf-3

5 where  $\text{R}^5$  is as defined earlier using a solvent selected from  $\text{CH}_2\text{Cl}_2$ ,  $\text{CHCl}_3$ , chlorobenzene, benzene, THF, in the presence of catalyst selected from p-toluenesulfonic acid, methanesulfonic acid, TFA,  $\text{TfOH}$ ,  $\text{BF}_3\text{-OEt}_2$  or in the presence of activated molecular sieves at a temperature in the range of 10 °C to 100 °C, preferably at a  
10 temperature in the range from 10 °C to 60 °C for a period in the range of 1 h to 48 h. The imine thus obtained is reduced in the presence of  $\text{Na}(\text{CN})\text{BH}_3\text{-HCl}$  to obtain the compound of formula (IIIIf) where  $\text{R}^5$  represents alkyl group and all other symbols are as defined earlier.


17. An intermediate of the formula (IIId)




15 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $\text{L}^1$  is a leaving group such as halogen atom, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate;  $\text{R}^1$  represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, acyl, substituted or unsubstituted aralkyl groups;  $\text{R}^2$  represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups;  $\text{R}^3$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl or heteroaralkyl groups;  $\text{Z}$  represents oxygen or  $\text{NR}^4$ , where  $\text{R}^4$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups or  $\text{R}^3$  and  $\text{R}^4$  together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms  
20  
25  
30

- selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; X represents O, NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl,  
5 hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups;  
R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted  
10 aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; n is an integer in the range of 1-4; m and p are integers ranging from 0-4.

18. A process for preparation of the compound of formula (IIId)



- where all the symbols are as defined in claim 17, which comprises reacting the compound  
15 of formula (IIIIf)




where X represents NHR<sup>5</sup> and all other symbols are as defined earlier with compound of formula (IIId-1)




- 20 where L<sup>1</sup> and n are as defined earlier and L<sup>2</sup> represents halogen, in the presence of a solvent selected from DCM, DCE, THF, DMF, DMSO, DME or a mixture thereof. The reaction is carried out in an inert atmosphere maintained by using inert a gase like N<sub>2</sub>, Ar or He, in the presence of a base selected from triethyl amine, lutidine, collidine or a mixture thereof at a temperature in the range of -20 °C – 120 °C for a period in the range  
25 of 1 to 48 hours, preferably from 2 to 12 hours to yield a compound of formula (IIId) where all symbols are as defined earlier.

19. An intermediate of the formula (IIId)




their derivatives, their analogs, their tautomeric forms, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $\text{L}^1$  is a leaving group such as halogen, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate;  $\text{R}^1$  represents hydrogen;  $\text{R}^2$  represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy, heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups;  $\text{R}^3$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl or heteroaralkyl groups; Z represents oxygen or  $\text{NR}^4$ , where  $\text{R}^4$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups or  $\text{R}^3$  and  $\text{R}^4$  together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted, divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; X represents O,  $\text{NHR}^5$ ,  $-\text{CO}(\text{CH}_2)_p\text{NR}^5(\text{CH}_2)_m-$ ,  $-(\text{CH}_2)_p\text{O}-$ ,  $-(\text{CH}_2)_p\text{NR}^5\text{CO}-$ ; where  $\text{R}^5$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups; Y represents O, S,  $\text{NR}^6$  or  $\text{CHR}^7$ ; where  $\text{R}^6$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups;  $\text{R}^7$  represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group  $\text{R}^1$ ; n is an integer in the range of 1-4; m and p are integers ranging from 0-4.

20. A process for preparation of the compound of formula (III)d)



30 where all the symbols are as defined in claim 19, which comprises reacting the compound of formula (III)f)




where X represents  $\text{NHR}^5$  and all other symbols are as defined above with compound of formula (IIId-1)



- 5 where  $\text{L}^1$  and n are as defined earlier and  $\text{L}^2$  represents halogen, in the presence of a solvent selected from DCM, DCE, THF, DMF, DMSO, DME or a mixture thereof. The reaction is carried out in an inert atmosphere maintained by using inert a gase like  $\text{N}_2$ , Ar or He, in the presence of a base selected from triethyl amine, lutidine, collidine or a mixture thereof at a temperature in the range of  $-20^\circ\text{C} - 120^\circ\text{C}$  for a period in the range  
10 of 1 to 48 hours, preferably from 2 to 12 hours to yield a compound of formula (IIId)  
where all symbols are as defined earlier.

21. An intermediate of the formula (IIId)




- their derivatives, their analogs, their tautomeric forms, their polymorphs, their  
15 pharmaceutically acceptable salts, their pharmaceutically acceptable solvates where  $\text{L}^1$  is a leaving group such as halogen, *p*-toluenesulfonate, methanesulfonate, trifluoromethanesulfonate;  $\text{R}^1$  represents hydrogen;  $\text{R}^2$  represents hydrogen, hydroxy, halogen, substituted or unsubstituted groups selected from alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, aryl, alkanoyl, alkanoyloxy, aroyl, aralkyl, aryloxy, aralkoxy,  
20 heterocycl, heteroaryl, heteroaralkyl, heteroaryloxy, heteroaralkoxy, alkoxyalkyl, alkoxycarbonyl, aryloxycarbonyl, alkylaminocarbonyl, arylaminocarbonyl groups;  $\text{R}^3$  represents hydrogen or substituted or unsubstituted groups selected from alkyl, cycloalkyl, aryl, aralkyl, heterocycl, heteroaryl or heteroaralkyl groups; Z represents oxygen or  $\text{NR}^4$ , where  $\text{R}^4$  represents hydrogen or substituted or unsubstituted groups  
25 selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocycl, heteroaryl or heteroaralkyl groups or  $\text{R}^3$  and  $\text{R}^4$  together may form a substituted or unsubstituted 5 or 6 membered cyclic structure containing carbon atoms, a nitrogen atom and which may optionally contain one or two additional heteroatoms selected from oxygen, sulfur or nitrogen; Ar represents substituted or unsubstituted,  
30 divalent, single or fused, aromatic, heteroaromatic or heterocyclic group; X represents O,


NHR<sup>5</sup>, -CO(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>(CH<sub>2</sub>)<sub>m</sub>-, -(CH<sub>2</sub>)<sub>p</sub>O-, -(CH<sub>2</sub>)<sub>p</sub>NR<sup>5</sup>CO-; where R<sup>5</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; Y represents O, S, NR<sup>6</sup> or CHR<sup>7</sup>; where R<sup>6</sup> represents hydrogen or substituted or unsubstituted groups selected from alkyl, aryl, aralkyl, hydroxyalkyl, carboxyalkyl, alkanoyl, aroyl, aralkanoyl, heterocyclyl, heteroaryl or heteroaralkyl groups; R<sup>7</sup> represents hydrogen atom, halogen, hydroxy, alkyl, alkoxy, substituted or unsubstituted aralkyl group or forms a bond together with the adjacent group R<sup>1</sup>; n is an integer in the range of 1-4; m and p are integers ranging from 0-4.

5

- 10 22. A process for preparation of the compound of formula (IIId)



where all the symbols are as defined in claim 19, which comprises reacting the compound of formula (IIIf)




- 15 where X represents NHR<sup>5</sup> and all other symbols are as defined above with compound of formula (IIId-1)



where L<sup>1</sup> and n are as defined earlier and L<sup>2</sup> represents halogen, in the presence of a solvent selected from DCM, DCE, THF, DMF, DMSO, DME or a mixture thereof. The 20 reaction is carried out in an inert atmosphere maintained by using inert a gase like N<sub>2</sub>, Ar or He, in the presence of a base selected from triethyl amine, lutidine, collidine or a mixture thereof at a temperature in the range of -20 °C – 120 °C for a period in the range of 1 to 48 hours, preferably from 2 to 12 hours to yield a compound of formula (IIId) where all symbols are as defined earlier.

- 25 23. A compound according to claim 1, wherein when the groups represented by R<sup>5</sup> are substituted, the substituents are selected from halogen, hydroxy, nitro or substituted or unsubstituted groups selected from alkyl, cycloalkyl, alkoxy, cycloalkoxy, aryl, aralkyl, aryloxy, aralkoxy, aralkoxyalkyl, heterocyclyl, heteroaryl, heteroaralkyl, hydroxyalkyl, amino, arylamino, aminoalkyl, alkylamino, alkoxyalkyl, alkylthio, thioalkyl groups, 30 carboxylic acid or its derivatives; sulfonic acid or its derivatives.

24. A pharmaceutical composition which comprises a compound of formula (I)



as defined in claim 1 and a pharmaceutically acceptable carrier, diluent, excipient or  
5 solvate.

25. A pharmaceutical composition as claimed in claim 24, in the form of a tablet, capsule, powder, syrup, solution or suspension.

26. A composition which comprises a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 4 and an HMG CoA reductase inhibitor; cholesterol absorption inhibitor; antiobesity drug; lipoprotein disorder treatment drug; hypoglycemic agent; insulin; biguanide; sulfonylurea; thiazolidinedione; dual PPAR $\alpha$  and  $\gamma$  agonist or a mixture thereof.

27. A method of preventing or treating hyperlipemia, hypercholesterolemia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering a compound of formula (I) as defined in claim 1 or a compound as claimed in claim 4 or a pharmaceutical composition according to claim 24 or 25 to a patient in need thereof.

28. A method according to claim 27, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidemia, disorders related to Syndrome X including hypertension, obesity, insulin resistance, coronary artery disease and other cardiovascular disorders; renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders to related endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, diabetic complications, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or osteoporosis or as inflammatory agents.

29. A method according to claim 27, for the treatment and/or prophylaxis of disorders related to Syndrome X, which comprises administering an agonist of PPAR $\alpha$  and/or PPAR $\gamma$  of formula (I) as claimed in claim 1 or a compound as claimed in claim 4 or a pharmaceutical composition according to claim 24 or 25 to a patient in need thereof.

30. A method of reducing total cholesterol, body weight, blood plasma glucose,

triglycerides, LDL, VLDL or free fatty acids or increasing HDL in the plasma comprising administering a compound of formula (I), as defined in claim 1 or a compound as claimed in claim 4 or a pharmaceutical composition according to claim 24 or 25 to a patient in need thereof.

- 5    31. A method of preventing or treating hyperlipemia, hypercholesterolemia, hyperglycemia, osteoporosis, obesity, impaired glucose tolerance, atherosclerosis, leptin resistance, insulin resistance, or diseases in which insulin resistance is the underlying pathophysiological mechanism comprising administering to a patient in need thereof an effective amount of a compound of formula (I) as defined in claim 1 or a compound as
- 10    claimed in claim 4 or a pharmaceutical composition according to claim 24 or 25 in combination/concomitant with a HMG CoA reductase inhibitor; cholesterol absorption inhibitor; antiobesity drug; lipoprotein disorder treatment drug; hypoglycemic agent; insulin; biguanide; sulfonylurea; thiazolidinedione; dual PPAR $\alpha$  and  $\gamma$  agonist or a mixture thereof within such a period so as to act synergistically.
- 15    32. A method according to claim 31, wherein the disease is type II diabetes, impaired glucose tolerance, dyslipidemia, disorders related to Syndrome X such as hypertension, obesity, insulin resistance, coronary artery disease and other cardiovascular disorders; certain renal diseases including glomerulonephritis, glomerulosclerosis, nephrotic syndrome, hypertensive nephrosclerosis, retinopathy, nephropathy, disorders related to
- 20    endothelial cell activation, psoriasis, polycystic ovarian syndrome (PCOS), dementia, diabetic complications, osteoporosis, inflammatory bowel diseases, myotonic dystrophy, pancreatitis, arteriosclerosis, xanthoma, eating disorders, cancer or as inflammatory agents.
- 25    33. A method according to claim 31, for the treatment and/or prophylaxis of disorders related to Syndrome X, which comprises administering to a patient in need thereof an agonist of PPAR $\alpha$  and/or PPAR $\gamma$  of formula (I) as claimed in claim 1 or a compound as claimed in claim 4 or a pharmaceutical composition according to claim 24 or 25 and a HMG CoA reductase inhibitor; cholesterol absorption inhibitor; antiobesity drug; lipoprotein disorder treatment drug; hypoglycemic agent; insulin; biguanide; sulfonylurea; thiazolidinedione; dual PPAR $\alpha$  and  $\gamma$  agonist or a mixture thereof within such a period as
- 30    to act synergistically.
34. A method of reducing plasma glucose, triglycerides, total cholesterol, LDL, VLDL or free fatty acids or increasing HDL in the plasma, which comprises administering a compound of formula (I) claimed in claim 1 or a compound as claimed in claim 4 or a

pharmaceutical composition according to claim 24 or 25, in combination/concomitant with a HMG CoA reductase inhibitor; cholesterol absorption inhibitor; antiobesity drug; lipoprotein disorder treatment drug; hypoglycemic agent; insulin; biguanide; sulfonylurea; thiazolidinedione; dual PPAR $\alpha$  and  $\gamma$  agonist or a mixture thereof which may be  
5 administered together or within such a period as to act synergistically together to a patient in need thereof.

## INTERNATIONAL SEARCH REPORT

Int'l	Application No
PC	02/05442

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D487/04	C07D473/00	A61K31/395	A61P3/06	A61P3/10
A61P9/10	A61P19/10	A61P29/02	A61P35/00	

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, CHEM ABS Data, BIOSIS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 254 590 A (YAMANOUCHI PHARMA CO LTD) 27 January 1988 (1988-01-27) abstract; claims 1-6 page 29; example 32 page 49; example 32; table 1 & EP 0 397 290 A 14 November 1990 (1990-11-14) Divisional application of EP0254590 abstract; claims 1-8 page 15; example 14 page 23; example 14; table 1	1-25,28, 29
X		1-25,28, 29
Y	WO 94 13650 A (SMITHKLINE BEECHAM PLC ; HAIGH DAVID (GB); RAMI HARSHAD KANTILAL (G) 23 June 1994 (1994-06-23) cited in the application the whole document ---	1-34 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

## \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the International filing date but later than the priority date claimed

- \*T\* later document published after the International filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*&\* document member of the same patent family

Date of the actual completion of the International search

28 April 2003

Date of mailing of the International search report

12/05/2003

## Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Papathoma, S

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/IB 02/05442

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 4 654 348 A (FUJIKAWA YOSHIHIRO ET AL) 31 March 1987 (1987-03-31) the whole document -----	1-34

# INTERNATIONAL SEARCH REPORT

In.

International application No.  
PCT/IB 02/05442

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:  

Although claims 27-34 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Interr. Application No  
PCT/US 02/05442

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
EP 0254590	A	27-01-1988	AT AT AU AU EP EP JP US US	391695 B 263487 A 604034 B2 7611687 A 0254590 A2 0397290 A1 63179840 A 4891432 A 4987147 A		12-11-1990 15-05-1990 06-12-1990 28-01-1988 27-01-1988 14-11-1990 23-07-1988 02-01-1990 22-01-1991
WO 9413650	A	23-06-1994	WO JP	9413650 A1 8504199 T		23-06-1994 07-05-1996
US 4654348	A	31-03-1987	JP JP JP CA CA EP	1727700 C 4012273 B 60231679 A 1254558 A1 1282409 A2 0157415 A2		19-01-1993 04-03-1992 18-11-1985 23-05-1989 02-04-1991 09-10-1985

**THIS PAGE BLANK (USPTO)**